



Blue Cross Blue Shield of Michigan
Blue Care Network
Preferred Drug List
Prior Authorization and Step Therapy Coverage Criteria
April 2024

Blue Cross Blue Shield of Michigan and Blue Care Network work to make sure you get the safest, most effective and most reasonably priced prescription drugs. Our pharmacists do this in many different ways. Prior authorization and step therapy are two of our tools.

What is prior authorization?

Blue Cross and BCN require a review of certain medications before your plan will cover them, which is called prior authorization. This ensures that you've tried the preferred alternatives — drugs with a proven track record that may be better tolerated, less expensive or less likely to cause interactions — and the drug is being prescribed appropriately. If your doctor doesn't get prior authorization when required, your drug may not be covered. You should consult with your doctor about an alternative therapy in those cases. Most approved prior authorizations last for a set period of time, usually one year. Once they expire, your doctor must request prior authorization again for future coverage.

What is step therapy?

Step therapy requires you try one or more preferred drugs before coverage for a more expensive alternative is approved. This ensures all clinically sound and cost-effective treatment options are tried before more expensive medications. If your prescribed treatment doesn't meet the step therapy criteria, it may not be covered. You should consult with your doctor about an alternative therapy.

What kinds of drugs need prior authorization or step therapy?

Blue Cross and BCN may require prior authorization or step therapy for drugs that:

- Have dangerous side effects or can be harmful when combined with other drugs
- Should only be used for certain health conditions
- Can be misused or abused
- Are prescribed when there are preferred drugs available that are just as effective

The criteria for medications that need prior authorization or step therapy are based on current medical information and the recommendations of Blue Cross and BCN's Pharmacy and Therapeutics Committee, a group of physicians, pharmacists and other experts.

Coverage of drugs depends on your prescription drug plan. Not all drugs included in these prior authorization and step therapy guidelines are necessarily covered by your plan. Also, some medications excluded from your prescription drug plan may be covered under your medical plan. Examples include medications that are generally administered in a physician's office or other sites of care, rather than at home by the patient. For drugs covered under commercial Blue Cross or BCN medical benefits, see the [Blue Cross and BCN Utilization Management Medical Drug List](#).

Requests for medications not covered by your prescription drug plan are reviewed by Blue Cross and BCN to determine if they're medically necessary for you or if there are other equally effective treatments already covered by your drug plan. In rare cases, Blue Cross and BCN may approve medications that aren't covered by your drug plan.

Prior authorization and pharmacy programs listed in this guideline:

- [Preferred Drug List](#)

Questions?

Call the Customer Service number on the back of your Blue Cross or BCN member ID card if you have questions about:

- Your drug plan's coverage or how these pharmacy programs apply
- A drug claim

Electronic prior authorization for doctors and other health care providers

Your doctor can click [here](#) to request an electronic review of your covered drugs that require prior authorization or step therapy.

New coverage criteria for certain drugs

Drug name	Current Blue Cross and BCN coverage criteria	New Blue Cross and BCN coverage criteria	Publish date for the new coverage criteria	Effective date for the new coverage criteria
Dexilant / dexlansoprazole	None	Coverage requires failure of or intolerance to four of the following generic alternatives: omeprazole (Prilosec), esomeprazole (Nexium), pantoprazole (Protonix), lansoprazole (Prevacid/Prevacid Solutab), and rabeprazole (Aciphex) Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit	3/1/24	5/1/24
Fetzima	None	Coverage requires trial and failure of at least three antidepressant agents Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit	3/1/24	5/1/24
naftifine gel (Naftin)	None	Coverage requires the following: <ol style="list-style-type: none"> 1. Diagnosis of tinea pedis, tinea cruris or tinea corporis 2. Treatment failure to two topical over-the-counter antifungal agents 3. Treatment failure to two oral generic antifungal agents 	3/1/24	5/1/24
Neupro	None	Coverage requires the following: <ol style="list-style-type: none"> 1. Diagnosis of Parkinson's disease 2. Treatment failure or intolerance to generic Mirapex (pramipexole) and generic Requip (ropinirole) OR <ol style="list-style-type: none"> 1. Diagnosis of Restless legs syndrome 2. Treatment failure or intolerance to generic Mirapex (pramipexole), generic Requip (ropinirole) and generic Neurontin (gabapentin) 	3/1/24	5/1/24

Drug name	Current Blue Cross and BCN coverage criteria	New Blue Cross and BCN coverage criteria	Publish date for the new coverage criteria	Effective date for the new coverage criteria
pyrimethamine (Daraprim)	None	Coverage is provided for the treatment of toxoplasmosis when used conjointly with a sulfonamide	3/1/24	5/1/24
Xifaxan 550mg	None	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of irritable bowel syndrome with diarrhea (IBS-D) 2. Trial and treatment failure, contraindication, or intolerance to a tricyclic antidepressant <p>OR</p> <ol style="list-style-type: none"> 1. Diagnosis of small intestinal bacterial overgrowth (SIBO) as detected by an appropriate breath test 2. Trial and failure of TWO generic antibiotics <p>OR</p> <ol style="list-style-type: none"> 1. Diagnosis of intestinal methanogen overgrowth (IMO) as detected by an appropriate breath test 2. Using in combination with neomycin unless contraindicated <p>Initial approval for IBS-D and SIBO: 60 days IBS-D and SIBO/IMO renewal: requires the presence of recurrent symptoms after the completion of the prior course of treatment (maximum of 2 renewals will be provided in accordance with FDA label for IBS-D)</p> <p>OR</p> <ol style="list-style-type: none"> 1. Diagnosis of hepatic encephalopathy (HE) 2. Trial and failure of lactulose <p>Initial approval for HE: 1 year HE renewal: requires that current criteria are met, and that the medication is providing clinical benefit</p>	3/1/24	5/1/24

Drug name	Current Blue Cross and BCN coverage criteria
Absorica LD	<p>Coverage is provided for the treatment of severe acne unresponsive to conventional therapy</p> <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>
Accrufer	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of Iron deficiency 2. Age ≥ 18 years old 3. Trial and failure or intolerance to two over-the-counter iron products <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>

Drug name	Current Blue Cross and BCN coverage criteria
Actemra SC	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of Rheumatoid Arthritis 2. Age ≥ 18 years old 3. Trial and treatment failure of one Disease-Modifying Anti-Rheumatic Drug (DMARD) after a minimum 3-month trial (examples include methotrexate, hydroxychloroquine, leflunomide, sulfasalazine) 4. Trial and treatment failure of two of the following: Enbrel, Humira, Cimzia, Simponi, Rinvoq, or Xeljanz/XR <p>OR</p> <ol style="list-style-type: none"> 1. Diagnosis of Polyarticular Juvenile Idiopathic Arthritis 2. Age ≥ 2 years old 3. Trial and treatment failure of one Disease Modifying Anti-Rheumatic Drug (DMARD) after a minimum 3-month trial (examples include methotrexate, leflunomide) 4. Trial and treatment failure with of two of the following: Enbrel, Humira, or Xeljanz <p>OR</p> <ol style="list-style-type: none"> 1. Diagnosis of Still's disease, including adult-onset Still's disease (AOSD) and systemic juvenile idiopathic arthritis (sJIA) 2. Age ≥ 2 years old 3. Trial and treatment failure of one of the following therapies: glucocorticoids or NSAIDs <p>OR</p> <ol style="list-style-type: none"> 1. Diagnosis of giant cell arteritis 2. Age ≥ 18 years old <p>OR</p> <ol style="list-style-type: none"> 1. Diagnosis of systemic sclerosis-associated interstitial lung disease (SSc-ILD) 2. Inadequate response to (as evidenced by disease progression - (e.g. worsening of pulmonary function) or not a candidate for either mycophenolate mofetil OR cyclophosphamide <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>
Acthar Gel	<p>Coverage is provided for the treatment of infantile spasms (West Syndrome) for children less than 2 years old</p> <p>Approval: 60 days</p>

Drug name	Current Blue Cross and BCN coverage criteria
Adbry	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of moderate to severe atopic dermatitis (AD) 2. Age ≥ 12 years old 3. Trial and treatment failure of one of the following: high potency topical corticosteroid, tacrolimus, pimecrolimus, cyclosporine, methotrexate, azathioprine, or mycophenolate mofetil 4. Cannot be used in combination with other biologic agents indicated for atopic dermatitis <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>
Addyi	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Premenopausal female ≥ 18 years old 2. Diagnosis of acquired, generalized hypoactive sexual desire disorder (HSDD) that has been ongoing for more than 6 months 3. Other causes (such as relationship difficulty, substance abuse, medication side effects) of HSDD must be ruled out <p>Initial approval: 60 days Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>
Adempas	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of persistent/recurrent Chronic Thromboembolic Pulmonary Hypertension (CTEPH) (WHO Group 4) after surgical treatment or inoperable CTEPH <p>OR</p> <ol style="list-style-type: none"> 2. Diagnosis of Pulmonary Arterial Hypertension (PAH)(WHO Group 1)

Drug name	Current Blue Cross and BCN coverage criteria
Adlarity	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of mild, moderate, and severe dementia of Alzheimer's type 2. Trial and failure or intolerance to generic oral donepezil <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>
Agamree	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of Duchenne Muscular Dystrophy (DMD) 2. Age ≥ 2 years old 3. Trial and failure, contraindication, or intolerance to adequate doses (0.75 mg/kg/day) of generic prednisone or generic prednisolone <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>
Adzenys XR-ODT	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of Attention Deficit Hyperactivity Disorder 2. Age ≥ 6 years old 3. Treatment failure or intolerance to both a generic methylphenidate and a generic amphetamine product, one of which must be a long-acting formulation <p>OR</p> <ol style="list-style-type: none"> 3. Member cannot swallow tablets/capsules and has tried and failed one of the agents that can be opened and sprinkled on applesauce (methylphenidate ER, Adderall XR) <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>

Drug name	Current Blue Cross and BCN coverage criteria
Aimovig	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Age ≥ 18 years old 2. Being used for preventive treatment of migraine headaches 3. Member has history of ≥ 4 headache days per month 4. Trial of two medications from two different classes for the prevention of migraines <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>
Ajovy	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Age ≥ 18 years old 2. Being used for preventive treatment of migraine headaches 3. Member has history of ≥ 4 headache days per month 4. Trial of two medications from two different classes for the prevention of migraines <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>
Akeega	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Age ≥ 18 years old 2. For the treatment of deleterious or suspected deleterious BRCA mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC) 3. Using in combination with prednisone <p>Initial approval: 1 year Continuation of treatment requires a lack of disease progression</p>

Drug name	Current Blue Cross and BCN coverage criteria
Alecensa	Coverage requires the following: Diagnosis of anaplastic lymphoma kinase (ALK) positive, metastatic non-small cell lung cancer Initial approval: 1 year Continuation of treatment requires a lack of disease progression
almotriptan (Axert)	Requires trial of 2 of the following generic triptans: Imitrex, Maxalt, Amerge, or Zomig/ZMT Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit
Alunbrig	Coverage requires the following: Diagnosis of anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test Initial approval: 1 year Continuation of treatment requires a lack of disease progression
ambrisentan (Letairis)	Coverage is provided for the treatment of pulmonary arterial hypertension (WHO Group 1)

*For drugs covered under the commercial Blue Cross or BCN medical benefit, please see the [Blue Cross and BCN Utilization Management Medical Drug List](#)
Blue Cross Blue Shield of Michigan and Blue Care Network are nonprofit corporations and independent licensees of the Blue Cross and Blue Shield Association.

Drug name	Current Blue Cross and BCN coverage criteria
amphetamine sulfate (Evekeo)	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Narcolepsy: <ol style="list-style-type: none"> a. ≥ 6 years of age b. Trial and treatment failure or intolerance to generic Adderall IR and a generic methylphenidate product 2. ADHD: (Attention deficit hyperactivity disorder) <ol style="list-style-type: none"> a. 3-6 years of age <ol style="list-style-type: none"> i. Trial and treatment failure or intolerance to generic amphetamine product or b. ≥ 6 years of age <ol style="list-style-type: none"> i. Trial and treatment failure or intolerance to of generic amphetamine and generic methylphenidate product 3. Obesity: <ol style="list-style-type: none"> a. ≥ 12 years of age b. BMI ≥ 30 kg/m² c. Current weight (within 30 days) must be submitted to the plan for review d. Active participation for a minimum of 6 months in a covered BCBSM/BCN lifestyle modification program OR active participation for a minimum of 6 months in an alternative concurrent lifestyle modification program (e.g. recent food diaries, exercise logs, program receipts, app participation, etc.) if member does not have access to a covered BCBSM/BCN program e. Previous failed weight loss therapies (examples include: repeated diets, group programs, or other weight loss medications) <p>Approval (Obesity): 60 days Initial approval (Narcolepsy and ADHD): 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>
anastrozole (Arimidex)	<p>Coverage for \$0 copayment will be provided when:</p> <ol style="list-style-type: none"> 1. The member is a woman at least 35 years of age 2. The medication is being used for prevention of primary breast cancer 3. Members is classified as high risk 4. Does not have a history of breast cancer 5. Member is currently post-menopausal

Drug name	Current Blue Cross and BCN coverage criteria
Aptensio XR	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of Attention Deficit Hyperactivity Disorder (ADHD) 2. Age ≥ 6 years old 3. Treatment failure or intolerance to both a generic methylphenidate and a generic amphetamine product, one of which must be a long-acting formulation <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>
Arcalyst	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS) 2. Age ≥ 12 years old 3. Laboratory evidence of a genetic mutation OR elevated inflammatory markers plus at least two of six typical CAPS manifestations: (urticaria-like rash, cold-triggered episodes, hearing loss, musculoskeletal symptoms, chronic aseptic meningitis, or skeletal abnormalities) <p>OR</p> <ol style="list-style-type: none"> 1. Diagnosis of deficiency of interleukin-1 receptor antagonist (DIRA) 2. Laboratory evidence of homozygous genetic mutations of IL1RN 3. Weight ≥ 10 kg 4. Trial and failure, contraindication, or intolerance to Kineret <p>OR</p> <ol style="list-style-type: none"> 1. Diagnosis of recurrent pericarditis (RP) 2. Age ≥ 12 years old 3. Trial and treatment failure or intolerance to nonsteroidal anti-inflammatory drugs (NSAIDs) in combination with colchicine 4. Trial and treatment failure or intolerance to Kineret <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>

Drug name	Current Blue Cross and BCN coverage criteria
Arikayce	Coverage requires the following: <ol style="list-style-type: none"> 1. Diagnosis of mycobacterium avium complex (MAC) 2. Age ≥ 18 years old Initial approval: 1 year
Augtyro	Coverage requires the following: <ol style="list-style-type: none"> 1. Diagnosis of locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) 2. Age ≥ 18 years old Initial approval: 1 year Continuation of treatment requires a lack of disease progression
Austedo	Coverage requires the following: <ol style="list-style-type: none"> 1. Diagnosis of chorea associated with Huntington's disease OR <ol style="list-style-type: none"> 1. Diagnosis of Tardive Dyskinesia Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit

Drug name	Current Blue Cross and BCN coverage criteria
Austedo XR	<p>Coverage requires the following:</p> <ul style="list-style-type: none"> 1. Diagnosis of chorea associated with Huntington's disease (HD) 2. Age ≥ 18 years old <p>OR</p> <ul style="list-style-type: none"> 1. Diagnosis of tardive dyskinesia 2. Age ≥ 18 years old <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>
Auvelity	<p>Coverage requires trial and failure of at least three antidepressant agents</p> <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>
Ayvakit	<p>Coverage requires the following:</p> <ul style="list-style-type: none"> 1. Treatment of unresectable or metastatic gastrointestinal stromal tumor harboring a PDGFRA exon 18 mutation 2. Age ≥ 18 years old <p>OR</p> <ul style="list-style-type: none"> 1. Diagnosis of advanced systemic mastocytosis (advSM) 2. Age ≥ 18 years old <p>OR</p> <ul style="list-style-type: none"> 1. Diagnosis of indolent systemic mastocytosis (ISM) 2. Age ≥ 18 years old <p>Initial approval: 1 year Continuation of treatment requires a lack of disease progression</p>

Drug name	Current Blue Cross and BCN coverage criteria
Azstarys	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of attention deficit hyperactivity disorder (ADHD) 2. Age ≥ 6 years old 3. Trial and treatment failure or intolerance to a generic methylphenidate product and a generic amphetamine product, one of which must be a generic long acting formulation <p>OR</p> <ol style="list-style-type: none"> 3. Member cannot swallow tablets/capsules and has tried and failed one product that can be opened and sprinkled on applesauce, such as methylphenidate ER or generic amphetamine-dextroamphetamine (Adderall XR) <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>
Balversa	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations 2. Disease progression during or following at least one line of prior systemic therapy <p>Initial approval: 1 year Continuation of treatment requires a lack of disease progression</p>
Belbuca	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of moderate to severe chronic pain requiring around the clock opioid analgesia for an extended period of time <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit Note: Coverage will not be provided if the patient is on more than one long acting opioid concurrently</p>

Drug name	Current Blue Cross and BCN coverage criteria
Belsomra	<p>Coverage requires trial and treatment failure or intolerance to one of the following: immediate-release zolpidem (Ambien), eszopiclone (Lunesta), zaleplon (Sonata), trazodone (Desyrel), or doxepin (Silenor)</p> <p>Coverage will not be approved for combination therapy with other sedative hypnotics</p> <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>
Benlysta	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Age ≥ 5 years old 2. Diagnosis of systemic lupus erythematosus (SLE) 3. Patients have tested positive for serum antibodies at 2 independent time points 4. If patient has lupus nephritis ONLY and no other symptoms of SLE, patient must have active disease of the kidney confirmed on biopsy 5. Does not have severe active CNS lupus 6. Previous treatment courses of at least 12 weeks each with 2 or more of the following have been ineffective: hydroxychloroquine, methotrexate, azathioprine, cyclophosphamide or mycophenolate, unless all are contraindicated or not tolerated 7. Patient is currently receiving, and will continue to receive standard of care regimen (examples include antimalarials, corticosteroids, and non-biologic immunosuppressants) 8. Not to be used in combination with other biologics, B-cell targeted therapies <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>
Besremi	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Treatment of polycythemia vera (PV) 2. Age ≥ 18 years old <p>Initial approval: 1 year Continuation of treatment requires a lack of disease progression</p>

Drug name	Current Blue Cross and BCN coverage criteria
bexarotene capsule (Targretin)	Coverage requires the following: <ol style="list-style-type: none"> 1. Diagnosis of cutaneous T-cell lymphoma (CTCL) 2. Treatment failure or intolerance to at least one systemic therapy Initial approval: 1 year Continuation of treatment requires a lack of disease progression
bexarotene gel (Targretin)	Coverage requires the following: <ol style="list-style-type: none"> 1. Diagnosis of Cutaneous T-cell lymphoma 2. Topical treatment of cutaneous lesions
Binosto	Coverage requires trial and treatment failure or intolerance to two of the following: <ol style="list-style-type: none"> 1. Actonel (risedronate) 2. Boniva (ibandronate) 3. Fosamax (alendronate) Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit
Bonjesta	Coverage requires the following: <ol style="list-style-type: none"> 1. Treatment of nausea and vomiting of pregnancy 2. Trial and treatment failure of the individual agents (doxylamine and pyridoxine) in combination Approval length: 9 months

Drug name	Current Blue Cross and BCN coverage criteria
bosentan (Tracleer)	Coverage is provided for the treatment of pulmonary arterial hypertension (WHO Group 1)
Bosulif	<p>Coverage requires the following:</p> <ul style="list-style-type: none"> 1. Diagnosis of chronic phase Philadelphia chromosome-positive (PH+) chronic myelogenous leukemia (CML) <p>OR</p> <ul style="list-style-type: none"> 1. Diagnosis of chronic, accelerated, or blast phase PH+ CML with resistance or intolerance to prior therapy <p>Initial approval: 1 year Continuation of treatment requires a lack of disease progression</p>
Braftovi	<p>Coverage requires the following:</p> <ul style="list-style-type: none"> 1. Diagnosis of unresectable or metastatic melanoma with a BRAF V600E or V600K mutation as detected by an FDA-approved test 2. Using in combination with Mektovi <p>OR</p> <ul style="list-style-type: none"> 1. Diagnosis of metastatic colorectal cancer with a BRAF V600E mutation as detected by an FDA approved test 2. Using in combination with Erbitux 3. Treatment failure or intolerance to prior therapy <p>OR</p> <ul style="list-style-type: none"> 1. Diagnosis of metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation as detected by an FDA approved test 2. Using in combination with Mektovi <p>Initial approval: 1 year Continuation of treatment requires a lack of disease progression</p>

Drug name	Current Blue Cross and BCN coverage criteria
Brexafemme	Coverage requires the following: <ol style="list-style-type: none"> 1. Treatment of acute vulvovaginal candidiasis (VVC) or recurrent vulvovaginal candidiasis (RVVC) 2. Trial and failure, contraindication, or intolerance to generic oral fluconazole alone Approval: 6 months
Bronchitol	Coverage requires the following: <ol style="list-style-type: none"> 1. Using as add-on maintenance therapy to improve pulmonary function in patients with cystic fibrosis (CF) 2. Age ≥ 18 years old 3. Must have passed the Bronchitol Tolerance Test 4. Member will be taking a short-acting bronchodilator 5-15 minutes before every dose of Bronchitol 5. Trial and failure, contraindication, or intolerance to nebulized hypertonic saline Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit
Briviact oral solution + tablet	Coverage requires the following: <ol style="list-style-type: none"> 1. Treatment of seizure disorder/epilepsy 2. Treatment failure or intolerance to 3 generic preferred alternatives Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit

Drug name	Current Blue Cross and BCN coverage criteria
Brukinsa	<p>Coverage requires the following:</p> <ul style="list-style-type: none"> 1. Diagnosis of mantle cell lymphoma (MCL) 2. Treatment failure or intolerance to Calquence <p>OR</p> <ul style="list-style-type: none"> 1. Diagnosis of Waldenström’s macroglobulinemia (WM) 2. Trial and failure or intolerance to Imbruvica <p>OR</p> <ul style="list-style-type: none"> 1. Diagnosis of marginal zone lymphoma (MZL) 2. Treatment failure or intolerance to one or more rounds of therapy with a CD20 inhibiting antibody <p>OR</p> <ul style="list-style-type: none"> 1. Diagnosis of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) 2. Treatment failure or intolerance to Calquence or Imbruvica <p>Initial approval: 1 year Continuation of treatment requires a lack of disease progression</p>
Bydureon	<p>Coverage requires the following:</p> <ul style="list-style-type: none"> 1. For the treatment of Type 2 Diabetes or trial of one generic or preferred medication for the treatment of Type 2 Diabetes 2. Cannot be used in combination with other glucagon-like peptide-1 (GLP-1) agonist-containing products <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>

Drug name	Current Blue Cross and BCN coverage criteria
Byetta	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. For the treatment of Type 2 Diabetes or trial of one generic or preferred medication for the treatment of Type 2 Diabetes 2. Cannot be used in combination with other glucagon-like peptide-1 (GLP-1) agonist-containing products <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>

Drug name	Current Blue Cross and BCN coverage criteria
Bylvay	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. For the treatment of pruritus in patients with a diagnosis of progressive familial intrahepatic cholestasis (PFIC) 2. Age ≥ 3 months old 3. Genetic testing does not show presence of the ABCB11 variants resulting in a nonfunctional or complete absence of the bile salt export pump protein (BSEP-3). 4. No history of liver transplant or planned future liver transplant 5. No clinical evidence of decompensated cirrhosis 6. Trial and failure, contraindication, or intolerance to generic ursodiol <p>OR</p> <ol style="list-style-type: none"> 1. For the treatment of cholestatic pruritus in patients with a diagnosis of Alagille syndrome (ALGS) 2. Diagnosis is confirmed by documentation of 1 of the following: <ol style="list-style-type: none"> a. Genetic testing shows presence of the JAG1 or NOTCH2 genetic mutation b. Liver biopsy shows bile duct scarcity c. Involvement of 3 of 7 of the main organ systems affected in ALGS: hepatic, ocular, skeletal, vascular, facial, cardiac, or renal involvement 3. Age ≥ 12 months old 4. No history of liver transplant or planned future liver transplant 5. No clinical evidence of decompensated cirrhosis 6. Trial and failure, contraindication, or intolerance to generic ursodiol <p>Initial approval: 6 months Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>

Drug name	Current Blue Cross and BCN coverage criteria
Cablivi	Coverage requires the following: <ol style="list-style-type: none"> 1. Diagnosis of acquired aTTP 2. Administered in addition to plasma exchange and immunosuppressive therapy 3. Continued 30 days after discontinuation of plasma exchange Approval: 60 days
Cabometyx	Coverage requires the following: <ol style="list-style-type: none"> 1. Diagnosis of advanced renal cell carcinoma 2. Age ≥ 18 years old 3. Using as a single agent or in combination with Opdivo (nivolumab) OR <ol style="list-style-type: none"> 1. Diagnosis of hepatocellular carcinoma (HCC) 2. Previous treatment with sorafenib 3. Age ≥ 18 years old OR <ol style="list-style-type: none"> 1. Diagnosis of locally advanced or metastatic differentiated thyroid cancer (DTC), radioactive iodine-refractory or ineligible 2. Previous treatment with VEGFR-targeted therapy 3. Age ≥ 12 years old Initial approval: 1 year Continuation of treatment requires a lack of disease progression

Drug name	Current Blue Cross and BCN coverage criteria
Calquence	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of mantle cell lymphoma (MCL) 2. Treatment failure or intolerance to at least one prior therapy <p>OR</p> <ol style="list-style-type: none"> 1. Diagnosis of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) <p>Initial approval: 1 year Continuation of treatment requires a lack of disease progression</p>
Camzyos	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of symptomatic obstructive hypertrophic cardiomyopathy (HCM) 2. New York Heart Association (NYHA) class II-III 3. Age ≥ 18 years old 4. Left ventricular ejection fraction (LVEF) > 55% 5. Trial and failure, contraindication, or intolerance to a beta blocker or calcium channel blocker <p>Initial approval: 1 year Renewal requires that the medication is providing clinical benefit and that LVEF is ≥ 50%</p>
Caplyta	<p>Coverage requires documentation to support the following: Trial and failure, contraindication, or intolerance to two preferred second generation antipsychotics (examples include: aripiprazole, clozapine, risperidone, quetiapine, olanzapine, ziprasidone)</p> <p>Initial approval: 1 year Renewal requires documentation since the previous approval to confirm that current criteria are met and that the medication is providing clinical benefit</p>

Drug name	Current Blue Cross and BCN coverage criteria
Caprelsa	<p>Coverage is provided for the treatment of patients with metastatic or unresectable locally advanced medullary thyroid cancer</p> <p>Initial approval: 1 year Continuation of treatment requires a lack of disease progression</p>
carglumic acid (Carbaglu)	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Adjunctive and maintenance therapy for the treatment of hyperammonemia due to NAGSD, a deficiency of the hepatic enzyme N-acetylglutamate synthase (NAGS) 2. Deficiency must be confirmed by enzyme or DNA mutation analysis <p>Initial approval for NAGSD: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p> <p>OR</p> <ol style="list-style-type: none"> 1. Adjunctive treatment of acute hyperammonemia due to propionic acidemia (PA) or methylmalonic acidemia (MMA) 2. Diagnosis must be confirmed by analysis of organic acids in urine and assessment of the acylcarnitine profile in blood <p>Approval for PA or MMA: 60 days</p>
Caverject	<p>May be covered for the diagnosis of erectile dysfunction dependent on the plan's benefit with quantity limit restrictions</p>
Cayston	<p>Coverage is provided for the treatment of Pseudomonas aeruginosa infection in members with cystic fibrosis</p> <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>

Drug name	Current Blue Cross and BCN coverage criteria
Cerdelga	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Age ≥ 18 years old 2. For the long-term treatment of Gaucher disease type 1 (GD1) 3. Confirmation of diagnosis by biochemical assay showing decreased glucocerebrosidase activity in white blood cells or skin fibroblasts AND genotyping revealing two pathogenic mutations of the glucocerebrosidase gene 4. Two symptomatic manifestations of the disease are present, such as anemia, thrombocytopenia, bone disease, hepatomegaly, or splenomegaly 5. CYP2D6 genotyping by an FDA-cleared test reveals an extensive metabolizer (EM), intermediate metabolizer (IM), or poor metabolizer (PM) <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>
Chenodal	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Treatment of gallstones 2. Ineligible for surgery 3. Treatment failure or intolerance to Actigall (ursodiol) <p>Coverage is limited to 24 months</p>
Cholbam	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Prescribed by or in consultation with hepatologist or gastroenterologist 2. Treatment of bile acid synthesis disorder due to single enzyme defects (SEDs) <p>OR</p> <ol style="list-style-type: none"> 1. Adjunctive treatment of peroxisomal disorders (PDs) including Zellweger spectrum disorders in patients who exhibit manifestation of liver disease, steatorrhea or complications from decreased fat-soluble vitamin deficiency 2. Prescribed by or in consultation with a hepatologist or gastroenterologist

Drug name	Current Blue Cross and BCN coverage criteria
Cibinqo	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of moderate to severe atopic dermatitis (AD) 2. Age ≥ 12 years old 3. Trial and treatment failure of one of the following: high potency topical corticosteroid, tacrolimus, pimecrolimus, cyclosporine, methotrexate, azathioprine, or mycophenolate mofetil 4. Cannot be used in combination with other biologic agents indicated for severe atopic dermatitis <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>

Drug name	Current Blue Cross and BCN coverage criteria
Cimzia	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of Crohn's Disease 2. Age ≥ 18 years old 3. Treatment with an adequate course of conventional therapy (such as steroids for 7 days, immunomodulators such as azathioprine for at least 2 months) has been ineffective or is contraindicated or not tolerated <p>OR</p> <ol style="list-style-type: none"> 1. Diagnosis of Rheumatoid Arthritis 2. Age ≥ 18 years old 3. Trial and treatment failure of Disease Modifying Anti-Rheumatic Drug (DMARD) after a minimum 3-month trial (examples include methotrexate, leflunomide, hydroxychloroquine, sulfasalazine) <p>OR</p> <ol style="list-style-type: none"> 1. Diagnosis of Ankylosing Spondylitis 2. Age ≥ 18 years old <p>OR</p> <ol style="list-style-type: none"> 1. Diagnosis of Psoriatic Arthritis 2. Age ≥ 18 years old <p>OR</p> <ol style="list-style-type: none"> 1. Diagnosis of Psoriasis 2. Age ≥ 18 years old 3. Trial and treatment failure of one topical steroid <p>OR</p> <ol style="list-style-type: none"> 1. Diagnosis of active Non-Radiographic Axial Spondyloarthritis with objective signs of inflammation 2. Age ≥ 18 years old <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>

*For drugs covered under the commercial Blue Cross or BCN medical benefit, please see the [Blue Cross and BCN Utilization Management Medical Drug List](#)
Blue Cross Blue Shield of Michigan and Blue Care Network are nonprofit corporations and independent licensees of the Blue Cross and Blue Shield Association.

Drug name	Current Blue Cross and BCN coverage criteria
Cometriq	<p>Coverage is provided for the treatment of patients with progressive, metastatic medullary thyroid cancer. Therapy is considered investigational for all other conditions</p> <p>Initial approval: 1 year Continuation of therapy requires a lack of disease progression</p>
Compounds	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. The compound is medically necessary for the member's condition 2. The compound contains only FDA-approved drugs 3. There are no appropriate FDA-approved commercial formulations of the compound available 4. There is medical literature to support the safety, effectiveness and route of administration of the compound
<p>Continuous Glucose Monitors Dexcom G6 Dexcom G7 Freestyle libre 14 day Freestyle Libre 2 14 day Freestyle Libre 3</p>	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Member is insulin-requiring <p>OR</p> <ol style="list-style-type: none"> 1. Member has a diagnosis of diabetes and history of problematic hypoglycemia with at least one of the following: <ol style="list-style-type: none"> a. Recurrent (more than one) level 2 hypoglycemia events (glucose < 54 mg/dL (3.0mmol/L)) that persist despite multiple (more than one) attempts to adjust medication(s) and/or modify the diabetes treatment plan b. A history of one level 3 hypoglycemia event (glucose < 54 mg/dL (3.0mmol/L)) characterized by altered mental and/or physical state requiring third-party assistance for treatment of hypoglycemia <p>OR</p> <ol style="list-style-type: none"> 1. Member has a diagnosis of diabetes and is currently pregnant and experiencing post prandial hyperglycemia <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>

Drug name	Current Blue Cross and BCN coverage criteria
Contraceptives	Coverage for \$0 copayment will be provided when: <ol style="list-style-type: none"> 1. Used for the prevention of pregnancy 2. Trial and treatment failure or intolerance to at least three generic contraceptive medications
Contrave	Coverage requires the following: <ol style="list-style-type: none"> 1. Age ≥ 18 years old 2. BMI ≥ 30, or ≥ 27 with one weight related comorbid condition 3. Current weight (within 30 days) must be submitted to the plan for review 4. Active participation for a minimum of 6 months in a covered BCBSM/BCN lifestyle modification program OR active participation for a minimum of 6 months in an alternative concurrent lifestyle modification program (e.g. recent food diaries, exercise logs, program receipts, app participation, etc.) if member does not have access to a covered BCBSM/BCN program 5. Not to be used in combination with other weight loss products <p>Initial approval: 6 months Continued coverage will be reviewed annually and may be provided if the member has maintained a 5% weight loss from baseline AND requires continued participation in a lifestyle modification program. Current weight (within 30 days) and BMI ≥ 18.5 kg/m² must be submitted to the plan for review</p>
Copiktra	Coverage requires the following: <ol style="list-style-type: none"> 1. Diagnosis of relapsed or refractory chronic lymphocytic leukemia (CLL or small lymphocytic lymphoma (SLL)) after at least two prior therapies

Drug name	Current Blue Cross and BCN coverage criteria
Cotellic	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of unresectable or metastatic melanoma with a BRAF V600E or V600K mutation 2. Using in combination with Zelboraf <p>OR</p> <ol style="list-style-type: none"> 1. Diagnosis of histiocytic neoplasms <p>Initial approval: 1 year Continuation of treatment requires a lack of disease progression</p>
Cuvitru	<p>Requires appropriate diagnosis for coverage, subcutaneous administration and other criteria may apply depending on diagnosis. Dosing must be based on ideal body weight (IBW) unless the patient's BMI is greater than 30. If the patient's BMI is greater than 30 or if actual body weight is 20-30% greater than IBW, adjusted body weight must be used</p> <p>Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>
Cystaran	<p>Coverage will be provided for the treatment of corneal cystine crystal accumulation in patients with cystinosis, when taking in combination with oral Cystagon</p>
Daurismo	<p>Coverage requires the following:</p> <p>Treatment of newly diagnosed acute myeloid leukemia (in combination with low-dose cytarabine) in adult patients who are ≥ 75 years of age or who have comorbidities that preclude use of intensive induction chemotherapy</p> <p>Limitations of use: Has not been studied in patients with severe renal impairment or moderate to severe hepatic impairment</p>

Drug name	Current Blue Cross and BCN coverage criteria
Daybue	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of classic Rett syndrome consistent with the RettSearch Consortium diagnostic criteria 2. Does not have atypical or variant Rett syndrome 3. Age \geq 2 years old <p>Initial approval: 6 months Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>
Dayvigo	<p>Coverage requires trial and treatment failure or intolerance to one of the following: immediate-release zolpidem (Ambien), eszopiclone (Lunesta), zaleplon (Sonata), trazodone (Desyrel), or doxepin (Silenor)</p> <p>Coverage will not be approved for combination therapy with other sedative hypnotics</p> <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>
deferasirox (Exjade)	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Chronic iron overload due to transfusions: 2. \geq 2 years of age <p>OR</p> <ol style="list-style-type: none"> 1. Chronic iron overload in nontransfusion-dependent thalassemia syndromes: 2. \geq 10 years of age <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>

Drug name	Current Blue Cross and BCN coverage criteria
deferasirox (Jadenu)	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Chronic iron overload due to transfusions: <ol style="list-style-type: none"> a. ≥ 2 years of age <p>OR</p> <ol style="list-style-type: none"> 2. Chronic iron overload in nontransfusion-dependent thalassemia syndromes: <ol style="list-style-type: none"> a. ≥ 10 years of age <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>
deferiprone tablets (Ferriprox)	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Age ≥ 8 years old 2. Diagnosis of transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate 3. Treatment failure or intolerance to generic Jadenu or generic Exjade <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>
deferiprone solution (Ferriprox)	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Age ≥ 3 years old 2. Diagnosis of transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate 3. Treatment failure or intolerance to generic Jadenu or generic Exjade <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>

Drug name	Current Blue Cross and BCN coverage criteria
deflazacort (Emflaza)	Coverage requires the following: <ol style="list-style-type: none"> 1. Diagnosis of Duchenne Muscular Dystrophy (DMD) 2. Age ≥ 2 years old 3. Trial and treatment failure, contraindication, or intolerance to adequate doses (0.75 mg/kg/day) of generic prednisone or generic prednisolone Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit
Descovy	Coverage with \$0 copayment will be provided when: <ol style="list-style-type: none"> 1. Using for pre exposure prophylaxis (PrEP) for HIV 2. Negative HIV test within the past 3 months 3. Trial and intolerance or contraindication to generic Truvada 200mg/300mg OR <ol style="list-style-type: none"> 1. Coverage will be provided for the treatment of HIV infection Initial approval: 2 years Renewal requires that current criteria are met, and that the medication is providing clinical benefit AND documentation of a negative HIV test result within the past 3 months
Desvenlafaxine ER	Coverage requires trial and failure of at least three antidepressant agents Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit

Drug name	Current Blue Cross and BCN coverage criteria
Diacomit	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of Dravet Syndrome 2. Trial and failure, contraindication, or intolerance to 2 of the following generic options: valproic acid, clobazam, or topiramate 3. Using in combination with clobazam <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>
dichlorphenamide (Keveyis)	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis and related variants as confirmed by a genetic test or positive family history 2. Trial and failure of lifestyle modifications such as diet (potassium intake alterations) and exercise modifications 3. Trial and treatment failure of acetazolamide
diclofenac 2% external solution (Pennsaid 2%)	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of osteoarthritis of the knee 2. Trial of or intolerance to generic oral diclofenac and at least two other oral, traditional NSAIDs 3. Trial of generic Pennsaid 1.5% topical solution <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit Please note: Coverage will not be provided in the presence of concurrent therapy with oral NSAIDs</p>

Drug name	Current Blue Cross and BCN coverage criteria
diclofenac sodium 3% gel (Solaraze)	Coverage requires the following: <ol style="list-style-type: none"> 1. Age ≥ 18 years old 2. Diagnosis of actinic keratosis 3. Trial and failure or intolerance to cryotherapy or phototherapy 4. Trial and treatment failure or intolerance to a generic or preferred topical fluorouracil 5. Trial and treatment failure or intolerance to generic imiquimod 5% Initial approval: 3 months Renewal requires recurrence and/or new lesions
Dojolvi	Coverage requires the following: <ol style="list-style-type: none"> 1. Treatment of molecularly confirmed long-chain fatty acid oxidation disorders 2. Following low fat/high carbohydrate diet and avoiding fasting 3. Trial of medium chain triglycerides at a maximally tolerated dose Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit

Drug name	Current Blue Cross and BCN coverage criteria
Doptelet	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of thrombocytopenia in chronic liver disease <ol style="list-style-type: none"> a. Age \geq 18 years old b. Platelet count $<$ 50,000/mcL c. Scheduled to undergo a procedure <p>OR</p> <ol style="list-style-type: none"> 2. Diagnosis of chronic immune thrombocytopenia (ITP) and persistent thrombocytopenia (platelet count $<$ 100,000/mcL) for \geq 3 months and requires all of the following: <ol style="list-style-type: none"> a. Age \geq 18 years old b. Current platelet count is $<$ 20,000/mcL or $<$ 30,000/mcL and has symptoms of active bleeding c. Diagnosis confirmed by, or in consultation with a hematologist d. Inadequate response to (e.g. unable to maintain platelet count \geq 30,000/mcL) OR are not candidates for therapy with corticosteroids, immunoglobulins, or splenectomy with an insufficient response to previous treatment <p>Initial approval for diagnosis of thrombocytopenia in chronic liver disease: 60 days Initial approval for diagnosis of chronic ITP: 3 months Renewal requires a recent platelet count between 50,000 and 200,000/mcL</p>
Doryx MPC	<p>Coverage requires the following:</p> <p>Trial and treatment failure or intolerance to generic doxycycline monohydrate (Monodox) AND generic doxycycline hyclate immediate release (Vibramycin)</p> <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>

Drug name	Current Blue Cross and BCN coverage criteria
Doxepin topical cream	Coverage requires the following: <ol style="list-style-type: none"> 1. Diagnosis of atopic pruritis or lichen simplex chronicus 2. Trial and treatment failure of two topical steroids, one of which must be a medium or high potency product 3. Trial and treatment failure to one preferred topical calcineurin inhibitor (tacrolimus, pimecrolimus) OR <ol style="list-style-type: none"> 1. Diagnosis of peripheral neuropathic pain 2. Trial and treatment failure of two over-the-counter topical analgesics 3. Trial and treatment failure of one preferred topical non-steroidal anti-inflammatory drug (NSAID) Initial approval: 60 days
doxycycline hyclate (Doryx)	Coverage requires the following: Trial and treatment failure or intolerance to generic doxycycline monohydrate (Monodox) AND generic doxycycline hyclate immediate release (Vibramycin) Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit
doxycycline monohydrate (Adoxa / Adoxa Pak)	Coverage requires the following: Trial and treatment failure or intolerance to generic doxycycline monohydrate (Monodox) AND generic doxycycline hyclate immediate release (Vibramycin) Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit

Drug name	Current Blue Cross and BCN coverage criteria
droxidopa (Northera)	Coverage requires the following: <ol style="list-style-type: none"> 1. Diagnosis of orthostatic hypotension 2. Age ≥18 years old 3. Trial and treatment failure of midodrine 4. Trial and treatment failure of fludrocortisone
Duopa	Coverage requires the following: <ol style="list-style-type: none"> 1. Diagnosis of advanced Parkinson's disease 2. Member has a feeding tube

Drug name	Current Blue Cross and BCN coverage criteria
Dupixent	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of moderate to severe atopic dermatitis 2. Age ≥ 6 months old 3. Trial and treatment failure of one of the following: high potency topical corticosteroid, tacrolimus, pimecrolimus, cyclosporine, methotrexate, azathioprine, or mycophenolate mofetil 4. Cannot be used in combination with other biologic agents indicated for severe atopic dermatitis <p>OR</p> <ol style="list-style-type: none"> 1. Diagnosis of eosinophilic asthma 2. Age ≥ 6 years old 3. Patient is currently receiving, and will continue to receive standard of care regimen 4. Eosinophil count ≥ 150 cells/microliter at initiation of treatment 5. Failure to maintain adequate control after at least a 3 month trial of daily oral corticosteroids or high dose inhaled corticosteroids in combination with: <ol style="list-style-type: none"> 1. LABA (long acting inhaled β2 agonist) OR 2. Leukotriene modifier OR 3. LAMA (long acting muscarinic antagonist) in adults and children ≥ 12 years old 6. Cannot be used in combination with other biologic agents indicated for asthma <p>(criteria continued next page)</p>

*For drugs covered under the commercial Blue Cross or BCN medical benefit, please see the [Blue Cross and BCN Utilization Management Medical Drug List](#). Blue Cross Blue Shield of Michigan and Blue Care Network are nonprofit corporations and independent licensees of the Blue Cross and Blue Shield Association.

Drug name	Current Blue Cross and BCN coverage criteria
Dupixent (continued)	<p>OR</p> <ol style="list-style-type: none"> 1. Diagnosis of oral corticosteroid dependent asthma 2. Age ≥ 6 years old 3. Patient is currently receiving, and will continue to receive standard of care regimen 4. Failure to maintain adequate control after at least a 3 month trial of daily oral corticosteroids AND high dose inhaled corticosteroids in combination with: <ol style="list-style-type: none"> a. LABA (long acting inhaled β2 agonist) OR b. Leukotriene modifier OR c. LAMA (long acting muscarinic antagonist) in adults and children ≥ 12 years old 5. Cannot be used in combination with other biologic agents indicated for asthma <p>OR</p> <ol style="list-style-type: none"> 1. Diagnosis of chronic rhinosinusitis with nasal polyposis (CRSwNP) 2. Age > 18 years old 3. Patient is currently receiving, and will continue to receive standard of care regimen 4. CRSwNP is recurring despite previous treatment with intranasal corticosteroids 5. Cannot be used in combination with other biologic agents indicated for CRSwNP <p>OR</p> <ol style="list-style-type: none"> 1. Diagnosis of eosinophilic esophagitis (EoE) 2. Weight ≥ 40 kilograms 3. Trial and treatment failure of a proton pump inhibitor (PPI) OR 3. Trial and treatment failure of a swallowed topical glucocorticoid <p>OR</p> <ol style="list-style-type: none"> 1. Diagnosis of Prurigo Nodularis (PN) 2. Age ≥ 18 years old 3. Trial and treatment failure with topical steroids or topical calcineurin inhibitors <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>

Drug name	Current Blue Cross and BCN coverage criteria
Dyanavel XR	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of ADHD (attention deficit hyperactivity disorder) 2. Age ≥ 6 years old 3. Treatment failure or intolerance to both a generic methylphenidate and a generic amphetamine product, one of which must be a long-acting formulation <p>OR</p> <ol style="list-style-type: none"> 1. Member cannot swallow tablets/capsules and has tried and failed one of the agents that can be opened and sprinkled on applesauce (methylphenidate ER, Adderall XR) <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>
Edluar	<p>Coverage requires treatment failure of 3 of the following: immediate-release zolpidem (Ambien), eszopiclone (Lunesta), zaleplon (Sonata), trazodone (Desyrel), or doxepin (Silenor), one of which must be generic Ambien</p> <p>Coverage will not be approved for combination therapy with other sedative hypnotics</p> <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>
Egrifta	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of HIV 2. Currently receiving antiretroviral therapy (ART) 3. Medical complication caused by excess abdominal fat 4. Medical complication due to excess abdominal fat is not responsive to conventional therapy <p>Initial approval: 6 months Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>

Drug name	Current Blue Cross and BCN coverage criteria
Elepsia XR	Coverage requires the following: <ol style="list-style-type: none"> 1. Treatment of seizure disorder/epilepsy 2. Treatment failure or intolerance to three generic or preferred alternatives, one of which must be generic Kepra Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit
eletriptan (Relpax)	Coverage requires trial of 2 of the following generic triptans: Imitrex, Maxalt, Amerge, or Zomig/ZMT Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit
Emgality 100mg/ml	Coverage requires the following: <ol style="list-style-type: none"> 1. For the treatment of episodic cluster headache 2. Age ≥18 years old Initial approval: 6 months Renewal requires that current criteria are met, and that the medication is providing clinical benefit
Emgality 120mg/ml	Coverage requires the following: <ol style="list-style-type: none"> 1. Age ≥ 18 years old 2. For preventive treatment of migraine headaches 3. Member has history of ≥ 4 headache days per month 4. Trial of two medications from two different classes for the prevention of migraines 5. Trial and treatment failure of Aimovig and Ajovy Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit

Drug name	Current Blue Cross and BCN coverage criteria
Empaveli	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of paroxysmal nocturnal hemoglobinuria (PNH) 2. Age \geq 18 years old 3. Flow cytometric confirmation of PNH type III red cells 4. Had at least 1 transfusion in 12 months preceding Empaveli <p>OR</p> <ol style="list-style-type: none"> 4. History of major adverse thrombotic vascular events from thromboembolism <p>OR</p> <ol style="list-style-type: none"> 4. Patient has high disease activity defined as a lactic dehydrogenase (LDH) level \geq 1.5 times the upper limit of normal with one of the following symptoms: <ol style="list-style-type: none"> i. Weakness ii. Fatigue iii. Hemoglobinuria iv. Abdominal pain v. Dyspnea vi. Hemoglobin $<$ 10 g/dL vii. A major vascular event viii. Dysphagia ix. Erectile dysfunction 5. Must not be used in combination with Soliris®, Ultomiris®, or other medications used to treat PNH <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>
Emsam	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Treatment of major depressive disorder 2. Age \geq 18 years old 3. Member has experienced treatment failure or intolerance to at least three different generic antidepressants

Drug name	Current Blue Cross and BCN coverage criteria
emtricitabine 200mg-tenofovir 300mg (Truvada)	Coverage for \$0 copayment will be provided when: <ol style="list-style-type: none"> 1. For prevention of HIV infection in members who are at a high risk of getting HIV 2. Member is not taking concomitant antiretroviral therapy
Enbrel	Coverage requires the following: <ol style="list-style-type: none"> 1. Diagnosis Psoriatic Arthritis 2. Age ≥ 2 years old OR <ol style="list-style-type: none"> 1. Diagnosis of Rheumatoid Arthritis 2. Age ≥ 18 years old 3. Trial and treatment failure of one Disease Modifying Anti-Rheumatic Drug (DMARD) after a minimum 3-month trial (examples include methotrexate, hydroxychloroquine, leflunomide, sulfasalazine) OR <ol style="list-style-type: none"> 1. Diagnosis of Ankylosing Spondylitis 2. Age ≥ 18 years old OR <ol style="list-style-type: none"> 1. Diagnosis of Psoriasis 2. Age ≥ 4 years old 3. Trial and treatment failure of one topical steroid OR <ol style="list-style-type: none"> 1. Diagnosis of Juvenile Idiopathic Arthritis (JIA) 2. Age ≥ 2 years old 3. Trial and treatment failure of one Disease Modifying Anti-Rheumatic Drug (DMARD) after a minimum 3-month trial (examples include methotrexate, leflunomide) Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit

Drug name	Current Blue Cross and BCN coverage criteria
Endari	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of sickle cell disease 2. Age ≥ 5 years old <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>
Endometrin	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. It is being prescribed in accordance with generally accepted medical practice 2. The members benefit provides coverage for infertility medications <p>Coverage is provided in accordance with your medical fertility benefit</p>
Enspryng	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive <p>Enspryng will not be approved for use in combination with Soliris or Uplizna</p> <p>Initial approval: 1 year Continuation of treatment requires a lack of disease progression</p>

*For drugs covered under the commercial Blue Cross or BCN medical benefit, please see the [Blue Cross and BCN Utilization Management Medical Drug List](#)
Blue Cross Blue Shield of Michigan and Blue Care Network are nonprofit corporations and independent licensees of the Blue Cross and Blue Shield Association.

Drug name	Current Blue Cross and BCN coverage criteria
Epclusa	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Age ≥ 3 years old or weight ≥ 17kg 2. Diagnosis of chronic hepatitis C genotype 1, 2, 3, 4, 5, or 6 3. If treatment experienced, documentation of previous treatment experience for Hepatitis C 4. If cirrhosis is present: documentation of decompensated or compensated cirrhosis <p>Drug will be reviewed based on a case by case basis utilizing AASLD guidelines and FDA approved package labeling</p>
Epidiolex	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of Lennox-Gastaut syndrome 2. Trial and failure, contraindication, OR intolerance to at least 2 generic alternatives for the treatment of seizures <p>OR</p> <ol style="list-style-type: none"> 2. Trial and failure, contraindication, OR intolerance of either Banzel or Onfi <p>OR</p> <ol style="list-style-type: none"> 1. Diagnosis of Dravet syndrome or tuberous sclerosis complex 2. Trial and failure, contraindication, OR intolerance of at least 2 generic alternatives for the treatment of seizures <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>

Drug name	Current Blue Cross and BCN coverage criteria
Eprontia	<p>Coverage requires the following:</p> <ul style="list-style-type: none"> 1. Treatment of seizure disorder/epilepsy 2. Treatment failure or intolerance to at least 3 generic alternatives, one of which must be generic topiramate (Topamax) <p>OR</p> <ul style="list-style-type: none"> 2. Member is unable to swallow tablets/capsules <p>OR</p> <ul style="list-style-type: none"> 1. Diagnosis of Lennox-Gastaut Syndrome 2. Treatment failure or intolerance to at least 2 generic alternatives, one of which must be generic topiramate (Topamax) <p>OR</p> <ul style="list-style-type: none"> 2. Member is unable to swallow tablets/capsules <p>OR</p> <ul style="list-style-type: none"> 1. For preventative treatment of migraine headaches 2. Age ≥ 12 years old 3. Treatment failure or intolerance to 3 generic alternatives for the prevention of migraines, one of which must be generic topiramate (Topamax) <p>OR</p> <ul style="list-style-type: none"> 3. Member is unable to swallow tablets/capsules <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>

Drug name	Current Blue Cross and BCN coverage criteria
Erivedge	Coverage requires the following: <ol style="list-style-type: none"> 1. Diagnosis of locally advanced basal cell carcinoma 2. Carcinoma occurred again following surgery OR the member not able to have surgery 3. Not a candidate for radiation OR <ol style="list-style-type: none"> 1. Diagnosis of metastatic basal cell carcinoma Initial approval: 1 year Continuation of treatment requires a lack of disease progression
Erleada	Coverage requires the following: <ol style="list-style-type: none"> 1. Metastatic castration-sensitive prostate cancer OR <ol style="list-style-type: none"> 1. Non-metastatic castration-resistant prostate cancer
erlotinib (Tarceva)	Coverage is provided for the treatment of the FDA approved indications
Eucrisa	Coverage requires trial and treatment failure of one of the following: a topical steroid, generic Protopic, or generic Elidel Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit

Drug name	Current Blue Cross and BCN coverage criteria
Eulexin	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of locally confined or metastatic carcinoma of the prostate 2. Age ≥ 18 years old 3. Using in combination with luteinizing hormone-releasing hormone (LHRH)-agonists 4. Trial and failure, contraindication, or intolerance to generic Casodex (bicalutamide) <p>Initial approval: 1 year Continuation of treatment requires a lack of disease progression</p>
everolimus (Afinitor)	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of HR-positive, HER-2 negative advanced breast cancer (in combination with exemestane) 2. Previous treatment failure with letrozole or anastrozole <p>OR</p> <ol style="list-style-type: none"> 1. Treatment of progressive pancreatic neuroendocrine tumors in patients with unresectable, locally advanced or metastatic disease <p>OR</p> <ol style="list-style-type: none"> 1. Treatment of progressive, well-differentiated nonfunctional gastrointestinal or lung neuroendocrine tumors in patients with unresectable, locally advanced or metastatic disease <p>OR</p> <ol style="list-style-type: none"> 1. Treatment of advanced renal cell carcinoma after Sutent (sunitinib) or Nexavar (sorafenib) failure <p>OR</p> <ol style="list-style-type: none"> 1. Treatment of renal angiomyolipoma with tuberous sclerosis complex (TSC) not requiring immediate surgery <p>OR</p> <ol style="list-style-type: none"> 1. Treatment of subependymal giant cell astrocytoma (SEGA) associated with TSC that requires therapeutic intervention but cannot be curatively resected 2. Age > 1 year old <p>Initial approval: 1 year Continuation of treatment requires a lack of disease progression</p>

Drug name	Current Blue Cross and BCN coverage criteria
everolimus (Afinitor Disperz)	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Adjunctive treatment of partial-onset seizures associated with tuberous sclerosis complex (TSC) 2. Age ≥ 2 years old <p>OR</p> <ol style="list-style-type: none"> 1. Treatment of subependymal giant cell astrocytoma (SEGA) associated with TSC that requires therapeutic intervention but cannot be curatively resected 2. Age ≥ 1 year old <p>Initial approval: 1 year Continuation of treatment requires a lack of disease progression</p>
Evrysdi	<p>Coverage requires the following:</p> <p>Diagnosis of type 1, 2, or 3 Spinal Muscular Atrophy (SMA) confirmed by genetic testing AND</p> <ol style="list-style-type: none"> 1. Prescribed by or in consultation with a neurologist specializing in neuromuscular disorders 2. Submission of a baseline, age appropriate exam to establish baseline motor function and ability 3. Patient is not currently taking SMN2-targeting antisense oligonucleotide or SMN2 splicing modifier AND patient has not had gene therapy treatment for SMA (or being considered for treatment with any other gene therapy for SMA) 4. Patient is not requiring invasive ventilation or tracheostomy 5. The requesting physician attests to providing clinical outcome information within the Audaire Health™ provider portal as requested by BCBSM <p>Initial approval: 1 year Continuation of treatment requires submission of repeat motor ability assessment and documentation of response to therapy defined as a clinically significant improvement in SMA-associated motor milestones and motor function (for example, progression, stabilization, or decreased functional motor decline) compared to predicted natural history and progression</p>

Drug name	Current Blue Cross and BCN coverage criteria
exemestane (Aromasin)	Coverage for \$0 copayment will be provided when: <ol style="list-style-type: none"> 1. The member is a woman at least 35 years of age 2. The medication is being used for prevention of primary breast cancer 3. Members classified as high risk 4. Does not have a history of breast cancer 5. Member is currently post-menopausal 6. Member is not taking any estrogen containing products
Exservan	Coverage requires the following: <ol style="list-style-type: none"> 1. Diagnosis of Amyotrophic Lateral Sclerosis (ALS) 2. Trial of generic riluzole tablets OR <ol style="list-style-type: none"> 2. Difficulty swallowing Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit

Drug name	Current Blue Cross and BCN coverage criteria
Fabhalta	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of paroxysmal nocturnal hemoglobinuria (PNH) 2. Age ≥ 18 years old 3. Flow cytometric confirmation of PNH type III red cells 4. Had at least 1 transfusion in 6 months preceding Fabhalta <p>OR</p> <ol style="list-style-type: none"> 4. Documented history of major adverse thrombotic vascular events from thromboembolism <p>OR</p> <ol style="list-style-type: none"> 4. Patient has high disease activity defined as a lactic dehydrogenase (LDH) level ≥ 1.5 times the upper limit of normal with one of the following symptoms: <ol style="list-style-type: none"> a. Weakness b. Fatigue c. Hemoglobinuria d. Abdominal pain e. Dyspnea f. Hemoglobin < 10 g/dL g. A major vascular event h. Dysphagia i. Erectile dysfunction 5. Must not be used in combination with Soliris, Ultomiris, or other medications to treat PNH <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>

*For drugs covered under the commercial Blue Cross or BCN medical benefit, please see the [Blue Cross and BCN Utilization Management Medical Drug List](#)
Blue Cross Blue Shield of Michigan and Blue Care Network are nonprofit corporations and independent licensees of the Blue Cross and Blue Shield Association.

Drug name	Current Blue Cross and BCN coverage criteria
Fabior / tazarotene	<p>Coverage requires the following:</p> <p>Trial and failure, contraindication, or intolerance to both generic adapalene (Differin) and generic tretinoin (Retin-A, Avita)</p> <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>
Fanapt	<p>Coverage requires the following:</p> <p>Trial and failure, contraindication, or intolerance to two preferred second generation antipsychotics (examples include: aripiprazole, clozapine, risperidone, quetiapine, olanzapine, ziprasidone)</p> <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>
Farydak	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of multiple myeloma 2. Will be used in combination with bortezomib and dexamethasone 3. Has received at least 2 prior regimens, including bortezomib and an immunomodulatory agent (e.g. lenalidomide (Revlimid), or thalidomide (Thalomid)) <p>Initial approval: 1 year Continuation of treatment requires a lack of disease progression</p>

Drug name	Current Blue Cross and BCN coverage criteria
Fasenra pen	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of severe uncontrolled eosinophilic asthma 2. Age ≥ 12 years old 3. Patient is currently receiving and will continue to receive standard of care regimen 4. Severe eosinophilic asthma identified by: <ol style="list-style-type: none"> a. Blood eosinophils greater than or equal to 150 cells/microliter at at initiation of treatment AND b. Failure to maintain adequate control after at least a 3 month trial of daily oral corticosteroids or high dose inhaled corticosteroids in combination with: <ol style="list-style-type: none"> i. LABA (long acting inhaled β2 agonist) OR ii. Leukotriene modifier OR iii. LAMA (long acting muscarinic antagonist) in adults and children ≥ 12 years old 5. Cannot be used in combination with other biologic agents indicated for uncontrolled eosinophilic asthma <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>
fentanyl citrate buccal lollipop (Actiq)	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Medication is being used for the treatment of breakthrough cancer pain 2. Member is tolerant to high dose opioids 3. Currently receiving a long acting opioid 4. Treatment failure or intolerance to oral immediate release opioids (examples include, but not limited to: morphine, oxycodone, or hydrocodone containing products) <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>

Drug name	Current Blue Cross and BCN coverage criteria
Fentora / fentanyl citrate buccal tablet	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Medication is being used for the treatment of breakthrough cancer pain 2. Member is tolerant to high dose opioids 3. Currently receiving a long acting opioid 4. Treatment failure or intolerance to oral immediate release opioids (examples include, but not limited to: morphine, oxycodone, or hydrocodone containing products) 5. Treatment failure or intolerance to generic Actiq <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>
Filspari	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. To reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression 2. Age ≥ 18 years old 3. Trial and failure to maximally tolerated dose of angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) therapy unless contraindicated 4. Trial and failure, contraindication, or intolerance to generic methylprednisolone, prednisolone, or prednisone <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>

Drug name	Current Blue Cross and BCN coverage criteria
Filsuvez	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. For the treatment of wounds associated with dystrophic epidermolysis bullosa (DEB) and junctional epidermolysis bullosa (JEB) 2. Age ≥ 6 months old 3. Open wounds requiring treatment 4. Must not have current evidence or a history of malignancy (e.g., basal cell carcinoma, squamous cell carcinoma), or active infection in the area undergoing treatment 5. Must not have undergone stem cell transplant or gene therapy for the treatment of inherited epidermolysis bullosa <p>Initial approval: 6 months Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>
Firdapse	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Treatment of Lambert-Eaton myasthenic syndrome 2. Age ≥ 6 years old 3. Prescribed by a neurologist <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>
Flector / diclofenac epolamine 1.3% patch	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of acute pain due to minor strains, sprains or contusions 2. Trial of or intolerance to generic oral diclofenac and at least two other oral, traditional NSAIDs <p>Initial approval: 3 months Renewal requires that current criteria are met, and that the medication is providing clinical benefit Please note: Coverage will not be provided in the presence of concurrent therapy with oral NSAIDs</p>

Drug name	Current Blue Cross and BCN coverage criteria
Fleqsuvy	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. For the treatment of spasticity resulting from multiple sclerosis (MS) OR for individuals with other spinal cord diseases or injuries 2. Treatment failure of or intolerance to generic baclofen tablets <p>OR</p> <ol style="list-style-type: none"> 2. Member is unable to swallow tablets <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>
Fosamax Plus D	<p>Coverage requires trial and treatment failure or intolerance to two of the following:</p> <ol style="list-style-type: none"> 1. Actonel (risedronate) 2. Boniva (ibandronate) 3. Fosamax (alendronate) <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>
Fotivda	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Age ≥ 18 years old 2. Diagnosis of relapsed or refractory advanced renal cell carcinoma (RCC) 3. Received at least 2 prior systemic therapies <p>Initial approval: 1 year Continuation of treatment requires a lack of disease progression</p>

Drug name	Current Blue Cross and BCN coverage criteria
frovatriptan (Frova)	Coverage requires trial of 2 of the following generic triptans: Imitrex, Maxalt, Amerge, or Zomig/ZMT Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit
Fruzaqla	Coverage requires the following: <ol style="list-style-type: none"> 1. Diagnosis of metastatic colorectal cancer (mCRC), previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-vascular endothelial growth factor (VEGF) therapy, and, if RAS wild-type and medically appropriate, an anti-epidermal growth factor receptor (EGFR) therapy 2. Age ≥ 18 years old Initial approval: 1 year Continuation of treatment requires a lack of disease progression
Fulphila	Coverage requires trial and failure or intolerance to Neulasta and Ziextenzo
Furoscix	Coverage requires the following: <ol style="list-style-type: none"> 1. Diagnosis of New York Heart Association (NYHA) Class II or Class III chronic heart failure 2. Age ≥ 18 years old 3. Patient is experiencing an increase in signs and symptoms of congestion due to fluid overload 4. Established on background therapy with a loop diuretic 5. Patient is stable and does not require emergency care or hospitalization for heart failure, acute pulmonary edema, or other conditions Approval: 60 days

Drug name	Current Blue Cross and BCN coverage criteria
Galafold	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of Fabry's disease confirmed by genetic testing showing an amenable mutation in the GLA gene <ol style="list-style-type: none"> a. In addition for males: serum assay of enzyme α-galactosidase showing decreased activity in plasma and/or leukocytes 2. Age \geq 18 years old 3. Prescribed by or in consultation with a geneticist or metabolic specialist 4. Initiation of therapy should begin as follows: <ol style="list-style-type: none"> a. Males with classic disease: at time of diagnosis b. Females and males with atypical disease: once patient is showing symptoms of Fabry's disease <p>Galafold will not be approved for use in combination or with any other molecular chaperone or enzyme replacement therapy for Fabry's disease</p>
Gammagard, Gammaked, Gamunex-C	<p>Requires appropriate diagnosis for coverage, subcutaneous administration and other criteria may apply depending on diagnosis. Dosing must be based on ideal body weight (IBW) unless the patient's BMI is greater than 30. If the patient's BMI is greater than 30 or if actual body weight is 20-30% greater than IBW, adjusted body weight must be used.</p> <p>Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>
Gattex	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of Short Bowel Syndrome (SBS) 2. Dependent on parenteral support \geq 12 months <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit, defined as a reduction in \geq 20% of weekly parenteral nutrition volume or intravenous fluid volume</p>

Drug name	Current Blue Cross and BCN coverage criteria
Gavreto	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Age \geq 18 years old 2. Treatment of metastatic RET fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA-approved test <p>OR</p> <ol style="list-style-type: none"> 1. Age \geq 12 years old 2. Treatment of advanced or metastatic RET fusion-positive thyroid cancer that requires systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate) <p>Initial approval: 1 year Continuation of treatment requires a lack of disease progression</p>
Gelnique	<p>Coverage requires treatment failure or intolerance to at least 2 generic OAB (Overactive Bladder) therapies</p> <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>
gefitinib (Iressa)	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of metastatic non-small cell lung cancer (NSCLC) 2. Epidermal growth factor (EGFR) exon 19 deletions or exon 21 (I858R) substitution mutations as detected by an FDA-approved test <p>Initial approval: 1 year Continuation of treatment requires a lack of disease progression</p>

Drug name	Current Blue Cross and BCN coverage criteria
Gilotrif	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test <p>OR</p> <ol style="list-style-type: none"> 2. Diagnosis of metastatic squamous NSCLC that has progressed following platinum-based chemotherapy <p>Initial approval: 1 year Continuation of treatment requires a lack of disease progression</p>
Glassia	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Age \geq 18 years old 2. Must be a nonsmoker 3. Member must have pre-treatment serum levels of alpha-1 antitrypsin (AAT) that are less than 11 micromol/L measured by ELISA (less than 80 mg/dL measured by radial immunodiffusion or less than 57 mg/dL measured by nephelometry) consistent with phenotypes PiZZ, PiZ (null), or Pi (null, null) of AAT <ol style="list-style-type: none"> a. Phenotype/genotype testing may be requested for additional support of alpha-1 antitrypsin deficiency diagnosis 4. Member must have symptoms with their emphysema 5. Member must have deteriorating lung function, as demonstrated by a decline in the FEV1 (35-60% of predictive value) <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>
Gralise	Coverage requires trial of gabapentin

*For drugs covered under the commercial Blue Cross or BCN medical benefit, please see the [Blue Cross and BCN Utilization Management Medical Drug List](#)
Blue Cross Blue Shield of Michigan and Blue Care Network are nonprofit corporations and independent licensees of the Blue Cross and Blue Shield Association.

Drug name	Current Blue Cross and BCN coverage criteria
Grastek	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Age 5 through 65 years old 2. Diagnosis of grass pollen-induced allergic rhinitis, confirmed by positive skin test or in vitro testing for pollen-specific IgE antibodies for Timothy grass or cross-reactive grass pollens 3. Trial of one agent from each of the following classes: <ol style="list-style-type: none"> a. Intranasal corticosteroid b. Oral or intranasal antihistamine <p>Initial approval: 3 years Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>

Drug name	Current Blue Cross and BCN coverage criteria
<p>Growth Hormone (adults)</p> <p>Preferred Genotropin Norditropin</p> <p>Non-preferred Humatrope Omnitrope Saizen Sogroya Zomacton</p>	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Documentation of at least one known cause for pituitary disease or condition affecting pituitary function (i.e. pituitary tumor, traumatic brain injury, surgical damage, hypothalamic disease, irradiation, trauma, history of childhood growth hormone deficiency, or infiltrative disease), with one of the following (A, B, C, or D): <ol style="list-style-type: none"> A. Failed at least one clinically validated, clearly documented growth hormone stimulation test <ol style="list-style-type: none"> i. IGF-1 level below age and BMI-corrected lower limit of reference labs normal range ii. For suspected growth hormone deficiency due to traumatic brain injury, GH stimulation test must be administered at least one-year post brain injury iii. For history of childhood growth hormone deficiency, GH stimulation test to be done after growth hormone has been discontinued for at least one month <p>OR</p> <ol style="list-style-type: none"> B. Failed at least one clearly documented, clinically validated growth hormone stimulation test <ol style="list-style-type: none"> i. IGF-1 level below age and BMI-corrected lower limit of reference labs normal range ii. Documentation of two additional pituitary hormone deficiencies clearly of pituitary origin (other than growth hormone) requiring hormone replacement <p>OR</p> <ol style="list-style-type: none"> C. Documentation of three pituitary hormone deficiencies clearly of pituitary origin (other than growth hormone) requiring hormone replacement <ol style="list-style-type: none"> i. IGF-1 level below age and BMI-corrected lower limit of reference labs normal range <p>OR</p> <ol style="list-style-type: none"> D. Failed at least two clearly documented, clinically validated GH stimulation tests <ol style="list-style-type: none"> i. IGF-1 level below age and BMI-corrected lower limit of reference lab's normal range <p>OR</p> <ol style="list-style-type: none"> 1. Diagnosis of AIDS wasting cachexia 2. Unexplained weight loss > 10% of baseline 3. Concomitant anti-viral therapy for the duration of treatment <p>(criteria continued next page)</p>

Drug name	Current Blue Cross and BCN coverage criteria
Growth Hormone (adults) (continued)	OR <ol style="list-style-type: none"> 1. Diagnosis of short bowel syndrome 2. Receiving specialized nutritional support, which may include dietary adjustments, enteral feedings, parenteral nutrition, fluid and micronutrient supplements <p>Authorization period for short bowel syndrome: 4 weeks of treatment Coverage for a non-preferred medication requires treatment failure to ALL preferred medications (Genotropin and Norditropin)</p>
Growth Hormone (pediatrics) Preferred Genotropin Norditropin Non-preferred Humatrope Omnitrope Saizen Skytrofa Sogroya Zomacton	<p>Coverage requires documentation to support the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of Growth Hormone Deficiency with ONE of the following: <ol style="list-style-type: none"> a. 2 subnormal growth hormone stimulation tests, or b. 1 subnormal growth hormone stimulation test AND IGF-1 and IGFBP3 levels below normal for children of the same age and gender, or c. Documentation of a hypothalamic pituitary defect (such as a major congenital malformation, tumor, surgery, irradiation, or trauma) AND a deficiency in at least one additional pituitary hormone <p>AND</p> <ol style="list-style-type: none"> 2. Initial height measurements < 5th percentile for age and gender 3. Abnormal growth velocity for at least 6 months 4. Open epiphyses <p>OR</p> <ol style="list-style-type: none"> 1. Diagnosis of Growth Hormone Deficiency due to congenital hypopituitarism in a newborn 2. Documentation of hypoglycemia with associated with growth hormone levels <5 mcg/L <p>AND</p> <ol style="list-style-type: none"> a. Documentation of deficiency of at least one additional pituitary hormone, or b. Imaging to support a pituitary defect (such as ectopic posterior pituitary and pituitary hypoplasia with abnormal stalk) <p>OR</p> <ol style="list-style-type: none"> 1. Diagnosis of Turners Syndrome, SHOX deficiency, or Noonan Syndrome 2. Initial height measurements < 5th percentile for age and gender 3. Abnormal growth velocity for at least 6 months 4. Open epiphyses <p>(criteria continued next page)</p>

*For drugs covered under the commercial Blue Cross or BCN medical benefit, please see the [Blue Cross and BCN Utilization Management Medical Drug List](#)
 Blue Cross Blue Shield of Michigan and Blue Care Network are nonprofit corporations and independent licensees of the Blue Cross and Blue Shield Association.

Drug name	Current Blue Cross and BCN coverage criteria
Growth Hormone (pediatrics) (continued)	<p>OR</p> <ol style="list-style-type: none"> 1. Chronic Renal Insufficiency 2. Initial height measurements < 5th percentile for age and gender 3. Abnormal growth velocity for at least 6 months 4. Open epiphyses 5. If post-transplant – persistent growth failure without spontaneous catch up one year post-transplant and in whom steroid-free immunosuppression is not feasible <p>OR</p> <ol style="list-style-type: none"> 1. Small for Gestational Age (SGA) 2. Birth weight and/or length at least 2 standard deviations below the mean for gestational age 3. Fails to manifest catch-up growth by 2 years of age 4. Open epiphyses <p>Approved until 18th birthday</p> <p>OR</p> <ol style="list-style-type: none"> 1. Diagnosis of Prader-Willi Syndrome <p>OR</p> <ol style="list-style-type: none"> 1. Pediatric Burn 2. Burns over at least 40% of total body surface area <p>Initial approval: 1 year Coverage for a non-preferred medication requires treatment failure to ALL preferred medications (Genotropin and Norditropin)</p>

*For drugs covered under the commercial Blue Cross or BCN medical benefit, please see the [Blue Cross and BCN Utilization Management Medical Drug List](#)
 Blue Cross Blue Shield of Michigan and Blue Care Network are nonprofit corporations and independent licensees of the Blue Cross and Blue Shield Association.

Drug name	Current Blue Cross and BCN coverage criteria
Haegarda	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of hereditary angioedema (HAE) 2. Diagnosis confirmed by genetic testing or with the following laboratory findings: <ol style="list-style-type: none"> i. C4 level below the limits of the laboratory's normal reference range (normal range = 16-58 mg/dL) ii. C1INH (antigenic or function) below the limits of the laboratory's normal reference range (normal range ≥ 41%) 3. History of at least 2 HAE attacks per month OR a history of attacks that are considered severe with swelling of the face, throat or gastrointestinal tract 4. Prescribed by an immunologist, allergist or hematologist 5. Not to be used in combination with other products indicated for HAE prophylaxis <p>Initial approval: 1 year Renewal requires improvement in HAE demonstrated by a 50% reduction in the number of attacks OR the severity of HAE attacks was reduced by 50% or more</p>
Harvoni	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Age 3 years or older 2. Diagnosis of chronic hepatitis C genotype 1,4,5 or 6 3. If treatment experienced, documentation of previous treatment experience for Hepatitis C 4. If cirrhosis is present: documentation of decompensated or compensated cirrhosis <p>Drug will be reviewed on a case by case basis utilizing AASLD guidelines and FDA approved package labeling</p>
Harvoni oral pellets	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Age 3 years or older 2. Diagnosis of chronic hepatitis C genotype 1,4,5 or 6 3. If treatment experienced, documentation of previous treatment experience for Hepatitis C 4. If cirrhosis is present: documentation of decompensated or compensated cirrhosis <p>Drug will be reviewed on a case by case basis utilizing AASLD guidelines and FDA approved package labeling</p>

Drug name	Current Blue Cross and BCN coverage criteria
Hemlibra	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. For prophylaxis of bleeding episodes in patients diagnosed with congenital hemophilia A with inhibitors <ol style="list-style-type: none"> a. Prescribed and dispensed by a specialist that works in a hemophilia treatment center b. Documentation of a historical or current high titer for factor VIII inhibitors measuring > 5 Bethesda Units per milliliter (BU/mL) c. Will not be used in combination with Immune Tolerance Induction (ITI) d. Medication is dispensed by a treatment center associated with hemophilia that provides high quality hemophilia care with outcome based results (ie: hemophilia treatment centers) <p>OR</p> <ol style="list-style-type: none"> 2. For prophylaxis of spontaneous bleeding episodes in patients diagnosed with congenital hemophilia A without inhibitors <ol style="list-style-type: none"> a. Prescribed and dispensed by a specialist that works in a hemophilia treatment center b. Documentation of severe hemophilia A with factor VIII level <1% OR moderate hemophilia A with factor VIII level between 1%-5% c. Documentation of optimally dosed prophylactic factor VIII product is ineffective for the prevention of spontaneous bleeding events (such as: continuing to have bleeding events or arthroscopic changes within a target joint) d. Documentation of the number of bleeds experienced within the past 12 months e. Medication is dispensed by a treatment center associated with hemophilia that provides high quality hemophilia care with outcome based results (ie: hemophilia treatment centers) <p>Initial approval: 1 year Continuation of coverage will be provided when treatment has been proven successful through a decrease in the number of bleeds and absence of anti-drug antibodies that impact the clearance or efficacy of Hemlibra</p>

*For drugs covered under the commercial Blue Cross or BCN medical benefit, please see the [Blue Cross and BCN Utilization Management Medical Drug List](#). Blue Cross Blue Shield of Michigan and Blue Care Network are nonprofit corporations and independent licensees of the Blue Cross and Blue Shield Association.

Drug name	Current Blue Cross and BCN coverage criteria
Hetlioz LQ	Coverage requires the following: <ol style="list-style-type: none"> 1. Age 3 to 15 years old 2. Diagnosis of nighttime sleep disturbances in Smith-Magenis Syndrome (SMS) confirmed by genetic testing showing deletion of chromosome 17p11.2 OR mutation in the retinoic acid-induced 1 (RAI1) gene 3. Trial and failure, contraindication, or intolerance to over-the-counter melatonin AND acebutolol Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit
Horizant	Coverage requires trial of gabapentin

Drug name	Current Blue Cross and BCN coverage criteria
Humira	<p>Coverage requires the following:</p> <ul style="list-style-type: none"> 1. Diagnosis of Psoriatic Arthritis 2. Age ≥ 18 years old <p>OR</p> <ul style="list-style-type: none"> 1. Diagnosis of Rheumatoid Arthritis 2. Age ≥ 18 years old 3. Trial and treatment failure of one Disease Modifying Anti-Rheumatic Drug (DMARD) after a minimum 3-month trial (examples include methotrexate, hydroxychloroquine, leflunomide, sulfasalazine) <p>OR</p> <ul style="list-style-type: none"> 1. Diagnosis of Juvenile Idiopathic Arthritis (JIA) 2. Age ≥ 2 years old 3. Trial and treatment failure of one Disease Modifying Anti-Rheumatic Drug (DMARD) after a minimum 3-month trial (examples include methotrexate, leflunomide) <p>OR</p> <ul style="list-style-type: none"> 1. Diagnosis of Ankylosing Spondylitis 2. Age ≥ 18 years old <p>OR</p> <ul style="list-style-type: none"> 1. Diagnosis of Psoriasis 2. Age ≥ 18 years old 3. Trial and treatment failure of one topical steroid <p>OR</p> <ul style="list-style-type: none"> 1. Diagnosis of Crohn's Disease 2. Age ≥ 6 years old 3. Treatment with an adequate course of conventional therapy (such as steroids for 7 days, immunomodulators such as azathioprine for at least 2 months) has been ineffective or is contraindicated or not tolerated <p>(criteria continued next page)</p>

Drug name	Current Blue Cross and BCN coverage criteria
Humira (continued)	<p>OR</p> <ol style="list-style-type: none"> 1. Diagnosis of Ulcerative Colitis 2. Age \geq 5 years old 3. Treatment with an adequate course of conventional therapy (such as steroids for 7 days, immunomodulators such as azathioprine for at least 2 months) has been ineffective or is contraindicated or not tolerated <p>OR</p> <ol style="list-style-type: none"> 1. Diagnosis of Hidradenitis Suppurativa 2. Age \geq 12 years old 3. Previous 3-month trial of oral antibiotics <p>OR</p> <ol style="list-style-type: none"> 1. Diagnosis of Noninfectious Uveitis 2. Age \geq 2 years old 3. Trial of an oral corticosteroid 4. Trial of an oral immunomodulatory agent (examples include methotrexate, azathioprine, cyclosporine) <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>
hydrocodone bitartrate (Hysingla ER)	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of moderate to severe chronic pain requiring around the clock opioid analgesia for an extended period of time 2. Trial and failure or intolerance to three generic long-acting opioids (examples include, but not limited to: buprenorphine transdermal patch, tramadol, morphine, fentanyl, and methadone) <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit Note: Coverage will not be provided if the patient is on more than one long acting opioid concurrently</p>

Drug name	Current Blue Cross and BCN coverage criteria
hydrocodone bitartrate (Zohydro ER)	Coverage requires the following: <ol style="list-style-type: none"> 1. Diagnosis of moderate to severe chronic pain requiring around the clock opioid analgesia for an extended period of time 2. Trial and failure or intolerance to three generic long-acting opioids (examples include, but not limited to: buprenorphine transdermal patch, tramadol, morphine, fentanyl, and methadone) Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit Note: Coverage will not be provided if the patient is on more than one long acting opioid concurrently
hydromorphone (Exalgo)	Coverage requires the following: <ol style="list-style-type: none"> 1. Diagnosis of moderate to severe chronic pain requiring around the clock opioid analgesia for an extended period of time 2. Trial and failure or intolerance to three generic long-acting opioids (examples include, but not limited to: buprenorphine transdermal patch, tramadol, morphine, fentanyl, and methadone) Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit. Note: Coverage will not be provided if the patient is on more than one long acting opioid concurrently.
Hyftor	Coverage requires the following: <ol style="list-style-type: none"> 1. Diagnosis of facial angiofibroma associated with tuberous sclerosis 2. Age ≥ 6 years old Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit

Drug name	Current Blue Cross and BCN coverage criteria
HyQvia	<p>Requires appropriate diagnosis for coverage, subcutaneous administration and other criteria may apply depending on diagnosis. Dosing must be based on ideal body weight (IBW) unless the patient's BMI is greater than 30. If the patient's BMI is greater than 30 or if actual body weight is 20-30% greater than IBW, adjusted body weight must be used</p> <p>Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>
Ibrance	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Initial therapy for the diagnosis of HR-positive, HER-2 negative advanced or metastatic breast cancer 2. Using in combination with an aromatase inhibitor <p>OR</p> <ol style="list-style-type: none"> 1. Diagnosis of HR-positive, HER-2 negative advanced or metastatic breast cancer in patients with disease progression following endocrine therapy 2. Using in combination with fulvestrant <p>Initial approval: 1 year Continuation of treatment requires a lack of disease progression</p>
Ibsrela	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Trial and treatment failure or intolerance to lactulose or polyethylene glycol 2. Trial and treatment failure or intolerance to Linzess <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>

Drug name	Current Blue Cross and BCN coverage criteria
icatibant (Firazyr)	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Treatment of acute attacks of hereditary angioedema (HAE) 2. Diagnosis confirmed by genetic testing or with the following laboratory findings: <ol style="list-style-type: none"> i. C4 level below the limits of the laboratory's normal reference range (normal range = 16-58 mg/dL) ii. C1INH (antigenic or function) below the limits of the laboratory's normal reference range (normal range \geq 41%) 3. Prescribed by an immunologist, allergist or hematologist 4. Not to be used in combination with other products indicated for acute HAE attacks <p>Initial approval: 1 year Renewal requires objective data documenting at least 50% improvement in time to relief of symptoms of acute attacks and maintenance of improvement of symptoms</p>
Iclusig	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Age \geq18 years old 2. Diagnosis of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) for whom no other tyrosine kinase inhibitor therapy is indicated or who are T315I-positive <p>OR</p> <ol style="list-style-type: none"> 2. Treatment of chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) for whom no other tyrosine kinase inhibitor therapy is indicated or who are T315I-positive <p>OR</p> <ol style="list-style-type: none"> 2. Treatment of chronic phase (CP) chronic myeloid leukemia (CML) with resistance or intolerance to at least two prior kinase inhibitors <p>Initial approval: 1 year Continuation of treatment requires a lack of disease progression</p>

Drug name	Current Blue Cross and BCN coverage criteria
Idhifa	Coverage requires the following: <ol style="list-style-type: none"> 1. Treatment of relapsed or refractory acute myeloid leukemia (AML) 2. Isocitrate dehydrogenase-2 (IDH2) mutation Initial approval: 1 year. Continuation of treatment requires a lack of disease progression
Imbruvica	Coverage requires the treatment of FDA approved indications Initial approval: 1 year Continuation of treatment requires a lack of disease progression

Drug name	Current Blue Cross and BCN coverage criteria
Imcivree	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Age ≥ 6 years old 2. Diagnosis of proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency confirmed by genetic testing 3. Genetic testing must demonstrate that the variants in POMC, PCSK1, or LEPR genes are interpreted as pathogenic, likely pathogenic, or of uncertain significance 4. Current weight and BMI (within 30 days) must be submitted to the plan for review 5. Patient has obesity defined as: <ol style="list-style-type: none"> a. Adults patients: BMI ≥ 30 kg/m² b. Pediatric patients: BMI ≥ 95th percentile for children and teens of the same age and sex <p>OR</p> <ol style="list-style-type: none"> 1. Age ≥ 6 years old 2. Diagnosis of Bardet-Biedl syndrome (BBS) 3. Current weight and BMI (within 30 days) must be submitted to the plan for review 4. Patient has obesity defined as: <ol style="list-style-type: none"> a. Adult patients: BMI ≥ 30 kg/m² b. Pediatric patients: BMI ≥ 95th percentile for children and teens of the same age and sex <p>Initial approval for POMC, PCSK1, or LEPR deficiency: 4 months Initial approval for BBS: 1 year Continued coverage will be reviewed annually and may be provided if the member has maintained at least a 5% reduction in baseline body weight OR at least a 5% reduction in baseline BMI for patients with continued growth potential</p>

Drug name	Current Blue Cross and BCN coverage criteria
imiquimod (Zyclara)	Coverage requires the following: <ol style="list-style-type: none"> 1. Age ≥ 18 years old 2. Diagnosis of actinic keratosis 3. Trial and failure or intolerance to cryotherapy or phototherapy 4. Trial and treatment failure or intolerance to a generic or preferred topical fluorouracil 5. Trial and treatment failure or intolerance to generic imiquimod 5% OR <ol style="list-style-type: none"> 1. Age ≥ 12 years old 2. Diagnosis of genital or perianal warts Initial approval: 60 days Renewal requires recurrence and or new lesions
Inbrija	Coverage requires the following: <ol style="list-style-type: none"> 1. Treatment of intermittent OFF episodes in patients with Parkinson's Disease 2. Currently experiencing "off" episodes while taking carbidopa/levodopa 3. Using in combination with carbidopa/levodopa Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit

Drug name	Current Blue Cross and BCN coverage criteria
Increlex	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of one of the following: <ol style="list-style-type: none"> a. Severe primary IGF-1 deficiency b. Growth hormone gene deletion c. Genetic mutation of growth hormone receptor (Laron Syndrome) 2. Current height measurement greater than or equal to 3 standard deviations below normal for age and sex 3. IGF-1 level greater than or equal to 3 standard deviations below normal for age and sex 4. Normal or elevated growth hormone levels based on at least one growth hormone stimulation test 5. Open epiphyses <p>Initial approval: 1 year Continued coverage requires documentation of growth velocity of > 2 cm/year and open epiphyses</p>
Ingrezza	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of tardive dyskinesia 2. Age ≥ 18 years old <p>OR</p> <ol style="list-style-type: none"> 1. Diagnosis of chorea associated with Huntington's disease 2. Age ≥ 18 years old 3. Trial and failure, contraindication or intolerance to generic Xenazine (tetrabenazine) <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>

Drug name	Current Blue Cross and BCN coverage criteria
Inlyta	Coverage requires the following <ol style="list-style-type: none"> 1. Diagnosis of advanced Renal Cell Carcinoma (RCC) AND <ol style="list-style-type: none"> 2. Used in combination with Bavencio (avelumab) as first-line treatment OR <ol style="list-style-type: none"> 2. Used in combination with Keytruda (pembrolizumab) as first-line treatment OR <ol style="list-style-type: none"> 2. After treatment failure of one prior therapy
Inqovi	Coverage requires the following: <ol style="list-style-type: none"> 1. Diagnosis of myelodysplastic syndromes 2. Age ≥ 18 years old Initial approval: 1 year Continuation of treatment requires a lack of disease progression
lwilfin	Coverage requires the following: <ol style="list-style-type: none"> 1. To reduce the risk of relapse for the diagnosis of high-risk neuroblastoma (HRNB) 2. Previously demonstrated at least a partial response to prior multiagent, multimodality therapy including anti-GD2 immunotherapy 3. Age ≥ 4 years old Initial approval: 1 year Continuation of treatment requires a lack of disease progression

Drug name	Current Blue Cross and BCN coverage criteria
Jakafi	<p>Coverage requires the following:</p> <ul style="list-style-type: none"> 1. Diagnosis of intermediate or high risk myelofibrosis 2. Prescribing physician is an oncologist/hematologist <p>OR</p> <ul style="list-style-type: none"> 1. Diagnosis of polycythemia vera 2. Trial of hydroxyurea 3. Prescribing physician is an oncologist or hematologist <p>OR</p> <ul style="list-style-type: none"> 1. Diagnosis of acute graft-versus-host disease (GVHD) 2. Trial and failure, contraindication, or intolerance to systemic glucocorticoids 3. Age ≥ 12 years old <p>OR</p> <ul style="list-style-type: none"> 1. Diagnosis of chronic graft-versus-host disease (cGVHD) 2. Trial and failure, or intolerance to one or two lines of systemic therapy 3. Age ≥ 12 years old <p>Initial approval: 6 months Continuation of treatment requires a lack of disease progression</p>
Jatenzo	<p>Coverage requires the following:</p> <ul style="list-style-type: none"> 1. Diagnosis of male hypogonadism 2. Two signs and symptoms specific to testosterone deficiency 3. Trial and failure, contraindication or intolerance to one generic or preferred testosterone product (examples include generic Androgel, Androderm, and generic Depo-Testosterone) <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>

Drug name	Current Blue Cross and BCN coverage criteria
Jaypirca	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of relapsed or refractory mantle cell lymphoma (MCL) 2. Age ≥ 18 years old 3. Failure of least two lines of systemic therapy, including a Bruton tyrosine kinase (BTK) inhibitor <p>OR</p> <ol style="list-style-type: none"> 1. Diagnosis of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) 2. Age ≥ 18 years old 3. Failure of at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor <p>Initial approval: 1 year Continuation of treatment requires a lack of disease progression</p>
Joenja	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) with an associated PI3Kδ mutation <ol style="list-style-type: none"> a. Documented variant in either PIK3CD or PIK3R1 2. Documented symptoms associated with APDS such as: <ol style="list-style-type: none"> a. Nodal and/or extranodal lymphoproliferation, history of repeated oto-sino-pulmonary infections and/or organ dysfunction (e.g. lung, liver) 3. Age ≥ 12 years old 4. Member will not use concurrently with an immunosuppressive medication <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>

Drug name	Current Blue Cross and BCN coverage criteria
Jornay PM	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of Attention Deficit Hyperactivity Disorder 2. Age ≥ 6 years old 3. Treatment failure or intolerance to both a generic methylphenidate and a generic amphetamine product, one of which must be a long-acting formulation <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>
Jublia	<p>Coverage requires trial of generic Penlac 8% solution</p>
Juxtapid	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of homozygous familial hypercholesterolemia (HoFH) 2. Receiving optimal adjunctive therapies including a low-fat diet and other lipid-lowering treatments 3. Trial and treatment failure of Repatha <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>
Jynarque	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Patient is ≥ 18 years of age 2. Diagnosis of autosomal dominant polycystic kidney disease (ADPKD) <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>

Drug name	Current Blue Cross and BCN coverage criteria
Kalydeco	Coverage requires the following: <ol style="list-style-type: none"> 1. Diagnosis of Cystic Fibrosis (CF) 2. FDA approved gene mutation confirmed by genetic testing Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit
Karbinal ER	Coverage requires trial and treatment failure of generic carbinoxamine and two other generic antihistamines
Kerendia	Coverage requires the following: <ol style="list-style-type: none"> 1. Age ≥ 18 years old 2. Diagnosis of chronic kidney disease associated with type 2 diabetes 3. Being used to reduce the risk of renal function decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit

*For drugs covered under the commercial Blue Cross or BCN medical benefit, please see the [Blue Cross and BCN Utilization Management Medical Drug List](#)
 Blue Cross Blue Shield of Michigan and Blue Care Network are nonprofit corporations and independent licensees of the Blue Cross and Blue Shield Association.

Drug name	Current Blue Cross and BCN coverage criteria
Kevzara	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of Rheumatoid Arthritis 2. Age ≥ 18 years old 3. Trial and treatment failure with one Disease Modifying Anti-Rheumatic Drug (DMARD) after a minimum 3-month trial (examples include methotrexate, hydroxychloroquine, leflunomide, sulfasalazine) 4. Trial and treatment failure of two of the following: Enbrel, Humira, Rinvoq, Cimzia, Simponi, or Xeljanz/XR 5. Trial and treatment failure of Actemra and Oencia <p>OR</p> <ol style="list-style-type: none"> 1. Diagnosis of polymyalgia rheumatica 2. Age ≥ 18 years old 3. History of treatment with corticosteroids at a dose of > 10 mg per day prednisone equivalent for at least 8 weeks 4. Inadequate response or intolerance to corticosteroids as demonstrated by a disease flare during corticosteroid taper <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>

Drug name	Current Blue Cross and BCN coverage criteria
Kineret	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of Rheumatoid Arthritis 2. Age ≥ 18 years old 3. Trial and treatment failure of one Disease Modifying Anti-Rheumatic Drug (DMARD) after a minimum 3-month trial (examples include methotrexate, hydroxychloroquine, leflunomide, sulfasalazine) 4. Trial and treatment failure of two of the following: Enbrel, Humira, Cimzia, Simponi, Rinvoq, or Xeljanz/XR 5. Trial and treatment failure of Actemra and Orencia <p>OR</p> <ol style="list-style-type: none"> 1. Diagnosis of Cryopyrin-Associated Periodic Syndromes (CAPS) with phenotype: Neonatal-onset multisystem inflammatory disease (NOMID) 2. Laboratory evidence of a genetic mutation OR elevated inflammatory markers plus at least two of six typical CAPS manifestations: (urticaria-like rash, cold-triggered episodes, hearing loss, musculoskeletal symptoms, chronic aseptic meningitis, or skeletal abnormalities) <p>OR</p> <ol style="list-style-type: none"> 1. Diagnosis of Still's disease: including adult onset Still's disease (AOSD) and systemic juvenile idiopathic arthritis (sJIA) 2. Trial and treatment failure of one of the following therapies: glucocorticoids or NSAIDs <p>OR</p> <ol style="list-style-type: none"> 1. Diagnosis of deficiency of interleukin-1 receptor antagonist (DIRA) 2. Laboratory evidence of homozygous genetic mutations of IL1RN <p>OR</p> <ol style="list-style-type: none"> 1. Diagnosis of recurrent pericarditis (RP) 2. Age ≥ 12 years old 3. Trial and treatment failure or intolerance to nonsteroidal anti-inflammatory drugs (NSAIDs) in combination with colchicine <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>

*For drugs covered under the commercial Blue Cross or BCN medical benefit, please see the [Blue Cross and BCN Utilization Management Medical Drug List](#)
Blue Cross Blue Shield of Michigan and Blue Care Network are nonprofit corporations and independent licensees of the Blue Cross and Blue Shield Association.

Drug name	Current Blue Cross and BCN coverage criteria
Kisqali	<p>Coverage requires the diagnosis of HR-positive, HER-2 negative advanced or metastatic breast cancer and ONE of the following:</p> <ul style="list-style-type: none"> a. Using in combination with an aromatase inhibitor as initial endocrine-based therapy <p>OR</p> <ul style="list-style-type: none"> b. Using in combination with fulvestrant as initial endocrine-based therapy in postmenopausal women or in men <p>OR</p> <ul style="list-style-type: none"> c. Using in combination with fulvestrant following disease progression on endocrine therapy in postmenopausal women or in men <p>Initial approval: 1 year Continuation of treatment requires a lack of disease progression</p>
Kisqali Femara Co-Pack	<p>Coverage requires the following:</p> <ul style="list-style-type: none"> 1. Treatment of FDA approved indications <p>Initial approval: 1 year Continuation of treatment requires a lack of disease progression</p>
Koselugo	<p>Coverage requires the following:</p> <ul style="list-style-type: none"> 1. Age ≥ 2 years old 2. Diagnosis of Neurofibromatosis Type 1 (NF1) 3. Diagnosis made using either genetic testing or diagnostic criteria established by the National Institutes of Health (NIH) <p>OR</p> <ul style="list-style-type: none"> 3. Receiving treatment by or in consultation with a neurofibromatosis clinic <p>Initial approval: 6 months Continuation of treatment requires a lack of disease progression</p>

Drug name	Current Blue Cross and BCN coverage criteria
Krazati	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA approved test 2. Age ≥ 18 years old 3. Received at least one prior systemic therapy <p>Initial approval: 1 year Continuation of treatment requires a lack of disease progression</p>
Kyzatrex	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of male hypogonadism 2. Two signs and symptoms specific to testosterone deficiency <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>
lapatinib (Tykerb)	Coverage is provided for the treatment of FDA approved indications

Drug name	Current Blue Cross and BCN coverage criteria
Lenvima	<p>Coverage requires the following:</p> <ul style="list-style-type: none"> 1. Diagnosis of locally recurrent or metastatic, progressive differentiated thyroid cancer (DTC) <ul style="list-style-type: none"> a. Progression of disease after treatment with standard therapy <p>OR</p> <ul style="list-style-type: none"> 1. Diagnosis of advanced renal cell carcinoma <ul style="list-style-type: none"> a. Using as first-line treatment in combination with pembrolizumab <p>OR</p> <ul style="list-style-type: none"> b. Treatment failure to one prior anti-angiogenic therapy AND using in combination with everolimus <p>OR</p> <ul style="list-style-type: none"> 1. Diagnosis of unresectable hepatocellular carcinoma <p>OR</p> <ul style="list-style-type: none"> 1. Diagnosis of advanced endometrial carcinoma <ul style="list-style-type: none"> a. Progression of disease after prior systemic therapy b. Not a candidate for curative surgery or radiation c. Using in combination with pembrolizumab <p>Initial approval: 1 year Continuation of treatment requires a lack of disease progression</p>
Levorphanol	<p>Coverage requires the following:</p> <ul style="list-style-type: none"> 1. When used for as needed pain: Treatment failure or intolerance to three generic immediate release opioids (examples include, but not limited to: tramadol, morphine, hydrocodone, and oxycodone containing products) <p>OR</p> <ul style="list-style-type: none"> 1. When used for chronic pain requiring around-the-clock analgesia: Treatment failure or intolerance to three generic long-acting opioids. Examples include but are not limited to: buprenorphine transdermal patch, tramadol extended release, morphine extended release, fentanyl, methadone. <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit Note: Coverage will not be provided if the patient is on more than one long acting opioid concurrently</p>

Drug name	Current Blue Cross and BCN coverage criteria
Litfulo	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of severe Alopecia Areata (AA), defined as $\geq 50\%$ scalp hair loss OR 21-49% scalp hair loss with at least one of the following: <ol style="list-style-type: none"> a. Significant impact on psychosocial functioning resulting from AA b. Eyebrow or eyelash involvement c. Inadequate response to previous treatment after at least 6 months d. Diffuse (multifocal) positive hair pull test consistent with rapidly progressive AA 2. Age ≥ 12 years old 3. Cannot be used in combination with other biologic agents or targeted DMARDs indicated for AA <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>
Livmarli	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Treatment of cholestatic pruritus in patients with a diagnosis Alagille syndrome (ALGS) confirmed by documentation of ONE of the following: <ol style="list-style-type: none"> i. Genetic testing shows presence of the JAG1 or NOTCH2 genetic mutation ii. Liver biopsy shows bile duct scarcity iii. Involvement of 3 of 7 of the main organ systems affected in ALGS: hepatic, ocular, skeletal, vascular, facial, cardiac, or renal involvement 2. Age ≥ 3 months old 3. No history of liver transplant or planned future transplant 4. No clinical evidence of decompensated cirrhosis 5. Trial and failure, contraindication, or intolerance to generic ursodiol <p>Initial approval: 6 months Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>

Drug name	Current Blue Cross and BCN coverage criteria
Livtency	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of post-transplant cytomegalovirus (CMV) infection/disease 2. Age ≥ 12 years old and weight ≥ 35 kg 3. Trial and treatment failure of one of the following: ganciclovir, valganciclovir, cidofovir or foscarnet <p>Initial approval: 3 months</p>
Lonsurf	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of metastatic colorectal cancer 2. Previous treatment with <ol style="list-style-type: none"> a. fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy b. anti-VEGF biological therapy 3. Test results showing RAS wild type have received treatment with an anti-EGFR therapy 4. Using alone or in combination with bevacizumab <p>OR</p> <ol style="list-style-type: none"> 1. Diagnosis of metastatic gastric or gastroesophageal junction adenocarcinoma 2. Previous treatment with at least 2 lines of chemotherapy prior systemic therapies which included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and a HER2/neu-targeted therapy (if appropriate) <p>Initial approval: 1 year Continuation of treatment requires a lack of disease progression</p>
Lorbrena	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Age ≥ 18 years old 2. Diagnosis of metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test

Drug name	Current Blue Cross and BCN coverage criteria
Iuliconazole	Coverage requires the following: <ol style="list-style-type: none"> 1. Diagnosis of tinea pedis, tinea cruris or tinea corporis 2. Treatment failure of 2 topical over-the-counter antifungal agents 3. Treatment failure of two oral generic antifungal agents (fluconazole, itraconazole or terbinafine)
Lumakras	Coverage requires the following: <ol style="list-style-type: none"> 1. Age ≥ 18 years old 2. Diagnosis of KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test 3. Received at least one prior systemic therapy Initial approval: 1 year Continuation of treatment requires a lack of disease progression
Lumryz	Coverage requires the following: <ol style="list-style-type: none"> 1. Diagnosis of narcolepsy and cataplexy 2. Age ≥ 18 years old 3. Trial and failure, contraindication, or intolerance to Wakix OR <ol style="list-style-type: none"> 1. Diagnosis of narcolepsy and excessive daytime sleepiness 2. Age ≥ 18 years old 3. Trial and failure, contraindication, or intolerance to at least one generic or preferred treatment such as methylphenidate or dextroamphetamine 4. Trial and failure, contraindication, or intolerance to modafinil or armodafinil, AND Sunosi, AND Wakix Lumryz will not be approved if patient is being treated with sedative hypnotic agents, other central nervous system (CNS) depressants or using alcohol Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit

Drug name	Current Blue Cross and BCN coverage criteria
Lynparza	Coverage requires the treatment of FDA approved indications Initial approval: 1 year Continuation of treatment requires a lack of disease progression
Lytgobi	Coverage requires the following: <ol style="list-style-type: none"> 1. Diagnosis of previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements 2. Age ≥ 18 years old Initial approval: 1 year Continuation of treatment requires a lack of disease progression
Lyvispah	Coverage requires the following: <ol style="list-style-type: none"> 1. Diagnosis of spasticity 2. Trial of baclofen tablets OR <ol style="list-style-type: none"> 2. Member is unable to swallow tablets Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit
Mavenclad	Coverage requires trial and failure or intolerance to one generic or preferred medication for the treatment of multiple sclerosis such as Avonex, Bafiertam, Betaseron, Copaxone, Kesimpta, or Vumerity

Drug name	Current Blue Cross and BCN coverage criteria
Mavyret	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Age ≥ 3 years old 2. Diagnosis of chronic hepatitis C genotype 1, 2, 3, 4, 5, or 6 3. If treatment experienced, documentation of previous treatment experience for Hepatitis C 4. Patients with HCV genotype 1 who have previously been treated with regimens containing an NS5A (nonstructural protein 5A) inhibitor or an NS3/4A protease inhibitor, but not both 6. If cirrhosis is present: documentation of decompensated or compensated cirrhosis <p>Drug will be reviewed on a case by case basis utilizing AASLD guidelines and FDA approved package labeling</p>

Drug name	Current Blue Cross and BCN coverage criteria
Mekinist	<p>Coverage requires the following:</p> <ul style="list-style-type: none"> 1. Diagnosis of melanoma 2. Presence of BRAF V600E or V600K mutation 3. Using as a single agent or in combination with Tafinlar (dabrafenib) <p>OR</p> <ul style="list-style-type: none"> 1. Diagnosis of metastatic non-small cell lung cancer or advanced or metastatic anaplastic thyroid cancer 2. Presence of BRAF V600 E mutation 3. Using in combination with Tafinlar (dabrafenib) <p>OR</p> <ul style="list-style-type: none"> 1. Age ≥ 1 year old 2. Diagnosis of unresectable or metastatic solid tumors who have progressed following prior treatment and have no satisfactory alternative treatment options 3. Presence of with BRAF V600E mutation 4. Using in combination with Tafinlar (dabrafenib) <p>OR</p> <ul style="list-style-type: none"> 1. Age ≥ 1 year old 2. Diagnosis of low-grade glioma (LGG) with a BRAF V600E mutation requiring systemic therapy 3. Using in combination with Tafinlar <p>Initial approval: 1 year Continuation of treatment requires a lack of disease progression</p>

Drug name	Current Blue Cross and BCN coverage criteria
Mektovi	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of unresectable or metastatic melanoma with a BRAF V600E or V600K mutation as detected by an FDA-approved test 2. Using in combination with Braftovi <p>OR</p> <ol style="list-style-type: none"> 1. Diagnosis of metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation as detected by an FDA approved test 2. Using in combination with Braftovi <p>Initial approval: 1 year Continuation of treatment requires a lack of disease progression</p>
meloxicam capsule (Vivlodex)	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Age ≥ 18 years old 2. Diagnosis of osteoarthritis 3. Trial and failure of generic Mobic (meloxicam tablet) 4. Trial and failure of two other preferred oral NSAIDs <p>Initial approval: 1 year</p>
metformin hcl extended release (Fortamet)	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Age ≥ 18 years old 2. Diagnosis of type 2 diabetes mellitus 3. Trial and treatment failure or intolerance to generic Glucophage XR (metformin extended release) <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>

Drug name	Current Blue Cross and BCN coverage criteria
methylergonovine (Methergine)	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Management of uterine atony, hemorrhage, and subinvolution of the uterus following delivery of the placenta or control of uterine hemorrhage following delivery of the anterior shoulder in the second stage of labor <p>OR</p> <ol style="list-style-type: none"> 1. Being used for the prevention of migraine headaches 2. Member has persistent history of recurring debilitating headaches (4 or more headache days per month with migraine headache lasting for 4 hours per day or longer) 3. Trial and treatment failure after a minimum of 2 month trial, contraindication, or intolerance to three of the following: <ol style="list-style-type: none"> a. Anticonvulsants b. ACE inhibitors or angiotensin receptor blockers c. Beta blockers d. Calcium channel blockers e. Antidepressants f. Botulinum toxin 4. Trial and treatment failure after a minimum 2 month trial, contraindication, or intolerance to at least one calcitonin gene related peptide (CGRP) antagonist (such as: Aimovig, Ajovy, Emgality, or Vyepti) <p>OR</p> <ol style="list-style-type: none"> 1. Being used for the treatment of episodic or chronic cluster headache 2. Trial and failure, contraindication, or intolerance to at least three of the following: suboccipital steroid injection, verapamil, lithium, melatonin, frovatriptan, prednisone, or topiramate 3. Trial and failure, contraindication, or intolerance to Emgality <p>Initial approval: 6 months Renewal requires that current criteria are met, and that the medication is providing clinical benefit. For headache indications, the member must have at least a 1 month drug holiday after 3-6 months of therapy has occurred prior to restarting methylergonovine</p>

Drug name	Current Blue Cross and BCN coverage criteria
methylphenidate ER 72mg	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of ADHD (attention deficit hyperactivity disorder) 2. Age \geq 6 years old 3. Treatment failure or intolerance to one generic methylphenidate or generic amphetamine product <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>
Miebo	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of dry eye disease (DED) 2. Age \geq 18 years old 3. Trial and failure or intolerance to two generic or preferred medications for the treatment of DED <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>

Drug name	Current Blue Cross and BCN coverage criteria
mifepristone (Korlym)	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Member is ≥ 18 years of age 2. Diagnosis of hypercortisolism as a result of endogenous Cushing's Syndrome 3. Diagnosis of type II diabetes mellitus (DM) or glucose intolerance secondary to hypercortisolism 4. Surgical treatment has been ineffective or not a candidate for surgery 5. Treatment failure or intolerance to a steroidogenesis inhibitor (such as ketoconazole, mitotane, or cabergoline), unless contraindicated 6. Failure to achieve adequate blood glucose control with maximally titrated therapy with an antidiabetic agent given for at least 3 months and which does not include metformin 7. Documentation of baseline 2 – hour glucose tolerance test if diagnosis is glucose intolerance 8. HbA1c is required if diagnosis is type II DM <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>
miglustat (Zavesca, Yargesa)	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Age ≥ 18 years old 2. For the treatment of mild to moderate Gaucher disease type 1 (GD1) 3. Confirmation of diagnosis by biochemical assay showing decreased glucocerebrosidase activity in white blood cells or skin fibroblasts AND genotyping revealing two pathogenic mutations of the glucocerebrosidase gene 4. Two symptomatic manifestations of the disease are present, such as anemia, thrombocytopenia, bone disease, hepatomegaly, or splenomegaly 5. Trial and failure, contraindication, or intolerance to enzyme replacement therapy (ERT) <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>

Drug name	Current Blue Cross and BCN coverage criteria
Motegrity	Coverage requires the following: Trial and treatment failure or intolerance to Linzess Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit
Mounjaro	Coverage requires the following: <ol style="list-style-type: none"> 1. For the treatment of Type 2 Diabetes or trial of one generic or preferred medication for the treatment of Type 2 Diabetes 2. Cannot be used in combination with other glucagon-like peptide-1 (GLP-1) agonist-containing products Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit
Mulpleta	Coverage requires the following: <ol style="list-style-type: none"> 1. Treatment of thrombocytopenia in chronic liver disease 2. Scheduled to undergo a procedure 3. Age ≥ 18 years old Approval: 60 days
Myalept	Coverage requires the following: <ol style="list-style-type: none"> 1. Replacement therapy to treat the complications of leptin deficiency, in addition to diet, in patients with congenital or acquired generalized lipodystrophy. 2. Optimally treated with insulin 3. Optimally treated with a statin (examples include atorvastatin, simvastatin)

Drug name	Current Blue Cross and BCN coverage criteria
Myfembree	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women 2. Age ≥ 18 years old 3. Trial of two hormone related therapies <p>OR</p> <ol style="list-style-type: none"> 1. Treatment of pain associated with endometriosis in premenopausal women 2. Age ≥ 18 years old 3. Trial of two hormone related therapies <p>Myfembree will be approved for a maximum of two years</p>
Myrbetriq granules	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of neurogenic detrusor overactivity (NDO) 2. Age ≥ 3 years old 3. Trial and treatment failure or intolerance to two generic anticholinergic agents for the treatment of NDO <p>OR</p> <ol style="list-style-type: none"> 3. Member cannot swallow tablets/capsules AND has tried and failed an anticholinergic medication available as a solution <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>

Drug name	Current Blue Cross and BCN coverage criteria
Myrbetriq tablets	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of overactive bladder (OAB) 2. Age ≥ 18 years old 3. Trial and treatment failure or intolerance to two preferred therapies for OAB <p>OR</p> <ol style="list-style-type: none"> 1. Diagnosis of neurogenic detrusor overactivity (NDO) 2. Weight ≥ 35 kg 3. Trial and treatment failure or intolerance to two generic anticholinergic agents for the treatment of NDO <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>
Natesto	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of male hypogonadism 2. Two signs and symptoms specific to testosterone deficiency 3. Trial and failure, contraindication or intolerance to one generic or preferred testosterone product (examples include generic AndroGel, Androderm, and generic Depo-Testosterone) <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>
Natpara	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Using as an adjunct to calcium and Vitamin D to control hypocalcemia in patients with hypoparathyroidism 2. Currently on calcium and Vitamin D and hypocalcemia is not well controlled

Drug name	Current Blue Cross and BCN coverage criteria
Nerlynx	Coverage requires the following: <ol style="list-style-type: none"> 1. Diagnosis of early stage HER2 positive breast cancer 2. Previous treatment with trastuzumab (Herceptin)-based therapy OR <ol style="list-style-type: none"> 1. Diagnosis of advanced or metastatic HER2 positive breast cancer 2. Previous treatment with two or more anti-HER2 based regimens 3. Using in combination with capecitabine
Nexletol	Coverage requires the following: <ol style="list-style-type: none"> 1. Diagnosis of established atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia 2. Age ≥ 18 years old 3. Trial of ezetimibe AND <ol style="list-style-type: none"> 4. Trial with one high intensity statin at maximum tolerated dose OR <ol style="list-style-type: none"> 4. History of statin intolerance (skeletal muscle related symptoms) after a trial of two generic statins (examples include: Crestor, Lescol, Lipitor, Livalo, Mevacor, Pravachol, Zocor) OR <ol style="list-style-type: none"> 4. History of rhabdomyolysis after a trial of one statin (Examples include: Crestor, Lescol, Lipitor, Livalo, Mevacor, Pravachol, Zocor)

Drug name	Current Blue Cross and BCN coverage criteria
Nexlizet	Coverage requires the following: <ol style="list-style-type: none"> 1. Diagnosis of established arterosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia 2. Age ≥ 18 years old AND <ol style="list-style-type: none"> 3. Trial with one high intensity statin at maximum tolerated dose OR <ol style="list-style-type: none"> 3. History of statin intolerance (skeletal muscle related symptoms) after a trial of two generic statins (examples include: Crestor, Lescol, Lipitor, Livalo, Mevacor, Pravachol, Zocor) OR <ol style="list-style-type: none"> 3. History of rhabdomyolysis after a trial of one statin (examples include: Crestor, Lescol, Lipitor, Livalo, Mevacor, Pravachol, Zocor)
Nicotrol, Nicotrol NS	Coverage for \$0 copayment will require trial and failure of 2 preferred agents such as generic bupropion extended release (Zyban), nicotine patch, nicotine gum, nicotine lozenge
nilutamide (Nilandron)	Coverage requires the following: <ol style="list-style-type: none"> 1. Treatment of metastatic prostate cancer in combination with surgical castration 2. Trial and failure, contraindication, or intolerance to generic Casodex (bicalutamide) Initial approval: 1 year Continuation of treatment requires a lack of disease progression
Ninlaro	Coverage requires the following: <ol style="list-style-type: none"> 1. Diagnosis of multiple myeloma 2. Using in combination with lenalidomide and dexamethasone 3. Have received at least one prior therapy

Drug name	Current Blue Cross and BCN coverage criteria
nitisinone (Orfadin)	Coverage requires the following: <ol style="list-style-type: none"> 1. Diagnosis of hereditary tyrosinemia type 1 2. Using along with dietary restriction of tyrosine and phenylalanine
Nityr	Coverage requires the following: <ol style="list-style-type: none"> 1. Diagnosis of hereditary tyrosinemia type 1 2. Using along with dietary restriction of tyrosine and phenylalanine
Nocdurna	Coverage requires the following: <ol style="list-style-type: none"> 1. Diagnosis of nocturnal polyuria 2. Lifestyle changes have been tried (including limiting fluids, elevation of legs) 3. Treatment failure or intolerance to one generic medication for overactive bladder (OAB) 4. Trial of generic oral desmopressin <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>
Nourianz	Coverage requires the following: <ol style="list-style-type: none"> 1. Treatment of intermittent OFF episodes in patients with Parkinson's Disease 2. Currently experiencing "off" episodes while taking carbidopa/levodopa 3. Using in combination with carbidopa/levodopa <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>

Drug name	Current Blue Cross and BCN coverage criteria
Novarel	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. It is being prescribed to treat infertility in accordance with generally accepted medical practice. 2. The members benefit provides for coverage for infertility medications 3. Coverage may be provided in accordance with your medical fertility benefit <p>OR</p> <p>For the diagnosis of:</p> <ol style="list-style-type: none"> 1. Hypogonadotropic hypogonadism secondary to a pituitary deficiency in males <p>OR</p> <ol style="list-style-type: none"> 1. Prepubertal cryptorchidism not caused by anatomic obstruction
Nubeqa	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Treatment of nonmetastatic castration-resistant prostate cancer <p>OR</p> <ol style="list-style-type: none"> 1. Treatment of metastatic hormone sensitive prostate cancer 2. Using in combination with docetaxel <p>Initial approval: 1 year Continuation of treatment requires a lack of disease progression</p>

Drug name	Current Blue Cross and BCN coverage criteria
Nucala	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of severe uncontrolled eosinophilic asthma 2. Age ≥ 6 years old 3. Patient is currently receiving, and will continue to receive standard of care regimen 4. Severe eosinophilic asthma identified by: <ol style="list-style-type: none"> a. Blood eosinophils greater than or equal to 150 cells/microliter at initiation of treatment AND b. Failure to maintain adequate control after at least a 3 month trial of daily oral corticosteroids or high dose inhaled corticosteroids in combination with: <ol style="list-style-type: none"> i. LABA (long acting inhaled β2 agonist) OR ii. or leukotriene modifier OR iii. LAMA (long acting muscarinic antagonist) in adults and children ≥ 12 years old 5. Cannot be used in combination with other biologic agents indicated for uncontrolled eosinophilic asthma <p>OR</p> <ol style="list-style-type: none"> 1. Diagnosis of eosinophilic granulomatosis with polyangiitis (EGPA) 2. Age ≥18 years old 3. Consult with an allergist/immunologist prior to initiation of Nucala therapy 4. History or presence of asthma 5. Presence of at least 2 of the following criteria that are typical of EGPA: histopathological evidence of eosinophilic vasculitis, perivascular eosinophilic infiltration, or eosinophil-rich granulomatous inflammation, neuropathy, pulmonary infiltrates, allergic rhinitis and nasal polyps, cardiomyopathy, glomerulonephritis, alveolar hemorrhage, palpable purpura, or antineutrophil cytoplasmic antibody (ANCA) positivity 6. Cannot be used in combination with other biologic agents indicated for EGPA <p>(criteria continued next page)</p>

*For drugs covered under the commercial Blue Cross or BCN medical benefit, please see the [Blue Cross and BCN Utilization Management Medical Drug List](#)
Blue Cross Blue Shield of Michigan and Blue Care Network are nonprofit corporations and independent licensees of the Blue Cross and Blue Shield Association.

Drug name	Current Blue Cross and BCN coverage criteria
Nucala (continued)	<p>OR</p> <ol style="list-style-type: none"> 1. Diagnosis of hypereosinophilic syndrome (HES) 2. Age ≥ 12 years old 3. At least 2 HES flares within the past 12 months (defined as HES-related worsening of clinical symptoms or blood eosinophil counts requiring an escalation in therapy) 4. Stable on HES therapy for at least 4 weeks (examples include: oral corticosteroids, immunosuppressive or cytotoxic therapy) 5. Eosinophil counts of 1,000 cells/microL or higher at initiation of therapy 6. Member does not have eosinophilia of unknown clinical significance, non-hematologic secondary HES (drug hypersensitivity, parasitic helminth infection, HIV infection, non-hematologic malignancy), or F1P1L1-PDGFRa kinase-positive HES 7. Cannot be used in combination with other biologic agents indicated for HES <p>OR</p> <ol style="list-style-type: none"> 1. Diagnosis of chronic rhinosinusitis with nasal polyposis (CRSwNP) 2. Age > 18 years old 3. Patient is currently receiving, and will continue to receive standard of care regimen 4. CRSwNP is recurring despite previous treatment with intranasal corticosteroids 5. Cannot be used in combination with other biologic agents indicated for CRSwNP <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>
Nuedexta	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of pseudobulbar affect (PBA) 2. Underlying neurological condition causing symptoms of PBA (ex. Multiple Sclerosis, amyotrophic lateral sclerosis, Parkinson’s Disease, stroke, traumatic brain injury)

*For drugs covered under the commercial Blue Cross or BCN medical benefit, please see the [Blue Cross and BCN Utilization Management Medical Drug List](#)
 Blue Cross Blue Shield of Michigan and Blue Care Network are nonprofit corporations and independent licensees of the Blue Cross and Blue Shield Association.

Drug name	Current Blue Cross and BCN coverage criteria
Nuplazid	Coverage requires the following: <ol style="list-style-type: none"> 1. Diagnosis of Parkinson's disease psychosis Initial approval: 1 year Renewal requires clinically significant improvement in psychosis symptoms
Nurtec ODT	Coverage requires the following: <ol style="list-style-type: none"> 1. For acute treatment of migraine 2. Age ≥ 18 years old 3. Treatment failure or contraindication with 2 generic triptan medications OR <ol style="list-style-type: none"> 1. For preventive treatment of migraine headaches 2. Age ≥ 18 years old 3. Member has history of ≥ 4 headache days per month 4. Trial of two medications from two different classes for the prevention of migraines Initial approval: 1 year Renewal for requires that current criteria are met, and that the medication is providing clinical benefit
Nyvepria	Coverage requires trial and failure or intolerance to Neulasta and Ziextenzo

Drug name	Current Blue Cross and BCN coverage criteria
Ocaliva	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of primary biliary cholangitis (PBC) confirmed by 2 of the 3 following American Association for the Study of Liver Diseases criteria: a positive test for antimitochondrial antibodies, elevated serum levels of alkaline phosphatase (ALP), histologic evidence of PBC based on liver biopsy 2. If cirrhosis is present: documentation of no evidence of portal hypertension 3. Inadequate response to ursodeoxycholic acid (UDCA) such as Actigall (ursodiol) after at least one year at a dose of 13-15mg/kg/day or inability to tolerate UDCA 4. Treatment plan must include UDCA unless unable to tolerate it <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>
Odactra	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. 12 to 65 years of age 2. Diagnosis of house dust mite (HDM)-induced allergic rhinitis confirmed by a positive skin test or in vitro testing for IgE antibodies to house dust mites 3. Trial of one agent from each of the following classes: <ol style="list-style-type: none"> a. Intranasal corticosteroid b. Oral or intranasal antihistamine <p>Initial approval: 3 years Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>
Odomzo	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of locally advanced basal cell carcinoma 2. Carcinoma occurred again following surgery or radiation therapy OR member is not able to receive treatment with surgery or radiation therapy

Drug name	Current Blue Cross and BCN coverage criteria
Ofev	Coverage requires the following: <ul style="list-style-type: none"> 1. Treatment of idiopathic pulmonary fibrosis (IPF) OR <ul style="list-style-type: none"> 1. Treatment of declining pulmonary function in patients with systemic sclerosis-associated interstitial lung disease OR <ul style="list-style-type: none"> 1. Treatment of chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit
Ogsiveo	Coverage requires the following: <ul style="list-style-type: none"> 1. Diagnosis of progressing desmoid tumors requiring systemic treatment 2. Age ≥ 18 years old Initial approval: 1 year Continuation of treatment requires a lack of disease progression
Ojjaara	Coverage requires the following: <ul style="list-style-type: none"> 1. Age ≥ 18 years old 2. For the treatment of intermediate or high-risk myelofibrosis (MF), including primary MF or secondary MF [post-polycythemia vera (PV) and post-essential thrombocythemia (ET)], with anemia Initial approval: 1 year Continuation of treatment requires a lack of disease progression

Drug name	Current Blue Cross and BCN coverage criteria
Olumiant	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of Rheumatoid Arthritis 2. Age ≥ 18 years old 3. Trial and treatment failure of one Disease Modifying Anti-Rheumatic Drug (DMARD) after a minimum 3-month trial (examples include methotrexate, hydroxychloroquine, leflunomide, sulfasalazine) 4. Trial and treatment failure of two of the following: Enbrel, Humira, Cimzia, Simponi, Rinvoq, or Xeljanz/XR 5. Trial and treatment failure of Actemra and Orencia <p>OR</p> <ol style="list-style-type: none"> 1. Diagnosis of severe Alopecia Areata (AA), defined as ≥ 50% scalp hair loss OR 21-49% scalp hair loss with at least one of the following: <ol style="list-style-type: none"> i. Significant impact on psychosocial functioning resulting from AA ii. Eyebrow or eyelash involvement iii. Inadequate response to previous treatment after at least 6 months iv. Diffuse (multifocal) positive hair pull test consistent with rapidly progressive AA 2. Age ≥ 18 years old 3. Cannot be used in combination with other biologic agents or targeted DMARDs indicated for AA <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>
Onureg	<p>Coverage requires the following:</p> <p>Maintenance treatment of acute myeloid leukemia (AML) in adults who achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRI) following intensive induction chemotherapy and are not able to complete intensive curative therapy</p> <p>Initial approval: 1 year Continuation of treatment requires a lack of disease progression</p>

Drug name	Current Blue Cross and BCN coverage criteria
Onzetra Xsail	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Treatment failure or intolerance to generic Imitrex (sumatriptan) nasal spray and one other generic triptan (examples include: generic Maxalt (rizatriptan), generic Amerge (naratriptan), generic Zomig/ZMT(zolmitriptan)) <p>OR</p> <ol style="list-style-type: none"> 1. Age 12-17 years old 2. Treatment failure or intolerance to generic Maxalt (rizatriptan) <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>
Opsumit	<p>Coverage is provided for the treatment of pulmonary arterial hypertension (WHO Group 1)</p>
Opzelura	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of atopic dermatitis (AD) 2. Age ≥ 12 years old 3. Trial and treatment failure with one topical steroid 4. Trial and treatment failure with generic Protopic (tacrolimus) or generic Elidel (pimecrolimus) 5. Trial and treatment failure with Eucrisa 6. Cannot be used in combination with therapeutic biologics, other JAK inhibitors or potent immunosuppressants such as azathioprine or cyclosporine <p>OR</p> <ol style="list-style-type: none"> 1. Diagnosis vitiligo 2. Age ≥ 12 years old 3. Trial and treatment failure of one topical steroid 4. Trial and treatment failure with generic Protopic (tacrolimus) or generic Elidel (pimecrolimus) 5. Not to be used in combination with therapeutic biologics, other JAK inhibitors, or potent immunosuppressants such as azathioprine or cyclosporine <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>

Drug name	Current Blue Cross and BCN coverage criteria
Oracea, doxycycline IR DR	Coverage requires the following: Trial and treatment failure or intolerance to generic doxycycline monohydrate (Monodox) AND generic doxycycline hyclate immediate release (Vibramycin) Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit
Oralair	Coverage requires the following: <ol style="list-style-type: none"> 1. Age 5 through 65 years old 2. Diagnosis of grass pollen-induced allergic rhinitis, confirmed by positive skin test or in vitro testing for pollen-specific IgE antibodies for any of the 5 grass species contained in this product 3. Trial of one agent from each of the following classes: <ol style="list-style-type: none"> a. Intranasal corticosteroid b. Oral or intranasal antihistamine Initial approval: 3 years Renewal requires that current criteria are met, and that the medication is providing clinical benefit

Drug name	Current Blue Cross and BCN coverage criteria
Orencia SC	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of Rheumatoid Arthritis 2. Age ≥ 18 years old 3. Trial and treatment failure of one Disease Modifying Anti-Rheumatic Drug (DMARD) after a minimum 3-month trial (examples include methotrexate, hydroxychloroquine, leflunomide, sulfasalazine) 4. Trial and treatment failure of two of the following: Enbrel, Humira, Cimzia, Simponi, Rinvoq, or Xeljanz/XR <p>OR</p> <ol style="list-style-type: none"> 1. Diagnosis of Juvenile Idiopathic Arthritis (JIA) 2. Age ≥ 2 years old 3. Trial and treatment failure of one DMARD after a minimum 3-month trial (examples include methotrexate, leflunomide) 4. Trial and treatment failure of two of the following: Enbrel, Humira, or Xeljanz <p>OR</p> <ol style="list-style-type: none"> 1. Diagnosis of Psoriatic Arthritis 2. Age 2 to 5 years old 3. Trial and treatment failure of Enbrel <p>OR</p> <ol style="list-style-type: none"> 2. Age 6 to 17 years old 3. Trial and treatment failure of Enbrel or Stelara <p>OR</p> <ol style="list-style-type: none"> 2. Age ≥ 18 years old 3. Trial and treatment failure of two of the following: Enbrel, Humira, Cimzia, Simponi, Stelara, Rinvoq, Skyrizi, Tremfya, or Xeljanz/XR <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>
Orenitram	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of pulmonary arterial hypertension (WHO Group 1) 2. Trial and treatment failure of sildenafil or tadalafil AND ambrisentan or bosentan

Drug name	Current Blue Cross and BCN coverage criteria
Orgovyx	Coverage requires the following: <ol style="list-style-type: none"> 1. Age ≥ 18 years old 2. Diagnosis of advanced prostate cancer Initial approval: 1 year Continuation of treatment requires a lack of disease progression
Oriahnn	Coverage requires the following: <ol style="list-style-type: none"> 1. Management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women 2. Age ≥18 years old 3. Trial of two hormone related therapies 4. Trial of Myfembree Oriahnn will be approved for a maximum of two years
Orilissa	Coverage requires the following: <ol style="list-style-type: none"> 1. Treatment of pain associated with endometriosis 2. Trial of two hormone related therapies 3. Age ≥ 18 years old. 150mg: Approval length 2 years 200mg: Approval length 6 months

Drug name	Current Blue Cross and BCN coverage criteria
Orkambi	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Age ≥ 1 year old 2. Diagnosis of cystic fibrosis (CF) 3. Presence of two copies of the F508del mutation confirmed by genetic test <p>Initial approval: 6 months Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>
Orladeyo	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Age ≥ 12 years old 2. Diagnosis of hereditary angioedema (HAE) 3. Diagnosis confirmed by genetic testing or with the following laboratory findings: <ol style="list-style-type: none"> i. C4 level below the limits of the laboratory's normal reference range (normal range = 16-58 mg/dL) ii. C1INH (antigenic or function) below the limits of the laboratory's normal reference range (normal range ≥ 41%) 4. History of at least 2 HAE attacks per month OR a history of attacks that are considered severe with swelling of the face, throat or gastrointestinal tract 5. Prescribed by an immunologist, allergist or hematologist 6. Trial and failure, contraindication, OR intolerance to Haegarda AND Takhzyro (if appropriate per age) 7. Not to be used in combination with other products indicated for HAE prophylaxis <p>Initial approval: 1 year Renewal requires improvement in HAE demonstrated by a 50% reduction in the number of attacks OR the severity of HAE attacks was reduced by 50% or more</p>

Drug name	Current Blue Cross and BCN coverage criteria
orlistat (Xenical)	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Age ≥ 18 years old 2. BMI ≥ 30 kg/m² or ≥ 27 kg/m² with one related comorbid condition 3. Current weight (within 30 days) must be submitted to the plan for review 4. Active participation for a minimum of 6 months in a covered BCBSM/BCN lifestyle modification program OR active participation for a minimum of 6 months in an alternative concurrent lifestyle modification program (e.g. recent food diaries, exercise logs, program receipts, app participation, etc.) if member does not have access to a covered BCBSM/BCN program 5. Not to be used in combination with other weight loss products <p>Initial approval: 4 months Continued coverage will be reviewed annually and may be provided if the member has maintained at least a 5% weight loss from baseline AND requires continued participation in a lifestyle modification program. Current weight (within 30 days) and BMI ≥ 18.5 kg/m² must be submitted to the plan for review</p>
Orserdu	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor 1 (ESR1)-mutated advanced or metastatic breast cancer in postmenopausal women or men 2. Age ≥ 18 years old 3. Disease progression following at least one line of endocrine therapy <p>Initial approval: 1 year Continuation of treatment requires a lack of disease progression</p>

Drug name	Current Blue Cross and BCN coverage criteria
Otezla	<p>Coverage requires the following:</p> <ul style="list-style-type: none"> 1. Diagnosis of Psoriatic Arthritis 2. Age ≥ 18 years old <p>OR</p> <ul style="list-style-type: none"> 1. Diagnosis of Psoriasis 2. Age ≥ 18 years old 3. Trial and treatment failure of one topical steroid <p>OR</p> <ul style="list-style-type: none"> 1. Diagnosis of oral ulcers associated with Behcet disease 2. Age ≥ 18 years old 3. Trial and treatment failure to one topical steroid for oral ulcers such as triamcinolone paste <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>
Oxbryta	<p>Coverage requires the following:</p> <ul style="list-style-type: none"> 1. Diagnosis of sickle cell disease 2. Age ≥ 4 years old 3. Hemoglobin ≤ 10.5 g/dl 4. Not receiving long-term red blood cell transfusion therapy 5. Trial and failure after a minimum 6 month trial, contraindication, OR intolerance to hydroxyurea <p>OR</p> <ul style="list-style-type: none"> 5. If requesting tablets for suspension, member cannot swallow tablets/capsules AND has tried and failed after a minimum 6-month trial, a contraindication, or intolerance to Siklos (hydroxyurea) <p>Initial approval: 1 year Renewal requires improved sickle cell disease control (including, but not limited to: improvement in hemoglobin, symptom improvement, or reduction in vaso-occlusive crises, and not receiving regular transfusion therapy)</p>

Drug name	Current Blue Cross and BCN coverage criteria
Oxervate	Coverage requires the following: Diagnosis of neurotrophic keratitis that has progressed to stage 2 or 3 Approval: 60 days
oxiconazole (Oxistat)	Coverage requires the following: <ol style="list-style-type: none"> 1. Diagnosis of tinea pedis, tinea cruris or tinea corporis 2. Treatment failure to two topical over-the-counter antifungal agents 3. Treatment failure to two oral generic antifungal agents
Oxtellar XR	Coverage requires the following: <ol style="list-style-type: none"> 1. Treatment of seizures in patients with epilepsy 2. Treatment failure or intolerance to at least 3 generic alternatives, one of which must be generic oxcarbazepine (Trileptal) Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit
oxymorphone HCl ER (Opana ER)	Coverage requires the following: <ol style="list-style-type: none"> 1. Diagnosis of moderate to severe chronic pain requiring around the clock opioid analgesia for an extended period of time 2. Trial and failure or intolerance to three generic long-acting opioids (examples include, but not limited to: buprenorphine transdermal patch, tramadol, morphine, fentanyl, and methadone) Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit Note: Coverage will not be provided if the patient is on more than one long acting opioid concurrently

Drug name	Current Blue Cross and BCN coverage criteria
Ozempic	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. For the treatment of Type 2 Diabetes or trial of one generic or preferred medication for the treatment of Type 2 Diabetes 2. Cannot be used in combination with other glucagon-like peptide-1 (GLP-1) agonist-containing products <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>
Ozobax / baclofen	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of spasticity 2. Trial and failure or intolerance to baclofen tablets OR member is unable to swallow tablets 3. Trial and failure or intolerance to Lyvispah <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>
Palforzia	<p>Coverage for maintenance treatment requires the following:</p> <ol style="list-style-type: none"> 1. FDA approved indication 2. Completion of all dose levels of up-dosing before starting maintenance <p>OR</p> <ol style="list-style-type: none"> 1. Stable on maintenance dose <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>

Drug name	Current Blue Cross and BCN coverage criteria
Palynziq	Coverage requires the following: <ol style="list-style-type: none"> 1. Diagnosis of phenylketonuria 2. Age ≥ 18 years old 3. Following a phenylalanine-restricted diet 4. Phenylalanine concentration ≥ 600 umol/L 5. Trial and failure of Kuvan (Requires prior authorization) Initial approval: 1 year Renewal requires current phenylalanine concentration < 600 μmol/L or at least a 20% reduction from baseline
Pancreaze	Coverage requires trial and treatment failure of Creon and Zenpep Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit
pazopanib (Votrient)	Coverage is provided for the treatment of the FDA approved indications

Drug name	Current Blue Cross and BCN coverage criteria
Pemazyre	Coverage requires the following: <ol style="list-style-type: none"> 1. Age ≥ 18 years old 2. For the treatment of previously treated, unresectable locally advanced or metastatic cholangiocarcinoma 3. Presence of fibroblast growth factor receptor 2 fusion or other rearrangement (as detected by an FDA-approved test) OR <ol style="list-style-type: none"> 1. Age ≥ 18 years old 2. For the treatment of relapsed or refractory myeloid/lymphoid neoplasms (MLNs) 3. Presence of fibroblast growth factor receptor 1 (FGFR1) rearrangement Initial approval: 1 year Continuation of treatment requires a lack of disease progression
Pheburane	Coverage requires the following: <ol style="list-style-type: none"> 1. Diagnosis of urea cycle disorder 2. Will be used as adjunctive therapy to dietary management (such as dietary protein restriction and/or amino acid supplementation) 3. Trial and treatment failure of Buphenyl (sodium phenylbutyrate) Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit

Drug name	Current Blue Cross and BCN coverage criteria
<p>phenoxy-benzamine HCl (Dibenzylamine)</p>	<p>Coverage is provided for the treatment of hypertension and sweating episodes due to pheochromocytoma:</p> <p>Age ≥ 18 years old</p> <p>Preoperative treatment: for members who have experienced treatment failure of or intolerance to a preferred selective alpha1-adrenergic receptor blocker (such as Cardura (doxazosin)) in combination with a preferred calcium channel blocker (such as Norvasc (amlodipine)) Approval: 60 days</p> <p>Non-preoperative treatment: for members who have experienced treatment failure of or intolerance to TWO selective alpha1-adrenergic receptor blockers (such as Cardura (doxazosin)) where both are used in combination with a preferred calcium channel blocker (such as Norvasc (amlodipine))</p> <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>
<p>Piqray</p>	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2) negative, advanced or metastatic breast cancer 2. Used in combination with fulvestrant 3. PIK3CA-mutation confirmed by FDA approved test 4. Progression of cancer after an endocrine-based regimen such as anastrozole (Arimidex), exemestane (Aromasin), and letrozole (Femara) <p>Initial approval: 1 year Continuation of treatment requires a lack of disease progression</p> <p>OR for Piqray 250 mg tablet strength:</p> <ol style="list-style-type: none"> 1. Diagnosis of PIK3CA - Related Overgrowth Spectrum (PROS) confirmed by detection of a PIK3CA mutation or based on clinical features suspected of PROS <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>

Drug name	Current Blue Cross and BCN coverage criteria
pirfenidone (Esbriet)	Coverage is provided for the treatment of idiopathic pulmonary fibrosis (IPF) Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit
pitavastatin (Livalo)	Coverage requires treatment failure or intolerance to at least one generic statin Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit
Pomalyst	Coverage requires the following: <ul style="list-style-type: none"> 1. Diagnosis of Multiple myeloma 2. Used in combination with dexamethasone 3. Received at least 2 prior therapies including an immunomodulatory agent (ex. thalidomide, lenalidomide) and a proteasome inhibitor (ex. bortezomib) 4. Disease progression within 60 days of completion of last therapy OR <ul style="list-style-type: none"> 1. Diagnosis of AIDS-related Kaposi Sarcoma after failure of highly active antiretroviral therapy (HAART) 2. Used in combination with HAART OR <ul style="list-style-type: none"> 1. Diagnosis of Kaposi Sarcoma in patients who are HIV-negative Initial approval: 1 year Continuation of treatment requires a lack of disease progression

Drug name	Current Blue Cross and BCN coverage criteria
Pregnyl	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. It is being prescribed to treat infertility in accordance with generally accepted medical practice. 2. The member's benefit provides for coverage for infertility medications 3. Coverage may be provided in accordance with your medical fertility benefit <p>For the diagnosis of:</p> <ol style="list-style-type: none"> 1. Hypogonadotropic hypogonadism secondary to a pituitary deficiency in males <p>OR</p> <ol style="list-style-type: none"> 1. Prepubertal cryptorchidism not caused by anatomic obstruction
Prodigy Voice Glucose Meter	<p>Coverage is provided when the member is visually impaired</p> <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>

Drug name	Current Blue Cross and BCN coverage criteria
Promacta	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of chronic immune thrombocytopenia (ITP) and persistent thrombocytopenia (platelet count < 100,000 mcL) for ≥ 3 months and requires all of the following: <ol style="list-style-type: none"> a. Age ≥ 1 year of age b. Inadequate response or patient must not be a candidate for corticosteroids, immunoglobulins or splenectomy c. Current platelet count is < 20,000 mcL or <30,000 mcL and has symptoms of active bleeding d. Dose does not exceed 75mg/day <p>OR</p> <ol style="list-style-type: none"> 2. Diagnosis of thrombocytopenia with chronic hepatitis C and requires all of the following: <ol style="list-style-type: none"> a. ≥ 18 years of age b. Platelets < 75,000 mcL c. Dose does not exceed 100mg/day <p>OR</p> <ol style="list-style-type: none"> 3. Diagnosis of severe aplastic anemia and requires all of the following: <ol style="list-style-type: none"> a. ≥ 2 years of age b. Current platelets ≤ 30,000/mcL c. Insufficient response to antithymocyte globulin based immunosuppressive therapy <p>OR</p> <ol style="list-style-type: none"> c. Using in combination with standard immunosuppressive therapy as first line treatment d. Dose does not exceed 150mg/day <p>Initial approval: 3 months Renewal of therapy requires ALL the following to be met:</p> <ol style="list-style-type: none"> 1. Recent platelet count between 50,000 and 200,000/mcL OR for platelet counts outside this range, dosage has been adjusted accordingly to FDA labeled recommendations 2. Dose does not exceed recommended maximum for indication

Drug name	Current Blue Cross and BCN coverage criteria
Pulmozyme	Coverage requires a diagnosis of cystic fibrosis
Pyrukynd	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of hemolytic anemia with pyruvate kinase (PK) deficiency 2. Age ≥ 18 years old 3. Must have clinical manifestations of disease, including, but not limited to, decreased hemoglobin (Hgb), increased reticulocytes, bilirubin, and/or lactate dehydrogenase (LDH) levels AND either one of the following: <ol style="list-style-type: none"> a. Serum assay showing a decrease of pyruvate kinase activity OR b. Genetic testing showing at least 2 variant alleles in the pyruvate kinase liver and red blood cell (PKLR) gene <p>Initial approval: 6 months Renewal requires improvement in pyruvate kinase (PK) deficiency, including, but not limited to, improvement in Hgb, hemolysis laboratory results, and transfusion requirements</p>
Qbrexza	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Treatment of primary axillary hyperhidrosis 2. Age ≥ 9 years of age <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>

Drug name	Current Blue Cross and BCN coverage criteria
Qsymia	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Age ≥ 18 years old 2. BMI ≥ 30, or ≥ 27 with one weight related comorbid condition 3. Current weight (within 30 days) must be submitted to the plan for review 4. Active participation for a minimum of 6 months in a covered BCBSM/BCN lifestyle modification program OR active participation for a minimum of 6 months in an alternative concurrent lifestyle modification program (e.g. recent food diaries, exercise logs, program receipts, app participation, etc.) if member does not have access to a covered BCBSM/BCN program 5. Not to be used in combination with other weight loss products <p>OR</p> <ol style="list-style-type: none"> 1. 12 to 17 years of age 2. BMI ≥ 95th percentile, standardized for age and sex 3. Current weight (within 30 days) must be submitted to the plan for review 4. Active participation for a minimum of 6 months in a covered BCBSM/BCN lifestyle modification program OR active participation for a minimum of 6 months in an alternative concurrent lifestyle modification program (e.g. recent food diaries, exercise logs, program receipts, app participation, etc.) if member does not have access to a covered BCBSM/BCN program 5. Not to be used in combination with other weight loss products <p>Initial approval: 6 months <u>For adults</u>, continued coverage will be reviewed annually and may be provided if the member has maintained at least a 5% weight loss from baseline AND requires continued participation in a lifestyle modification program. Current weight (within 30 days) and BMI ≥ 18.5 kg/m² must be submitted to the plan for review <u>For pediatrics</u>, continued coverage will be reviewed annually and may be provided if the member has maintained at least a 3% reduction in BMI from baseline AND requires continued participation in a lifestyle modification program. Current weight (within 30 days) and BMI-for-age percentile ≥ 5th percentile must be submitted to the plan for review</p>

*For drugs covered under the commercial Blue Cross or BCN medical benefit, please see the [Blue Cross and BCN Utilization Management Medical Drug List](#)
Blue Cross Blue Shield of Michigan and Blue Care Network are nonprofit corporations and independent licensees of the Blue Cross and Blue Shield Association.

Drug name	Current Blue Cross and BCN coverage criteria
Quillichew ER	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. The member is ≥ 6 years of age and diagnosed with ADHD or ADD 2. And has tried and failed both a generic methylphenidate and a generic amphetamine product, one of which must be a generic long acting formulation <p>OR</p> <ol style="list-style-type: none"> 2. Member cannot swallow tablets/capsules and has tried and failed one of the agents that can be opened and sprinkled on applesauce, methylphenidate ER or generic amphetamine-dextroamphetamine (Adderall XR) <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>
Quillivant XR	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. The member is ≥ 6 years of age and diagnosed with ADHD or ADD 2. And has tried and failed both a generic methylphenidate and a generic amphetamine product, one of which must be a generic long acting formulation <p>OR</p> <ol style="list-style-type: none"> 2. Member cannot swallow tablets/capsules and has tried and failed one of the agents that can be opened and sprinkled on applesauce, methylphenidate ER or generic amphetamine-dextroamphetamine (Adderall XR) <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>
Qulipta	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. For preventive treatment of migraine headaches 2. Age ≥ 18 years old 3. Member has history of ≥ 4 headache days per month 4. Trial of two medications from two different classes for the prevention of migraines <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>

Drug name	Current Blue Cross and BCN coverage criteria
Quviviq	<p>Coverage requires treatment failure of 3 of the following: immediate-release zolpidem (Ambien), eszopiclone (Lunesta), zaleplon (Sonata), trazodone (Desyrel), or doxepin (Silenor)</p> <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>
Radicava ORS	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of Amyotrophic Lateral Sclerosis (ALS) 2. Prescribed by or in consultation with a neurologist 3. Start of treatment is within 2 years of diagnosis with amyotrophic lateral sclerosis (ALS) <p>OR</p> <ol style="list-style-type: none"> 3. After 2 years of diagnosis, with a percent predicted vital capacity value of $\geq 80\%$ 4. Submission of a baseline metrics from the ALSFRS-R (Revised ALS Functional Rating Scale) 5. Currently receiving treatment and will continue to receive treatment with Riluzole, if tolerated <p>Initial approval: 1 year Renewal requires submission of patient assessments using the ALSFRS-R or other clinical documentation, to determine if Radicava is slowing the progression of ALS</p>

Drug name	Current Blue Cross and BCN coverage criteria
Ragwitek	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Age 5 through 65 years old 2. Diagnosis of short ragweed pollen induced allergic rhinitis, confirmed by positive skin test or in vitro testing for pollen-specific IgE antibodies for short ragweed pollen 3. Trial of one agent from each of the following classes: <ol style="list-style-type: none"> a. Intranasal corticosteroid b. Oral or intranasal antihistamine <p>Initial approval: 3 years Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>
raloxifene (Evista)	<p>Coverage for \$0 copayment will be provided when:</p> <ol style="list-style-type: none"> 1. The member is a woman, at least 35 years of age and post-menopausal 2. The medication is being used for prevention of primary breast cancer in members classified as high risk 3. Cost share will not be waived for members with a history of breast cancer or venous thrombotic event (VTE)
Rasuvo	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, or psoriasis 2. Trial and treatment failure of oral or injectable methotrexate

Drug name	Current Blue Cross and BCN coverage criteria
Ravicti	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of urea cycle disorder 2. Will be used as adjunctive therapy to dietary management (such as dietary protein restriction and/or amino acid supplementation) 3. Trial and treatment failure of Buphenyl (sodium phenylbutyrate) <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>
Rayos	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of rheumatoid arthritis 2. Trial or intolerance of two systemically absorbed generic oral corticosteroids, one of which must be prednisone <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>
Rebif	<p>Coverage requires trial and failure or intolerance to two generic or preferred medications for the treatment of multiple sclerosis (examples include: Avonex, Bafiertam, Betaseron, Copaxone, Kesimpta, and Vumerity)</p>
Recorlev	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Treatment of endogenous hypercortisolemia in patients with Cushing's syndrome for whom surgery is not an option or has not been curative 2. Age ≥ 18 years old 3. Trial and treatment failure, contraindication, or intolerance to ketoconazole, mitotane, or cabergoline <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>

Drug name	Current Blue Cross and BCN coverage criteria
Relyvrio	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of Amyotrophic Lateral Sclerosis (ALS) 2. Age ≥ 18 years old 3. Prescribed by or in consultation with a neurologist 4. Start of treatment is within 18 months of diagnosis of ALS 5. Vital capacity greater than 60% predicted 6. Submission of a baseline metrics from the ALSFRS-R (Revised ALS Functional Rating Scale) 7. Currently receiving treatment and will continue to receive treatment with riluzole, if tolerated <p>Initial approval: 1 year Renewal requires submission of patient assessments using the ALSFRS-R or other clinical documentation to determine if Relyvrio is slowing the progression of ALS</p>

Drug name	Current Blue Cross and BCN coverage criteria
Repatha	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of primary hyperlipidemia, or prevention of cardiovascular events in patients with established cardiovascular disease <ol style="list-style-type: none"> a. Age ≥ 18 years old b. Trial and failure of one high intensity statin <p>OR</p> <ol style="list-style-type: none"> b. History of statin intolerance (skeletal muscle related symptoms) after a trial of two generic statins (Examples include: Crestor, Lescol, Lipitor, Livalo, Mevacor, Pravachol, Zocor) <p>OR</p> <ol style="list-style-type: none"> b. History of rhabdomyolysis after a trial of one statin (Examples include: Crestor, Lescol, Lipitor, Livalo, Mevacor, Pravachol, Zocor) c. Not to be used in combination with other PCSK9 inhibitors <p>OR</p> <ol style="list-style-type: none"> 2. Diagnosis of homozygous familial hypercholesterolemia or heterozygous familial hypercholesterolemia <ol style="list-style-type: none"> a. Age ≥ 10 years old b. Trial and treatment failure with one high intensity statin <p>OR</p> <ol style="list-style-type: none"> b. History of statin intolerance (skeletal muscle related symptoms) after a trial of two generic statins (Examples include: Crestor, Lescol, Lipitor, Livalo, Mevacor, Pravachol, Zocor) <p>OR</p> <ol style="list-style-type: none"> b. History of rhabdomyolysis after a trial of one statin (Examples include: Crestor, Lescol, Lipitor, Livalo, Mevacor, Pravachol, Zocor) c. Not to be used in combination with other PCSK9 inhibitors <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>

Drug name	Current Blue Cross and BCN coverage criteria
Retevmo	<p>Coverage requires the following:</p> <ul style="list-style-type: none"> 1. Age ≥ 18 years old 2. Diagnosis of Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer <p>OR</p> <ul style="list-style-type: none"> 1. Age ≥ 12 years old 2. Diagnosis of RET-Mutant Medullary Thyroid Cancer <p>OR</p> <ul style="list-style-type: none"> 1. Age > 12 years old 2. Diagnosis of RET Fusion-Positive Thyroid Cancer Refractory to radioactive iodine (if radioactive iodine is appropriate) <p>OR</p> <ul style="list-style-type: none"> 1. Age ≥ 18 years old 2. Diagnosis of RET Fusion-Positive solid tumor 3. Disease progression following prior systemic treatment OR there are no satisfactory alternative treatment options <p>Initial approval: 1 year Continuation of treatment requires a lack of disease progression</p>
Revcovi	<p>Coverage requires the following:</p> <ul style="list-style-type: none"> 1. Diagnosis of adenosine deaminase (ADA) deficiency in patients with severe combined immunodeficiency disease (SCID) 2. Prescribed by or in consultation with an immunologist 3. Confirmation of diagnosis by serum assay showing a decrease of adenosine deaminase activity followed by genetic testing showing a mutation in the adenosine deaminase gene 4. Treatment failure of or not a suitable candidate for a bone marrow transplant <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>

Drug name	Current Blue Cross and BCN coverage criteria
Reyvow	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Age ≥ 18 years old 2. For the acute treatment of migraines 3. Treatment failure or contraindication with 2 generic triptan medications 4. Trial and treatment failure, contraindication, or intolerance to Ubrelvy and Nurtec ODT <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>
Rezlidhia	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of relapsed or refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test 2. Age ≥ 18 years old <p>Initial approval: 1 year Continuation of treatment requires a lack of disease progression</p>
Rezurock	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Age ≥ 12 years old 2. Diagnosis of chronic graft versus - host disease (cGVHD) after failure of at least two prior lines of systemic therapy <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit Please note: For quantity requests greater than one tablet per day due to concomitant proton pump inhibitor therapy, use of a H2-receptor antagonist is recommended</p>

Drug name	Current Blue Cross and BCN coverage criteria
Rinvoq	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of Rheumatoid Arthritis 2. Age ≥ 18 years old 3. Trial and treatment failure of one Disease Modifying Anti-Rheumatic Drug (DMARD) after a minimum 3-month trial (examples include methotrexate, hydroxychloroquine, leflunomide, sulfasalazine) 4. Trial and treatment failure of one or more tumor necrosis factor (TNF) inhibitor(s) <p>OR</p> <ol style="list-style-type: none"> 1. Diagnosis of Psoriatic Arthritis 2. Age > 18 years old 3. Trial and treatment failure of one or more tumor necrosis factor (TNF) inhibitor(s) <p>OR</p> <ol style="list-style-type: none"> 1. Diagnosis of moderate to severe Atopic Dermatitis 2. Age ≥ 12 years old 3. Weight ≥ 40 kg 4. Trial and treatment failure of one of the following: high potency topical corticosteroid, tacrolimus, pimecrolimus, cyclosporine, methotrexate, azathioprine, or mycophenolate mofetil 5. Cannot be used in combination with other biologic agents indicated for severe atopic dermatitis <p>OR</p> <ol style="list-style-type: none"> 1. Diagnosis of Ulcerative Colitis 2. Age ≥ 18 years old 3. Treatment with an adequate course of conventional therapy (such as steroids for 7 days, immunomodulators such as azathioprine for at least 2 months) has been ineffective or is contraindicated or not tolerated 4. Trial and treatment failure of one or more tumor necrosis factor (TNF) inhibitor(s) <p>OR</p> <ol style="list-style-type: none"> 1. Diagnosis of Crohn's Disease 2. Age ≥ 18 years old 3. Treatment with an adequate course of conventional therapy (such as steroids for 7 days, immunomodulators such as azathioprine for at least 2 months) has been ineffective or is contraindicated or not tolerated 4. Trial and treatment failure of one or more tumor necrosis factor (TNF) inhibitor(s) <p>(criteria continued next page)</p>

Drug name	Current Blue Cross and BCN coverage criteria
Rinvoq (continued)	<p>OR</p> <ol style="list-style-type: none"> 1. Diagnosis of ankylosing spondylitis 2. Age ≥ 18 years old 3. Trial and treatment failure of one or more tumor necrosis factor (TNF) inhibitor(s) <p>OR</p> <ol style="list-style-type: none"> 1. Diagnosis of Non-Radiographic Axial Spondyloarthritis with objective signs of inflammation 2. Age ≥ 18 years old 3. Trial and treatment failure of one or more tumor necrosis factor (TNF) inhibitor(s) <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>
risedronate DR (Atelvia)	<p>Coverage requires trial and treatment failure or intolerance to two of the following:</p> <ol style="list-style-type: none"> 1. Actonel (risedronate) 2. Boniva (ibandronate) 3. Fosamax (alendronate) <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>

Drug name	Current Blue Cross and BCN coverage criteria
Rivfloza	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of primary hyperoxaluria type 1 (PH1) confirmed by genetic testing of the AGXT mutation 2. Age ≥ 9 years old 3. Patient has an estimated glomerular filtration rate (eGFR) ≥ 30 ml/min/1.73 m² 4. Patient does not have a history of kidney or liver transplant 5. Trial and failure (for at least 3 months), contraindication, OR intolerance to a course of high-dose vitamin B-6 therapy 6. Will not be used in combination with Oxlumo <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>
Rolvedon	<p>Coverage requires trial and failure or intolerance to Neulasta and Ziextenzo</p> <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>
Rozlytrek	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Treatment of metastatic non-small cell lung cancer in adults whose tumors are ROS1-positive, as detected by an FDA-approved test 2. Age ≥ 18 years old <p>OR</p> <ol style="list-style-type: none"> 1. Treatment of solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion as detected by an FDA-approved test without a known acquired resistance mutation 2. Age ≥ 1 month old 3. Tumor is metastatic or where surgical resection is not an option 4. Tumor has progressed following treatment or there is no alternative therapy <p>Initial approval: 1 year Continuation of treatment requires a lack of disease progression</p>

Drug name	Current Blue Cross and BCN coverage criteria
Ruconest	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Treatment of acute attacks of hereditary angioedema (HAE) 2. Diagnosis confirmed by genetic testing or with the following laboratory findings: <ol style="list-style-type: none"> i. C4 level below the limits of the laboratory's normal reference range (normal range = 16-58 mg/dL) ii. C1INH (antigenic or function) below the limits of the laboratory's normal reference range (normal range ≥ 41%) 3. Prescribed by an immunologist, allergist or hematologist 4. Trial and treatment failure of generic Firazyr (icatibant) 5. Not to be used in combination with other products indicated for acute HAE attacks <p>Initial approval: 1 year Renewal requires objective data documenting at least 50% improvement in time to relief of symptoms of acute attacks and maintenance of improvement of symptoms</p>
rufinamide tablet (Banzel)	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Treatment of seizures associated with Lennox-Gastaut syndrome 2. Age ≥ 1 year old 3. Trial and failure, contraindication, OR intolerance to two generic alternatives for the treatment of Lennox-Gastaut Syndrome <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>

Drug name	Current Blue Cross and BCN coverage criteria
Rybelsus	Coverage requires the following: <ol style="list-style-type: none"> 1. For the treatment of Type 2 Diabetes or trial of one generic or preferred medication for the treatment of Type 2 Diabetes 2. Cannot be used in combination with other glucagon-like peptide-1 (GLP-1) agonist-containing products Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit
Rydapt	Coverage requires the following: <ol style="list-style-type: none"> 1. Diagnosis of acute myeloid leukemia (AML) that is FLT3 mutation-positive as detected by an FDA-approved test. 2. Using in combination with cytarabine and daunorubicin induction and cytarabine consolidation OR <ol style="list-style-type: none"> 1. Diagnosis of mast cell leukemia (MCL) OR <ol style="list-style-type: none"> 1. Diagnosis of aggressive systemic mastocytosis or systemic mastocytosis with associated hematological neoplasm (SM-AHN)
Rytary	Coverage requires trial and treatment failure of generic Sinemet CR Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit
Sancuso	Coverage requires the following: <ol style="list-style-type: none"> 1. Using for prevention and/or treatment of nausea/vomiting associated with chemotherapy and/or radiation therapy 2. Treatment trial and failure with generic ondansetron (Zofran)/ODT and generic granisetron (Kytril) Initial approval: 1 year Renewal requires continuation of chemotherapy

Drug name	Current Blue Cross and BCN coverage criteria
sapropterin (Kuvan, Javygtor)	Coverage requires the following: <ol style="list-style-type: none"> 1. Treatment of phenylketonuria (PKU) 2. Following a phenylalanine-restricted diet
Savella	Coverage requires the following <ol style="list-style-type: none"> 1. Diagnosis of fibromyalgia 2. Treatment failure or intolerance to gabapentin 3. Treatment failure or intolerance to 3 of the following: <ol style="list-style-type: none"> a. Tricyclic antidepressant b. Selective serotonin reuptake inhibitor (SSRI) c. Serotonin norepinephrine reuptake inhibitor (SNRI) d. Cyclobenzaprine (Flexeril) e. Tramadol (Ultram) <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>

Drug name	Current Blue Cross and BCN coverage criteria
Saxenda	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Age ≥ 18 years old 2. BMI ≥ 30, or ≥ 27 with one weight related comorbid condition 3. Current weight (within 30 days) must be submitted to the plan for review 4. Active participation for a minimum of 6 months in a covered BCBSM/BCN lifestyle modification program OR active participation for a minimum of 6 months in an alternative concurrent lifestyle modification program (e.g. recent food diaries, exercise logs, program receipts, app participation, etc.) if member does not have access to a covered BCBSM/BCN program 5. Not to be used in combination with other weight loss products 6. Cannot be used in combination with other glucagon-like peptide-1(GLP-1) agonist containing products <p>OR</p> <ol style="list-style-type: none"> 1. 12 to 17 years of age 2. BMI corresponding to 30 or greater for adults 3. Current weight (within 30 days) above 132 lb (60 kg) must be submitted to the plan for review 4. Active participation for a minimum of 6 months in a covered BCBSM/BCN lifestyle modification program OR active participation for a minimum of 6 months in an alternative concurrent lifestyle modification program (e.g. recent food diaries, exercise logs, program receipts, app participation, etc.) if member does not have access to a covered BCBSM/BCN program 5. Not to be used in combination with other weight loss products 6. Cannot be used in combination with other glucagon-like peptide-1(GLP-1) agonist containing products <p>Initial approval: 6 months</p> <p><u>For adults</u>, continued coverage will be reviewed annually and may be provided if the member has maintained at least a 4% weight loss from baseline AND requires continued participation in a lifestyle modification program. Current weight (within 30 days) and BMI ≥ 18.5kg/m2 must be submitted to the plan for review. Saxenda cannot be used in combination with other glucagon-like peptide-1 (GLP-1) agonist containing products</p> <p><u>For pediatrics</u>, continued coverage will be reviewed annually and may be provided if the member has maintained at least a 1% reduction in BMI from baseline AND requires continued participation in a lifestyle modification program. Current weight (within 30 days) and BMI-for-age percentile ≥ 5th percentile must be submitted to the plan for review. Saxenda cannot be used in combination with other glucagon-like peptide-1 (GLP-1) agonist containing products</p>

Drug name	Current Blue Cross and BCN coverage criteria
Scemblix	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Treatment of philadelphia chromosome - positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) 2. Previously treated with two or more tyrosine kinase inhibitors (TKIs) 3. Age ≥ 18 years old <p>OR</p> <ol style="list-style-type: none"> 1. Treatment of philadelphia chromosome - positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) 2. Presence of T315I mutation 3. Age ≥ 18 years old <p>Initial approval: 1 year Continuation of treatment requires a lack of disease progression</p>
Secuado	<p>Coverage requires the following:</p> <p>Trial and failure, contraindication, or intolerance to two preferred second generation antipsychotics (examples include: aripiprazole, clozapine, risperidone, quetiapine, olanzapine, ziprasidone)</p> <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>
Serostim	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of AIDS wasting cachexia 2. Concomitant anti-viral therapy for the duration of treatment
sertraline HCl capsule	<p>Coverage requires that the member has been stable on generic sertraline tablets at a dose of 150 mg or 200 mg daily for at least 3 months</p> <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>

Drug name	Current Blue Cross and BCN coverage criteria
Seysara	Coverage requires trial of a generic tetracycline product Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit
Signifor	Coverage requires the following: <ol style="list-style-type: none"> 1. Treatment of hypercortisolism as a result of endogenous Cushing's syndrome 2. Surgical treatment has not been effective or is not an option 3. Treatment failure or intolerance to ketoconazole, mitotane, or cabergoline, unless contraindicated Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit
sildenafil citrate suspension (Revatio)	Coverage is provided for the treatment of pulmonary arterial hypertension (WHO Group 1) when the member is unable to swallow tablets/capsules Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit
sildenafil citrate tablet (Revatio)	Coverage is provided for the treatment of pulmonary arterial hypertension (WHO Group 1) Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit
sildenafil (Viagra)	May be covered for the diagnosis of erectile dysfunction dependent on the plan's benefit with quantity limit restrictions

Drug name	Current Blue Cross and BCN coverage criteria
Simponi	<p>Coverage requires the following:</p> <ul style="list-style-type: none"> 1. Diagnosis of Ankylosing Spondylitis 2. Age ≥ 18 years old <p>OR</p> <ul style="list-style-type: none"> 1. Diagnosis of Rheumatoid Arthritis 2. Age ≥ 18 years old 3. Trial and treatment failure to one Disease Modifying Anti-Rheumatic Drug (DMARD) after a minimum 3-month trial (examples include methotrexate, hydroxychloroquine, leflunomide, sulfasalazine) <p>OR</p> <ul style="list-style-type: none"> 1. Diagnosis of Psoriatic Arthritis 2. Age ≥ 18 years old <p>OR</p> <ul style="list-style-type: none"> 1. Diagnosis of Ulcerative Colitis 2. Age ≥ 18 years old 3. Treatment with an adequate course of conventional therapy (such as steroids for 7 days, immunomodulators such as azathioprine for at least 2 months) has been ineffective or is contraindicated or not tolerated <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>
Sirturo	<p>Coverage requires the following:</p> <ul style="list-style-type: none"> 1. Age ≥ 5 years old and weighting at least 15 kg 2. Treatment of pulmonary multi-drug resistant tuberculosis (MDR-TB)

Drug name	Current Blue Cross and BCN coverage criteria
Skyclarys	Coverage requires the following: <ol style="list-style-type: none"> 1. Diagnosis of Friedreich's ataxia 2. Age ≥ 16 years old 3. Confirmation of diagnosis via genetic testing revealing two pathogenic mutations of the frataxin (FXN) gene Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit
Skyrizi	Coverage requires the following: <ol style="list-style-type: none"> 1. Diagnosis of Psoriasis 2. Age ≥ 18 years old 3. Trial and treatment failure of one topical steroid OR <ol style="list-style-type: none"> 1. Diagnosis of Psoriatic Arthritis 2. Age ≥ 18 years old OR <ol style="list-style-type: none"> 1. Diagnosis of Crohn's Disease 2. Age ≥ 18 years old 3. Treatment with an adequate course of conventional therapy (such as steroids for 7 days, immunomodulators such as azathioprine for at least 2 months) has been ineffective or is contraindicated or not tolerated Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit

Drug name	Current Blue Cross and BCN coverage criteria
Sohonos	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Age ≥ 8 years old for females OR age ≥ 10 years old for males 2. Diagnosis of fibrodysplasia ossificans progressiva (FOP) confirmed by genetic testing showing an ACVR1 mutation, for the reduction in the volume of new heterotopic ossification (HO) <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>
Somavert	<p>Coverage requires the following:</p> <p>Diagnosis of acromegaly in patients who have had an inadequate response to surgery and/or for whom surgery is not an option</p>
sorafenib (Nexavar)	<p>Coverage is provided for the treatment of FDA approved indications</p>
Sotyktu	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of Psoriasis 2. Age ≥ 18 years old 3. Trial and treatment failure of one topical steroid 4. Trial and treatment failure of three of the following: Cimzia, Enbrel, Humira, Skyrizi, Stelara, or Tremfya 5. Trial and treatment failure of Taltz <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>

Drug name	Current Blue Cross and BCN coverage criteria
Spritam	Coverage requires the following: <ol style="list-style-type: none"> 1. Treatment of seizure disorder/epilepsy 2. Member is unable to swallow tablets or capsules 3. Trial of 3 generic or preferred alternatives, one of which must be generic levetiracetam (Keppra) solution Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit
Sprycel	Coverage is provided for the treatment of the FDA approved indications
Staxyn	May be covered for the diagnosis of erectile dysfunction dependent on the plan's benefit with quantity limit restrictions

Drug name	Current Blue Cross and BCN coverage criteria
Stelara	<p>Coverage requires the following:</p> <ul style="list-style-type: none"> 1. Diagnosis of Psoriasis 2. Age ≥ 6 years old 3. Trial and treatment failure of one topical steroid <p>OR</p> <ul style="list-style-type: none"> 1. Diagnosis of Psoriatic Arthritis 2. Age ≥ 6 years old <p>OR</p> <ul style="list-style-type: none"> 1. Diagnosis of Crohn's Disease 2. Age ≥ 18 years old 3. Treatment with an adequate course of conventional therapy (such as steroids for 7 days, immunomodulators such as azathioprine for at least 2 months) has been ineffective or is contraindicated or not tolerated <p>OR</p> <ul style="list-style-type: none"> 1. Diagnosis of Ulcerative Colitis 2. Age ≥ 18 years old 3. Treatment with an adequate course of conventional therapy (such as steroids for 7 days, immunomodulators such as azathioprine for at least 2 months) has been ineffective or is contraindicated or not tolerated <p>Initial approval: 1 year Renewal requires current medical necessity criteria are met, and that the medication is effective</p>
Stendra	May be covered for the diagnosis of erectile dysfunction dependent on the plan's benefit with quantity limit restrictions

Drug name	Current Blue Cross and BCN coverage criteria
Stivarga	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of metastatic or unresectable gastrointestinal stromal tumors and disease progression or intolerance to treatment with imatinib and sunitinib <p>OR</p> <ol style="list-style-type: none"> 2. Diagnosis of metastatic colorectal cancer (mCRC) and prior treatment with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild type, an anti-EGFR therapy <p>OR</p> <ol style="list-style-type: none"> 3. Treatment of hepatocellular cancer in patients who have previously been treated with sorafenib <p>Initial approval: 1 year Continuation of treatment requires a lack of disease progression</p>
Strensiq	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of perinatal/infantile and juvenile-onset hypophosphatasia. 2. < 18 years old at onset of symptoms 3. Diagnosis confirmed by one or two pathogenic variants in the ALPL gene + 4. Must have active disease manifestations such as: skeletal malformations/fractures, respiratory difficulties, dental manifestations, kidney damage, or seizures <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>
Sucraid	Coverage is provided for the treatment of congenital sucrase-isomaltase deficiency

Drug name	Current Blue Cross and BCN coverage criteria
sumatriptan succinate/ naproxen sodium (Treximet)	Coverage requires the following: <ol style="list-style-type: none"> 1. Treatment failure or intolerance to generic sumatriptan (Imitrex) and naproxen used in combination 2. Treatment failure or intolerance to a second generic triptan (Maxalt, Amerge, Zomig/ZMT) OR <ol style="list-style-type: none"> 1. Age 12-17 years old 2. Treatment failure or intolerance to generic Maxalt (rizatriptan) Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit
sunitinib (Sutent)	Coverage requires the following: <ol style="list-style-type: none"> 1. Treatment of advanced renal cell carcinoma (RCC) OR <ol style="list-style-type: none"> 1. Treatment of gastrointestinal stromal tumor (GIST) 2. Disease progression or intolerance to imatinib (Gleevec) OR <ol style="list-style-type: none"> 1. Treatment of progressive, well-differentiated pancreatic neuroendocrine tumors in patients with unresectable locally advanced or metastatic disease OR <ol style="list-style-type: none"> 1. Adjuvant treatment of adult patients at high risk of recurrent RCC following nephrectomy
Sunosi	Coverage requires the following: <ol style="list-style-type: none"> 1. Diagnosis of excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (OSA) 2. Age ≥ 18 years old 3. For a diagnosis of OSA: Nonpharmacologic treatment has been initiated (ex. CPAP) for at least one month Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit

Drug name	Current Blue Cross and BCN coverage criteria
Symdeko	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Age \geq 6 years old 2. Diagnosis of cystic fibrosis (CF) 3. Presence of two copies of the F508del mutation OR at least one mutation in the CFTR gene that is responsive to Symdeko as confirmed by genetic test <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>
Sympazan	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of Lennox-Gastaut syndrome <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>
Synribo	<p>Coverage requires the following:</p> <p>Treatment of adult patients with chronic or accelerated phase chronic myeloid leukemia (CML) with resistance and/or intolerance to two or more tyrosine kinase inhibitors</p> <p>Initial approval: 1 year Continuation of treatment requires a lack of disease progression</p>

Drug name	Current Blue Cross and BCN coverage criteria
Tabrecta	Coverage requires the following: <ol style="list-style-type: none"> 1. Age ≥ 18 years old 2. Diagnosis of metastatic non-small cell lung cancer (NSCLC) 3. Tumor has a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping Initial approval: 1 year Continuation of treatment requires a lack of disease progression
tadalafil (Adcirca, Alyq)	Coverage requires the diagnosis of pulmonary arterial hypertension (WHO Group 1) Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit
tadalafil (Cialis)	May be covered for the diagnosis of erectile dysfunction dependent on the plan's benefit with quantity limit restrictions
Tadliq	Coverage requires the following: <ol style="list-style-type: none"> 1. Diagnosis of pulmonary arterial hypertension (WHO Group 1) 2. Member is unable to swallow tablets 3. Trial and failure, intolerance or contraindication to generic sildenafil suspension Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit

Drug name	Current Blue Cross and BCN coverage criteria
Tafinlar	<p>Coverage requires the following:</p> <ul style="list-style-type: none"> 1. Diagnosis of melanoma 2. Presence of BRAF V600E or V600K mutation 3. Using as a single agent or in combination with Mekinist (trametinib) <p>OR</p> <ul style="list-style-type: none"> 1. Diagnosis of metastatic non-small cell lung cancer or advanced or metastatic anaplastic thyroid cancer 2. Presence of BRAF V600 E mutation 3. Using in combination with Mekinist (trametinib) <p>OR</p> <ul style="list-style-type: none"> 1. Age ≥ 1 year old 2. Diagnosis of unresectable or metastatic solid tumors who have progressed following prior treatment and have no satisfactory alternative treatment options 3. Presence of with BRAF V600E mutation 4. Using in combination with Mekinist (trametinib) <p>OR</p> <ul style="list-style-type: none"> 1. Age ≥ 1 year old 2. Diagnosis of low-grade glioma (LGG) with a BRAF V600E mutation requiring systemic therapy 3. Using in combination with Mekinist <p>Initial approval: 1 year Continuation of treatment requires a lack of disease progression</p>

Drug name	Current Blue Cross and BCN coverage criteria
Tagrisso	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of metastatic epidermal growth factor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC) as detected by an FDA-approved test 2. Progression on or after EGFR tyrosine kinase inhibitor (TKI) therapy <p>OR</p> <ol style="list-style-type: none"> 1. Diagnosis of metastatic non-small cell lung cancer (NSCLC) 2. Presence of EGFR exon 19 deletions or exon 21 L858R mutation <p>OR</p> <ol style="list-style-type: none"> 1. Adjuvant treatment of non-small cell lung cancer (NSCLC) after tumor resection 2. Presence of EGFR exon 19 deletion or exon 21 L858R mutation as detected by an FDA-approved test <p>OR</p> <ol style="list-style-type: none"> 1. Diagnosis of locally advanced or metastatic non-small cell lung cancer (NSCLC) 2. Presence of EGFR exon 19 deletion or exon 21 L858R mutation as detected by an FDA-approved test 3. Using as first-line treatment in combination with pemetrexed and platinum-based chemotherapy <p>Initial approval: 1 year Continuation of treatment requires a lack of disease progression</p>

Drug name	Current Blue Cross and BCN coverage criteria
Takhzyro	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of hereditary angioedema (HAE) 2. Diagnosis confirmed by genetic testing or with the following laboratory findings: <ol style="list-style-type: none"> i. C4 level below the limits of the laboratory's normal reference range (normal range = 16-58 mg/dL) ii. C1INH (antigenic or function) below the limits of the laboratory's normal reference range (normal range ≥41%) 3. History of at least 2 HAE attacks per month OR a history of attacks that are considered severe with swelling of the face, throat or gastrointestinal tract 4. Prescribed by an immunologist, allergist or hematologist 5. Not to be used in combination with other products indicated for HAE prophylaxis <p>Initial approval: 1 year Renewal requires improvement in HAE demonstrated by a 50% reduction in the number of attacks OR the severity of HAE attacks was reduced by 50% or more</p>

Drug name	Current Blue Cross and BCN coverage criteria
Taltz	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of Psoriasis 2. Age ≥ 6 years old 3. Trial and treatment failure of one topical steroid 4. Trial and treatment failure of one of the following: Enbrel, Humira, Cimzia, Skyrizi, Stelara, or Tremfya <p>OR</p> <ol style="list-style-type: none"> 1. Diagnosis of Psoriatic Arthritis 2. Age ≥ 18 years old 3. Trial and treatment failure of one of the following: Enbrel, Humira, Cimzia, Simponi, Stelara, Skyrizi, Rinvoq, Tremfya, or Xeljanz/XR <p>OR</p> <ol style="list-style-type: none"> 1. Diagnosis of active Non-Radiographic Axial Spondyloarthritis with objective signs of inflammation 2. Age ≥ 18 years old 3. Trial and treatment failure of Cimzia or Rinvoq <p>OR</p> <ol style="list-style-type: none"> 1. Diagnosis of active Ankylosing Spondylitis 2. Age ≥ 18 years old 3. Trial and treatment failure of Enbrel, Humira, Cimzia, Simponi, Xeljanz/XR, or Rinvoq <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>

Drug name	Current Blue Cross and BCN coverage criteria
Talzenna	Coverage requires the following: <ol style="list-style-type: none"> 1. Diagnosis of HER2-negative locally advanced or metastatic breast cancer 2. Presence of deleterious BRCA mutation, as detected by an FDA approved test OR <ol style="list-style-type: none"> 1. Diagnosis of metastatic castration-resistant prostate cancer (mCRPC) 2. Presence of homologous recombination repair (HRR) gene mutation 3. Using in combination with enzalutamide Initial approval: 1 year Continuation of treatment requires a lack of disease progression
tamoxifen	Coverage for \$0 copayment will be provided when: <ol style="list-style-type: none"> 1. The member is a woman at least 35 years of age 2. The medication is being used for prevention of primary breast cancer in members classified as high risk 3. Does not have a history of breast cancer 4. Does not have a family or personal history of venous thromboembolic events (VTE)
Targretin gel	Coverage requires the following: <ol style="list-style-type: none"> 1. Diagnosis of Cutaneous T-cell lymphoma 2. Topical treatment of cutaneous lesions

Drug name	Current Blue Cross and BCN coverage criteria
Tarpeyo	Coverage requires the following: <ol style="list-style-type: none"> 1. Intended to reduce the loss of kidney function for the diagnosis of primary immunoglobulin A nephropathy (IgAN) at risk of disease progression 2. Age ≥ 18 years old 3. Trial and failure to maximally tolerated dose of angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) therapy unless contraindicated 4. Trial and failure, contraindication, or intolerance to generic methylprednisolone, prednisolone, or prednisone Initial approval: 9 months
Tascenso ODT	Coverage requires the following: <ol style="list-style-type: none"> 1. Diagnosis of multiple sclerosis (MS) 2. Age ≥ 10 years old 3. Will not be used in combination with other disease-modifying treatments for multiple sclerosis Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit
Tasigna	Coverage is provided for the treatment of the FDA approved indications

Drug name	Current Blue Cross and BCN coverage criteria
tasimelteon (Hetlioz)	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Age ≥ 18 years old 2. Diagnosis of Non-24-hour sleep-wake disorder in patients who are totally blind and unable to perceive light 3. Trial and failure, contraindication, or intolerance to over-the-counter melatonin AND Rozerem (ramelteon) <p>OR</p> <ol style="list-style-type: none"> 1. Age ≥ 16 years old 2. Diagnosis of nighttime sleep disturbances in Smith-Magenis Syndrome (SMS) confirmed by genetic testing showing deletion of chromosome 17p11.2 OR mutation in the retinoic acid-induced 1 (RAI1) gene 3. Trial and failure, contraindication, or intolerance to over-the-counter melatonin AND acebutolol 4. For adults only- Trial and failure, contraindication, or intolerance to Rozerem (ramelteon) <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>
Tavalisse	<p>Coverage requires the following:</p> <p>Diagnosis of chronic immune thrombocytopenia (IT) and persistent thrombocytopenia (platelet count < 100,000 mcL) for ≥ 3 months and all of the following:</p> <ol style="list-style-type: none"> 1. Age ≥ 18 years old 2. Prescribed by or in consultation with a hematologist 3. Trial and treatment failure or not a candidate for treatment with corticosteroids, immunoglobulins or splenectomy 4. Current platelet count is < 20,000 mcL or < 30,000 mcL and symptoms of active bleeding 5. Trial of Promacta <p>Initial approval: 3 months Renewal requires a stable platelet count of at least 50,000/mcL</p>

Drug name	Current Blue Cross and BCN coverage criteria
Tavneos	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Adjunctive treatment of severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis [GPA] and microscopic polyangiitis [MPA]) in combination with standard therapy including glucocorticoids 2. Age ≥ 18 years old 3. Must be initiated in combination with a standard therapy regimen that includes either cyclophosphamide plus glucocorticoids or rituximab/rituximab biosimilar plus glucocorticoids <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>
Tazverik	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Age ≥ 16 years old 2. Diagnosis of epithelioid sarcoma 3. Not eligible for complete resection <p>OR</p> <ol style="list-style-type: none"> 1. Age ≥ 18 years old 2. Diagnosis of relapsed or refractory follicular lymphoma with tumors that are positive for an EZH2 mutation as detected by an FDA-approved test 3. Received at least 2 prior therapies <p>OR</p> <ol style="list-style-type: none"> 1. Age ≥ 18 years old 2. Diagnosis of relapsed or refractory follicular lymphoma 3. No satisfactory alternative treatment options

Drug name	Current Blue Cross and BCN coverage criteria
Tegsedi	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Age ≥ 18 years old 2. Diagnosis of peripheral nerve disease caused by hereditary transthyretin-mediated amyloidosis (hATTR) with a TTR gene mutation 3. Signs and symptoms of ocular or cerebral area involvement (such as intraocular amyloidosis or primary/leptomeningeal amyloidosis), if present, must not predominate over polyneuropathy symptomology associated with hATTR 4. Clinical signs and symptoms of peripheral neuropathy (such as: tingling or increased pain in the hands, feet and/or arms, loss of feeling in the hands and/or feet, numbness or tingling in the wrists, carpal tunnel syndrome, loss of ability to sense temperature, difficulty with fine motor skills, weakness in the legs, difficulty walking)AND/OR clinical signs and symptoms of autonomic neuropathy symptoms (such as: orthostasis, abnormal sweating, dysautonomia [constipation and/or diarrhea, nausea, vomiting, anorexia, early satiety]) 5. Must have a baseline polyneuropathy disability (PND) score ≤ IIIb and/or baseline FAP Stage 1 or 2 6. Must not have New York Heart Association (NYHA) heart failure classification > 2 7. Must not have undergone a prior liver transplant <p>Tegsedi will not be approved for use in combination with other therapies approved for transthyretin-mediated amyloidosis Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>

Drug name	Current Blue Cross and BCN coverage criteria
teriparatide (Forteo)	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. History of fragility fracture 2. Will not be used in combination with bisphosphonates, another anabolic bone-modifying agent or denosumab <p>OR</p> <ol style="list-style-type: none"> 1. Diagnosis of osteoporosis 2. Treatment with a bisphosphonate has been ineffective after at least a 12-month treatment period based on objective documentation (such as reduction in T score or fracture) UNLESS one of the following: <ol style="list-style-type: none"> a. Treatment with bisphosphonates (both oral and intravenous) are not tolerated or contraindicated b. History of fracture(s) c. T-score less than -3.0 3. Will not be used in combination with bisphosphonates, another anabolic bone-modifying agent or denosumab <p>Initial approval: 2 years Use of Forteo for more than 2 years should only be considered if high risk for fracture remains or has returned</p>
Testosterone, topical Androgel, generic Androgel, Androderm	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of male hypogonadism 2. Two signs and symptoms specific to testosterone deficiency <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>

Drug name	Current Blue Cross and BCN coverage criteria
Testosterone, topical generic Axiron, generic Fortesta generic Testim, Testosterone 10mg (2%) Testosterone 30mg Testosterone 50mg (1%) generic Vogelxo	Coverage requires the following: <ol style="list-style-type: none"> 1. Diagnosis of male hypogonadism 2. Two signs and symptoms specific to testosterone deficiency Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit
tetrabenazine (Xenazine)	Coverage requires the diagnosis of chorea associated with Huntington's disease Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit

Drug name	Current Blue Cross and BCN coverage criteria
Tezspire	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of eosinophilic asthma 2. Age ≥ 12 years old 3. Patient is currently receiving, and will continue to receive standard of care regimen 4. Failure to maintain adequate control after at least a 3-month trial of daily oral corticosteroids or high dose inhaled corticosteroids in combination with: <ol style="list-style-type: none"> a. LABA (long acting inhaled β2 agonist) OR <ol style="list-style-type: none"> b. Leukotriene modifier OR <ol style="list-style-type: none"> c. LAMA (long acting muscarinic antagonist) 5. Cannot be used in combination with other biologic agents indicated for asthma <p>OR</p> <ol style="list-style-type: none"> 1. Diagnosis of allergic asthma 2. Age ≥ 12 years old 3. Patient is currently receiving, and will continue to receive standard of care regimen 4. Failure to maintain adequate control after at least a 3-month trial of daily oral corticosteroids or high dose inhaled corticosteroids in combination with: <ol style="list-style-type: none"> a. LABA (long acting inhaled β2 agonist) OR <ol style="list-style-type: none"> b. Leukotriene modifier OR <ol style="list-style-type: none"> c. LAMA (long acting muscarinic antagonist) 5. Cannot be used in combination with other biologic agents indicated for asthma <p>(criteria continued next page)</p>

Drug name	Current Blue Cross and BCN coverage criteria
Tezspire (continued)	<p>OR</p> <ol style="list-style-type: none"> 1. Diagnosis of oral corticosteroid dependent asthma 2. Age ≥ 12 years old 3. Patient is currently receiving, and will continue to receive standard of care regimen 4. Failure to maintain adequate control after at least a 3-month trial of daily oral corticosteroids or high dose inhaled corticosteroids in combination with: <ol style="list-style-type: none"> a. LABA (long acting inhaled β2 agonist) <p>OR</p> <ol style="list-style-type: none"> b. Leukotriene modifier <p>OR</p> <ol style="list-style-type: none"> c. LAMA (long acting muscarinic antagonist) 5. Cannot be used in combination with other biologic agents indicated for asthma <p>OR</p> <ol style="list-style-type: none"> 1. Diagnosis of severe asthma 2. Age ≥ 12 years old 3. Patient is currently receiving, and will continue to receive standard of care regimen 4. Failure to maintain adequate control after at least a 3-month trial of daily oral corticosteroids or high dose inhaled corticosteroids in combination with: <ol style="list-style-type: none"> a. LABA (long acting inhaled β2 agonist) <p>OR</p> <ol style="list-style-type: none"> b. Leukotriene modifier <p>OR</p> <ol style="list-style-type: none"> c. LAMA (long acting muscarinic antagonist) 5. Cannot be used in combination with other biologic agents indicated for asthma <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>
Tibsovo	Coverage requires the treatment of FDA approved indications

*For drugs covered under the commercial Blue Cross or BCN medical benefit, please see the [Blue Cross and BCN Utilization Management Medical Drug List](#)
 Blue Cross Blue Shield of Michigan and Blue Care Network are nonprofit corporations and independent licensees of the Blue Cross and Blue Shield Association.

Drug name	Current Blue Cross and BCN coverage criteria
Teglutik	Coverage requires the following: <ol style="list-style-type: none"> 1. Diagnosis of Amyotrophic Lateral Sclerosis (ALS) 2. Trial of generic riluzole tablets OR <ol style="list-style-type: none"> 2. Difficulty swallowing Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit
tiopronin (Thiola)	Coverage requires the following: <ol style="list-style-type: none"> 1. For the prevention of cystine stone formation in patients weighing ≥ 20 kilograms 2. Resistant to treatment with conservative measures of high fluid intake, sodium restriction, limited protein intake and urine alkalization Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit
tiopronin (Thiola EC)	Coverage requires the following: <ol style="list-style-type: none"> 1. For the prevention of cystine stone formation in patients weighing ≥ 20 kilograms 2. Resistant to treatment with conservative measures of high fluid intake, sodium restriction, limited protein intake and urine alkalization Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit

Drug name	Current Blue Cross and BCN coverage criteria
Tivorbex	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Age ≥ 17 years old 2. Diagnosis of acute pain 3. Trial and treatment failure of oral indomethacin 4. Trial and treatment failure of two other oral preferred NSAIDs <p>Initial approval: 3 months</p>
Tlando	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of male hypogonadism 2. Two signs and symptoms specific to testosterone deficiency 3. Trial and failure, contraindication, or intolerance to one generic or preferred testosterone product (examples include generic AndroGel, Androderm, and generic Depo-Testosterone) <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>
tolvaptan (Samsca)	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Age ≥ 18 years old 2. Diagnosis of clinically significant hyponatremia 3. Hyponatremia is defined as serum sodium <125 mEq/L or less marked hyponatremia that is symptomatic and has resisted correction with fluid restriction 4. Therapy is initiated/re-initiated in a hospital <p>Approval: 60 days</p>

Drug name	Current Blue Cross and BCN coverage criteria
topiramate ER (Qudexy XR)	<p>Coverage requires the following:</p> <ul style="list-style-type: none"> 1. Treatment of seizure disorder/epilepsy 2. Treatment failure or intolerance to at least 3 generic alternatives, one of which must be generic topiramate (Topamax) <p>OR</p> <ul style="list-style-type: none"> 1. For preventative treatment of migraine headaches 2. Age ≥ 12 years old 3. Treatment failure or intolerance to 3 generic alternatives for the prevention of migraines, one of which must be generic topiramate (Topamax) <p>OR</p> <ul style="list-style-type: none"> 1. Diagnosis of Lennox-Gastaut Syndrome 2. Treatment failure or intolerance to at least 2 generic alternatives, one of which must be generic topiramate (Topamax) <p>Initial approval: 1 year Renewal requires that current criteria are met and that the medication is providing clinical benefit</p>
topiramate extended release (Trokendi XR)	<p>Coverage requires the following:</p> <ul style="list-style-type: none"> 1. Treatment of seizure disorder/epilepsy 2. Treatment failure or intolerance to at least 3 generic alternatives, one of which must be generic topiramate (Topamax) <p>OR</p> <ul style="list-style-type: none"> 1. For preventative treatment of migraine headaches 2. Age ≥ 12 years old 3. Treatment failure or intolerance to 3 generic alternatives for the prevention of migraines, one of which must be generic topiramate (Topamax) <p>OR</p> <ul style="list-style-type: none"> 1. Diagnosis of Lennox-Gastaut Syndrome 2. Treatment failure or intolerance to at least 2 generic alternatives, one of which must be generic topiramate (Topamax) <p>Initial approval: 1 year Renewal requires that current criteria are met and that the medication is providing clinical benefit</p>

Drug name	Current Blue Cross and BCN coverage criteria
Tracleer (suspension)	Coverage requires the following: <ol style="list-style-type: none"> 1. Diagnosis of pulmonary arterial hypertension (WHO Group 1) 2. Trial and treatment failure of sildenafil or tadalafil AND ambrisentan or bosentan
Tremfya	Coverage requires the following: <ol style="list-style-type: none"> 1. Diagnosis of Psoriasis 2. Age ≥ 18 years old 3. Trial and treatment failure of one topical steroid OR <ol style="list-style-type: none"> 1. Diagnosis of Psoriatic Arthritis 2. Age ≥ 18 years old Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit
trientine hydrochloride (Syprine)	Coverage requires the following: <ol style="list-style-type: none"> 1. Diagnosis of Wilson's disease Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit

Drug name	Current Blue Cross and BCN coverage criteria
Trikafta	Coverage requires the following: <ol style="list-style-type: none"> 1. Diagnosis of cystic fibrosis 2. Age \geq 2 years old 3. Presence of at least one copy of the F508del mutation OR at least one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to Trikafta as confirmed by genetic test 4. Member is not using Trikafta in combination with an additional CFTR potentiator such as: Orkambi, Kalydeco, or Symdeko Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit
Trintellix	Coverage requires trial and failure, contraindication, or intolerance to two antidepressant agents
Trulance	Coverage requires the following: Trial and treatment failure or intolerance to Linzess
Trulicity	Coverage requires the following: <ol style="list-style-type: none"> 1. For the treatment of Type 2 Diabetes or trial of one generic or preferred medication for the treatment of Type 2 Diabetes 2. Cannot be used in combination with other glucagon-like peptide-1 (GLP-1) agonist-containing products Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit

Drug name	Current Blue Cross and BCN coverage criteria
Truqap	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer 2. Age ≥ 18 years old 3. Presence of one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test 4. Progression on at least one endocrine-based regimen in the metastatic setting OR recurrence on or within 12 months of completing adjuvant therapy 5. Using in combination with fulvestrant <p>Initial approval: 1 year Continuation of treatment requires a lack of disease progression</p>
Tukysa	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Age ≥ 18 years old 2. Diagnosis of advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer 3. Have received one or more prior anti-HER2-based regimens in the metastatic setting 4. Using in combination with trastuzumab and capecitabine <p>OR</p> <ol style="list-style-type: none"> 1. Age ≥ 18 years old 2. Diagnosis of unresectable or metastatic RAS wild-type HER2-positive colorectal cancer 3. Previous treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy 4. Using in combination with trastuzumab <p>Initial approval: 1 year Continuation of treatment requires a lack of disease progression</p>

Drug name	Current Blue Cross and BCN coverage criteria
Turalio	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) 2. Condition is associated with severe morbidity or functional limitations 3. Will not be amenable to improvement with surgery. <p>Initial approval: 1 year Continuation of treatment requires a lack of disease progression</p>
Tymlos	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. History of fragility fracture 2. Will not be used in combination with bisphosphonates, another anabolic bone-modifying agent or denosumab <p>OR</p> <ol style="list-style-type: none"> 1. Diagnosis of osteoporosis 2. Treatment with a bisphosphonate has been ineffective after at least a 12-month treatment period based on objective documentation (such as reduction in T score or fracture) UNLESS one of the following: <ol style="list-style-type: none"> a. Treatment with bisphosphonates (both oral and intravenous) are not tolerated or contraindicated b. History of fracture(s) c. T-score less than -3.0 3. Will not be used in combination with bisphosphonates, another anabolic bone-modifying agent or denosumab <p>Tymlos will be approved for a maximum of 2 years</p>

Drug name	Current Blue Cross and BCN coverage criteria
Tyvaso / Tyvaso DPI	Coverage requires the following: <ol style="list-style-type: none"> 1. Treatment of pulmonary arterial hypertension (WHO Group 1) 2. Trial and treatment failure of sildenafil or tadalafil AND ambrisentan or bosentan OR <ol style="list-style-type: none"> 1. Treatment of pulmonary arterial hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit
Ubrelyv	Coverage requires the following: <ol style="list-style-type: none"> 1. For acute treatment of migraine 2. Age ≥ 18 years old 3. Treatment failure or contraindication to 2 generic triptan medications Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit
Uptravi	Coverage requires the following: <ol style="list-style-type: none"> 1. Diagnosis of pulmonary arterial hypertension (WHO Group 1) 2. Trial and treatment failure of sildenafil or tadalafil AND ambrisentan or bosentan

*For drugs covered under the commercial Blue Cross or BCN medical benefit, please see the [Blue Cross and BCN Utilization Management Medical Drug List](#)
 Blue Cross Blue Shield of Michigan and Blue Care Network are nonprofit corporations and independent licensees of the Blue Cross and Blue Shield Association.

Drug name	Current Blue Cross and BCN coverage criteria
Valchlor	Coverage requires the following: <ol style="list-style-type: none"> 1. Diagnosis of Stage 1A or 1B mycosis fungoides type cutaneous T cell lymphoma 2. Trial and failure of two skin directed therapies (examples include phototherapy, total skin electron beam therapy, topical retinoids, corticosteroids, carmustine) Initial approval: 1 year Continuation of treatment requires a lack of disease progression
Vanflyta	Coverage requires the following: <ol style="list-style-type: none"> 1. Age ≥ 18 years old 2. For the treatment of newly diagnosed acute myeloid leukemia (AML) that is FLT3 internal tandem duplication (ITD)-positive as detected by an FDA-approved test 3. Using in combination with standard cytarabine and anthracycline induction and cytarabine consolidation OR <ol style="list-style-type: none"> 3. Using as maintenance monotherapy following consolidation chemotherapy Initial approval: 1 year Continuation of treatment requires a lack of disease progression
vardenafil (Levitra)	May be covered for the diagnosis of erectile dysfunction dependent on the plans benefit with quantity limit restrictions
varenicline (Chantix)	Coverage requires trial and failure of 2 preferred agents such as generic bupropion extended release (Zyban), nicotine patch, nicotine gum, nicotine lozenge for \$0 copayment

Drug name	Current Blue Cross and BCN coverage criteria
Vecamyl	Coverage requires treatment failure with or intolerance to all of the following drug classes: <ol style="list-style-type: none"> 1. Diuretic 2. Beta-Blocker 3. Ace-inhibitor 4. Angiotensin II receptor blocker 5. Calcium channel blocker
Venclexta	Coverage requires the treatment of FDA approved indications Initial approval: 1 year Continuation of treatment requires a lack of disease progression
Ventavis	Coverage requires the following: <ol style="list-style-type: none"> 1. Diagnosis of pulmonary arterial hypertension (WHO Group 1) 2. Trial and treatment failure of sildenafil or tadalafil AND ambrisentan or bosentan
Veozah	Coverage requires the following: <ol style="list-style-type: none"> 1. Treatment of moderate-to-severe vasomotor symptoms due to menopause 2. Age ≥ 18 years old 3. Trial and failure, contraindication, or intolerance to one preferred or generic medication for the treatment of vasomotor symptoms Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit

Drug name	Current Blue Cross and BCN coverage criteria
Verkazia	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of vernal keratoconjunctivitis 2. Age ≥ 4 years old 3. Trial and failure, or intolerance to a dual acting, topical antihistamine/mast-cell stabilizer such as epinastine, ketotifen and olopatadine 4. Trial and failure or intolerance to ophthalmic corticosteroids such as dexamethasone eye drops, Generic FML liquifilm, FML, FML forte, loteprednol and generic Pred Forte 5. Trial and failure or intolerance to generic Restasis <p>OR</p> <ol style="list-style-type: none"> 1. Diagnosis of vernal keratoconjunctivitis with compromised corneal epithelium/ corneal ulcers 2. Age ≥ 4 years old 3. Trial and failure or intolerance to generic Restasis <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>

Drug name	Current Blue Cross and BCN coverage criteria
Verquvo	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Age ≥ 18 years old 2. Diagnosis of chronic heart failure New York Heart Association (NYHA) Class II-IV 3. Left ventricular ejection fraction (LVEF) of less than 45% 4. History of ONE of the following: <ol style="list-style-type: none"> a. Previous hospitalization for heart failure within prior 6 months OR b. Outpatient intravenous (IV) diuretic treatment for heart failure within prior 3 months 5. Taken in combination with at least TWO of the following unless contraindicated or not tolerated: <ol style="list-style-type: none"> a. Metoprolol succinate, carvedilol, or bisoprolol b. An ACE-inhibitor (ACE, such as lisinopril), angiotensin receptor blocker (ARB, such as losartan), or angiotensin receptor-neprilysin inhibitor (ARNI, such as sacubitril/valsartan) c. A sodium glucose cotransporter-2 (SGLT2) inhibitor approved for heart failure d. A mineralocorticoid receptor antagonist <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>

*For drugs covered under the commercial Blue Cross or BCN medical benefit, please see the [Blue Cross and BCN Utilization Management Medical Drug List](#)
Blue Cross Blue Shield of Michigan and Blue Care Network are nonprofit corporations and independent licensees of the Blue Cross and Blue Shield Association.

Drug name	Current Blue Cross and BCN coverage criteria
Verzenio	<p>Coverage requires the following:</p> <ul style="list-style-type: none"> 1. Diagnosis of HR-positive, HER-2 negative advanced or metastatic breast cancer and ONE of the following: <ul style="list-style-type: none"> a. Using in combination with an aromatase inhibitor as initial therapy <p>OR</p> <ul style="list-style-type: none"> b. Using in combination with fulvestrant following endocrine therapy <p>OR</p> <ul style="list-style-type: none"> c. If metastatic, using as monotherapy following endocrine therapy AND prior chemotherapy <p>OR</p> <ul style="list-style-type: none"> 1. Diagnosis of early HR-positive, HER-2 negative, node-positive breast cancer at high risk of recurrence 2. Using in combination with adjuvant endocrine therapy <p>Initial approval: 1 year Continuation of coverage requires a lack of disease progression</p>
Viberzi	Coverage requires the diagnosis of irritable bowel syndrome with diarrhea (IBS-D) in adults
Victoza	<p>Coverage requires the following:</p> <ul style="list-style-type: none"> 1. For the treatment of Type 2 Diabetes or trial of one generic or preferred medication for the treatment of Type 2 Diabetes 2. Cannot be used in combination with other glucagon-like peptide-1 (GLP-1) agonist-containing products <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>

Drug name	Current Blue Cross and BCN coverage criteria
vigabatrin powder (Sabril)	Coverage requires the following: <ul style="list-style-type: none"> 1. Diagnosis of infantile spasms OR <ul style="list-style-type: none"> 1. Treatment of seizure disorder/epilepsy as adjunctive therapy 2. Trial and failure, contraindication, OR intolerance to three generic alternatives for the treatment of seizures Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit
vigabatrin tablet (Sabril)	Coverage requires the following: <ul style="list-style-type: none"> 1. Diagnosis of infantile spasms OR <ul style="list-style-type: none"> 1. Treatment of seizure disorder/epilepsy as adjunctive therapy 2. Trial and treatment failure of three generic alternatives for seizure 3. Trial of Sabril powder Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit
Viokace	Coverage requires trial and treatment failure of Creon and Zenpep Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit
Vitrakvi	Coverage requires the treatment of FDA approved indications Initial approval: 1 year Continuation of treatment requires a lack of disease progression

Drug name	Current Blue Cross and BCN coverage criteria
Vivjoa	Coverage requires the following: <ol style="list-style-type: none"> 1. Diagnosis recurrent vulvovaginal candidiasis (RVVC) in females with history of RVVC who are not of reproductive potential 2. Trial and failure, contraindication, or intolerance to generic oral fluconazole alone Approval: 12 weeks
Vizimpro	Coverage requires the following: Diagnosis of metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test
Vioice 50mg, 125mg tablet	Coverage requires the following: <ol style="list-style-type: none"> 1. Age \geq 2 years old 2. Diagnosis of PIK3CA - Related Overgrowth Spectrum (PROS) confirmed by detection of a PIK3CA mutation or based on clinical features suspected of PROS Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit
Vonjo	Coverage requires the following: <ol style="list-style-type: none"> 1. Diagnosis of intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count $<$ 50,000 mcl 2. Age \geq 18 years old Initial approval: 1 year Continuation of treatment requires a lack of disease progression

Drug name	Current Blue Cross and BCN coverage criteria
Voquezna	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. For the treatment of Helicobacter pylori (H. pylori) infection 2. Age ≥ 18 years old 3. Trial of a generic, guideline recommended, first-line regimen for H. pylori infection such as clarithromycin triple therapy (proton pump inhibitor (PPI) + clarithromycin + amoxicillin or metronidazole) or bismuth quadruple therapy (PPI + bismuth subcitrate or subsalicylate + tetracycline + metronidazole) <p>OR</p> <ol style="list-style-type: none"> 1. For the treatment of erosive esophagitis (EE) 2. Age ≥ 18 years old 3. Trial and failure, contraindication, or intolerance to three of the following generic or over the counter (OTC) PPIs: omeprazole (Prilosec), esomeprazole (Nexium), pantoprazole (Protonix), lansoprazole (Prevacid/Prevacid Solutab), and rabeprazole (Aciphex) <p>Approval for H. pylori: 60 days Approval for EE: 1 year</p>
Vosevi	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Age 18 years or older 2. For patients with chronic hepatitis C genotype 1, 2, 3, 4, 5, or 6 infection that have failed treatment regimen containing an NS5A (nonstructural protein 5A) inhibitor and have no liver damage or have liver damage and showing no symptoms from the damage 3. For patients with chronic hepatitis C genotype 1a or 3 that have previously failed sofosbuvir containing regimen without an NS5A inhibitor and have no liver damage or have liver damage and showing symptoms of the damage 4. If treatment experienced, documentation of previous treatments for Hepatitis C 5. If cirrhosis is present: documentation of decompensated or compensated cirrhosis <p>Drug will be reviewed based on a case by case basis utilizing AASLD guidelines and FDA approved package labeling</p>

Drug name	Current Blue Cross and BCN coverage criteria
Vowst	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. To prevent the recurrence of Clostridioides difficile infection (CDI) 2. Age ≥ 18 years old 3. Had at least 1 recurrence after a primary episode of CDI AND completed one or more round(s) of standard-of-care antibiotic therapy (ex: metronidazole, vancomycin, fidaxomicin) <p>OR</p> <ol style="list-style-type: none"> 3. Two or more episodes of severe CDI resulting in hospitalization within the past year 4. Positive C. difficile stool test with toxin A/B results within the previous 30 days 5. Not to be used in combination with other products for prevention of CDI, such as Zinplava or Rebyota <p>Approval: 60 days</p>
Voxzogo	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of achondroplasia 2. Presence of fibroblast growth factor receptor 3 (FGFR3) gene mutation confirming diagnosis 3. Open epiphyses 4. Recent growth velocity and height (growth velocity must be > 1.5 cm/year) <p>Initial approval: 1 year Renewal requires the presence of open epiphyses, and an updated height and growth velocity to show that growth has been maintained or increased from baseline</p>

Drug name	Current Blue Cross and BCN coverage criteria
Vtama	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Age ≥ 18 years old 2. Diagnosis of plaque psoriasis 3. Trial and failure, contraindication, or intolerance to a generic medium or high potency topical corticosteroid 4. Trial and failure, contraindication, or intolerance to at least one of the following generic topical steroid-sparing agents: calcipotriene, tazarotene, tacrolimus, or pimecrolimus <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>
Vyleesi	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Premenopausal female ≥ 18 years old 2. Diagnosis of acquired, generalized hypoactive sexual desire disorder (HSDD) that has been ongoing for more than 6 months 3. Other causes (such as relationship difficulty, substance abuse, medication side effects) of HSDD must be ruled out <p>Initial approval: 60 days Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>

Drug name	Current Blue Cross and BCN coverage criteria
Vyndamax	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-CM) confirmed by BOTH of the following: <ol style="list-style-type: none"> a. A negative monoclonal light chain screen ruling out amyloid light chain cardiomyopathy b. Technetium-labeled bone scintigraphy 2. Age \geq 18 years old 3. Clinical signs and symptoms of ATTR-CM <p>Vyndamax will not be approved for use in combination with other therapies approved for transthyretin-mediated amyloidosis Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>
Vyndaqel	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-CM) confirmed by BOTH of the following: <ol style="list-style-type: none"> a. A negative monoclonal light chain screen ruling out amyloid light chain cardiomyopathy b. Technetium-labeled bone scintigraphy 2. Age \geq 18 years old 3. Clinical signs and symptoms of ATTR-CM <p>Vyndaqel will not be approved for use in combination with other therapies approved for transthyretin-mediated amyloidosis Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>

Drug name	Current Blue Cross and BCN coverage criteria
Vyzulta	Coverage requires the following: <ol style="list-style-type: none"> 1. Diagnosis of elevated intraocular pressure Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit
Wakix	Coverage requires a diagnosis of narcolepsy AND: <ol style="list-style-type: none"> 1. Age ≥ 18 years old 2. Cataplexy OR <ol style="list-style-type: none"> 2. Excessive daytime sleepiness 3. Trial and failure, contraindication, or intolerance to either a generic stimulant or modafinil or armodafinil Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit

Drug name	Current Blue Cross and BCN coverage criteria
Wegovy	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Age ≥ 18 years old 2. BMI ≥ 30, or ≥ 27 with one weight related comorbid condition 3. Current weight (within 30 days) must be submitted to the plan for review 4. Active participation for a minimum of 6 months in a covered BCBSM/BCN lifestyle modification program OR active participation for a minimum of 6 months in an alternative concurrent lifestyle modification program (e.g. recent food diaries, exercise logs, program receipts, app participation, etc.) if member does not have access to a covered BCBSM/BCN program 5. Not to be used in combination with other weight loss products 6. Cannot be used in combination with other glucagon-like peptide-1(GLP-1) agonist containing products <p>OR</p> <ol style="list-style-type: none"> 1. 12 to 17 years of age 2. BMI ≥ 95th percentile, standardized for age and sex 3. Current weight (within 30 days) must be submitted to the plan for review 4. Active participation for a minimum of 6 months in a covered BCBSM/BCN lifestyle modification program OR active participation for a minimum of 6 months in an alternative concurrent lifestyle modification program (e.g. recent food diaries, exercise logs, program receipts, app participation, etc.) if member does not have access to a covered BCBSM/BCN program 5. Not to be used in combination with other weight loss products 6. Cannot be used in combination with other glucagon-like peptide-1(GLP-1) agonist containing products <p>Initial approval: 6 months</p> <p><u>For adults</u>, continued coverage will be reviewed annually and may be provided if the member has maintained at least a 5% weight loss from baseline AND requires continued participation in a lifestyle modification program. Current weight (within 30 days) and BMI ≥ 18.5kg/m2 must be submitted to the plan for review. Wegovy cannot be used in combination with other glucagon-like peptide-1 (GLP-1) agonist containing products</p> <p><u>For pediatrics</u>, continued coverage will be reviewed annually and may be provided if the member has maintained at least a 1% reduction in BMI from baseline AND requires continued participation in a lifestyle modification program. Current weight (within 30 days) and BMI-for-age percentile ≥ 5th percentile must be submitted to the plan for review. Wegovy cannot be used in combination with other glucagon-like peptide-1 (GLP-1) agonist containing products</p>

Drug name	Current Blue Cross and BCN coverage criteria
Welireg	<p>Coverage requires the following:</p> <ul style="list-style-type: none"> 1. Age ≥ 18 years old 2. Treatment of von Hippel - Lindau (VHL) disease requiring therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery <p>OR</p> <ul style="list-style-type: none"> 1. Diagnosis of advanced renal cell carcinoma (RCC) 2. Age ≥ 18 years old 3. Previously treated with a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI) <p>Initial approval: 1 year Continuation of treatment requires a lack of disease progression</p>
Xalkori	<p>Coverage requires the following:</p> <ul style="list-style-type: none"> 1. Diagnosis of metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK) or ROS1-positive as detected by an FDA-approved test <p>OR</p> <ul style="list-style-type: none"> 1. Diagnosis of relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive in pediatric patients 1 year of age and older and young adults <p>OR</p> <ul style="list-style-type: none"> 1. Diagnosis of unresectable, recurrent, or refractory inflammatory myofibroblastic tumor (IMT) that is ALK-positive <p>Initial approval: 1 year Continuation of treatment requires a lack of disease progression</p>

Drug name	Current Blue Cross and BCN coverage criteria
Xcopri	Coverage requires the following: <ol style="list-style-type: none"> 1. Treatment of seizures in patients with epilepsy 2. Has experienced treatment failure or intolerance to at least 3 generic alternatives for the treatment of seizures Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit
Xdemvy	Coverage requires the following: <ol style="list-style-type: none"> 1. Diagnosis of Demodex blepharitis confirmed via the presence of collarettes upon examination with a slit lamp 2. Age ≥ 18 years old Approval: 60 days

Drug name	Current Blue Cross and BCN coverage criteria
Xeljanz tablet	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of Rheumatoid Arthritis 2. Age ≥ 18 years old 3. Trial and failure of one Disease-Modifying Anti-Rheumatic Drug (DMARD) after a minimum 3-month trial (examples include methotrexate, hydroxychloroquine, leflunomide, sulfasalazine) 4. Trial and treatment failure of one or more tumor necrosis factor (TNF) inhibitor(s) <p>OR</p> <ol style="list-style-type: none"> 1. Diagnosis of Psoriatic Arthritis 2. Age ≥ 18 years old 3. Trial and treatment failure of one or more tumor necrosis factor (TNF) inhibitor(s) <p>OR</p> <ol style="list-style-type: none"> 1. Diagnosis of Ulcerative Colitis 2. Age ≥ 18 years old 3. Treatment with an adequate course of conventional therapy (such as steroids for 7 days, immunomodulators such as azathioprine for at least 2 months) has been ineffective or is contraindicated or not tolerated 4. Trial and treatment failure of one or more tumor necrosis factor (TNF) inhibitor(s) <p>OR</p> <ol style="list-style-type: none"> 1. Diagnosis of Polyarticular Juvenile Idiopathic Arthritis (JIA) 2. Age ≥ 2 years old 3. Trial and treatment failure of one Disease-Modifying Anti-Rheumatic Drug (DMARD) after a minimum 3-month trial (examples include methotrexate, leflunomide) 4. Trial and treatment failure of one or more tumor necrosis factor (TNF) inhibitor(s) <p>OR</p> <ol style="list-style-type: none"> 1. Diagnosis of ankylosing spondylitis 2. Age ≥ 18 years old 3. Trial and treatment failure of one or more tumor necrosis factor (TNF) inhibitor(s) <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>

Drug name	Current Blue Cross and BCN coverage criteria
Xeljanz solution	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of Polyarticular Juvenile Idiopathic Arthritis (JIA) 2. Age ≥ 2 years old 3. Trial and treatment failure to one Disease-Modifying Anti-Rheumatic Drug (DMARD) after a minimum 3-month trial (examples include methotrexate, leflunomide) 4. Trial and treatment failure of one or more tumor necrosis factor (TNF) inhibitor(s) <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>

Drug name	Current Blue Cross and BCN coverage criteria
Xeljanz XR	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of Rheumatoid Arthritis 2. Age ≥ 18 years old 3. Trial and failure of one Disease-Modifying Anti-Rheumatic Drug (DMARD) after a minimum 3-month trial (examples include methotrexate, hydroxychloroquine, leflunomide, sulfasalazine) 4. Trial and treatment failure of one or more tumor necrosis factor (TNF) inhibitor(s) <p>OR</p> <ol style="list-style-type: none"> 1. Diagnosis of Psoriatic Arthritis 2. Age ≥ 18 years old 3. Trial and treatment failure of one or more tumor necrosis factor (TNF) inhibitor(s) <p>OR</p> <ol style="list-style-type: none"> 1. Diagnosis of Ulcerative Colitis 2. Age ≥ 18 years old 3. Treatment with an adequate course of conventional therapy (such as steroids for 7 days, immunomodulators such as azathioprine for at least 2 months) has been ineffective or is contraindicated or not tolerated 4. Trial and treatment failure of one or more tumor necrosis factor (TNF) inhibitor(s) <p>OR</p> <ol style="list-style-type: none"> 1. Diagnosis of ankylosing spondylitis 2. Age ≥ 18 years old 3. Trial and treatment failure of one or more tumor necrosis factor (TNF) inhibitor(s) <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>

*For drugs covered under the commercial Blue Cross or BCN medical benefit, please see the [Blue Cross and BCN Utilization Management Medical Drug List](#).
Blue Cross Blue Shield of Michigan and Blue Care Network are nonprofit corporations and independent licensees of the Blue Cross and Blue Shield Association.

Drug name	Current Blue Cross and BCN coverage criteria
Xelpros	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Treatment of elevated intraocular pressure 2. Trial and treatment failure of two preferred medications such as generic Xalatan, Lumigan or Travatan Z <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>
Xelstrym	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of Attention Deficit Hyperactivity Disorder 2. Age ≥ 6 years old 3. Treatment failure or intolerance to both a generic methylphenidate and a generic amphetamine product, one of which must be a long-acting formulation <p>OR</p> <ol style="list-style-type: none"> 3. Member cannot swallow tablets/capsules and has tried and failed one of the agents that can be opened and sprinkled on applesauce (methylphenidate ER, Adderall XR) <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>
Xembify	<p>Requires appropriate diagnosis for coverage, subcutaneous administration and other criteria may apply depending on diagnosis. Dosing must be based on ideal body weight (IBW) unless the patient's BMI is greater than 30. If the patient's BMI is greater than 30 or if actual body weight is 20-30% greater than IBW, adjusted body weight must be used.</p> <p>Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>

Drug name	Current Blue Cross and BCN coverage criteria
Xepi	Coverage requires the following: <ol style="list-style-type: none"> 1. Diagnosis of impetigo Approval: 60 days
Xermelo	Coverage requires the following: <ol style="list-style-type: none"> 1. Diagnosis of carcinoid syndrome diarrhea 2. Age ≥ 18 years' old 3. Trial and treatment failure of somatostatin analog (SSA) (octreotide, lanreotide) 4. Using in combination with SSA
Xhance	Coverage requires trial and treatment failure of one generic steroid nasal spray, such as Flonase, Nasalide, or Nasonex Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit

Drug name	Current Blue Cross and BCN coverage criteria
Xolair	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of uncontrolled moderate to severe allergic asthma 2. Age ≥ 6 years old 3. Positive skin test or in-vitro reactivity to a perennial aeroallergen 4. Failure to maintain adequate control after at least a 3 month trial of daily oral corticosteroids or high dose inhaled corticosteroids in combination with: <ol style="list-style-type: none"> a. LABA (long acting inhaled β2 agonist) <p>OR</p> <ol style="list-style-type: none"> b. Leukotriene modifier <p>OR</p> <ol style="list-style-type: none"> c. LAMA (long acting muscarinic antagonist) in adults and children ≥ 12 years old <ol style="list-style-type: none"> 5. IgE level > 30 but < 700 IU/ml for patients 12 years of age and older <p>OR</p> <ol style="list-style-type: none"> IgE level > 30 but < 1300 IU/ml for patients between the ages of 6 to < 12 years old <ol style="list-style-type: none"> 6. Cannot be used in combination with other biologic agents indicated for asthma 7. For self-administration of Xolair prefilled syringe: the patient has received the first 3 doses under the guidance of a health care provider <p>(criteria continued next page)</p>

Drug name	Current Blue Cross and BCN coverage criteria
Xolair (continued)	<p>OR</p> <ol style="list-style-type: none"> 1. Diagnosis of chronic idiopathic urticaria per the American Academy of Allergy Asthma and Immunology (AAAI) guidelines: <ol style="list-style-type: none"> a. Must have occurrence of almost daily hives and itching for at least 6 weeks 2. Age ≥ 12 years old 3. Past trial and failure all of the following for at least 2 months: <ol style="list-style-type: none"> a. Trial and failure of a second-generation antihistamine at the maximal tolerated dose for at least 2 months b. Trial and failure one of the following at maximal dosing: <ol style="list-style-type: none"> i. Another second-generation antihistamine ii. H2 antagonist iii. Leukotriene receptor antagonist iv. First generation antihistamine given at bedtime v. Hydroxyzine vi. Doxepin 4. Other diagnoses have been ruled out 5. Cannot be used in combination with other biologic agents indicated for chronic idiopathic urticaria 6. For self-administration of Xolair prefilled syringe: the patient has received the first 3 doses under the guidance of a health care provider <p>OR</p> <ol style="list-style-type: none"> 1. Diagnosis of nasal polyps 2. Age ≥ 18 years old 3. Patient is currently receiving and will continue to receive standard of care regimen 4. Inadequate response to treatment with intranasal corticosteroids 5. Baseline serum total IgE level of 30 IU/mL to 1,500 IU/mL prior to initiating treatment with Xolair 6. Cannot be used in combination with other biologic agents indicated for nasal polyps 7. For self-administration of Xolair prefilled syringe: the patient has received the first 3 doses under the guidance of a health care provider <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>

Drug name	Current Blue Cross and BCN coverage criteria
Xospata	Coverage requires the following: Treatment of relapsed or refractory acute myeloid leukemia (AML) in adult patients with an FMS-like tyrosine kinase 3 (FLT3) mutation as detected by an approved test
Xphozah	Coverage requires the following: <ol style="list-style-type: none"> 1. Age ≥ 18 years old 2. For the reduction of serum phosphorus for the diagnosis of chronic kidney disease (CKD) on dialysis 3. Using as add on therapy for those with inadequate response to phosphate binders or intolerance of any dose of phosphate binder therapy Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit
Xtampza ER	Coverage requires the following: <ol style="list-style-type: none"> 1. Diagnosis of moderate to severe chronic pain requiring around the clock opioid analgesia for an extended period of time Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit Note: Coverage will not be provided if the patient is on more than one long acting opioid concurrently

Drug name	Current Blue Cross and BCN coverage criteria
Xtandi	<p>Coverage requires the following:</p> <ul style="list-style-type: none"> 1. Treatment of castration-resistant prostate cancer <p>OR</p> <ul style="list-style-type: none"> 1. Treatment of metastatic castration-sensitive prostate cancer <p>OR</p> <ul style="list-style-type: none"> 1. Treatment of non-metastatic castration-sensitive prostate cancer with biochemical recurrence at high risk for metastasis <p>Initial approval: 1 year Continuation of treatment requires a lack of disease progression</p>
Xuriden	<p>Coverage requires the following:</p> <ul style="list-style-type: none"> 1. Diagnosis of Hereditary Orotic Aciduria <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>
Xyosted	<p>Coverage requires the following:</p> <ul style="list-style-type: none"> 1. Diagnosis of male hypogonadism 2. Two signs and symptoms specific to testosterone deficiency <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>

Drug name	Current Blue Cross and BCN coverage criteria
Xyrem	<p>Coverage requires a diagnosis of narcolepsy AND:</p> <ol style="list-style-type: none"> 1. Age ≥ 7 years of age 2. Cataplexy <p>OR</p> <ol style="list-style-type: none"> 1. Excessive daytime sleepiness, AND 2. Trial and failure, contraindication, or intolerance to at least one generic or preferred treatment such as methylphenidate or dextroamphetamine 3. For adults only - Trial and failure, contraindication, or intolerance to modafinil or armodafinil <p>Xyrem will not be approved if patient is being treated with sedative hypnotic agents, other CNS depressants or using alcohol</p> <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>

Drug name	Current Blue Cross and BCN coverage criteria
Xywav	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Age ≥ 7 years old 2. Diagnosis of narcolepsy and cataplexy 3. For adults only - Trial and failure, contraindication, or intolerance to Wakix <p>OR</p> <ol style="list-style-type: none"> 1. Diagnosis of narcolepsy and excessive daytime sleepiness 2. Trial and failure, contraindication, or intolerance to at least one generic or preferred treatment such as methylphenidate or dextroamphetamine 3. For adults only - Trial and failure, contraindication, or intolerance to modafinil or armodafinil, AND Sunosi, AND Wakix <p>OR</p> <ol style="list-style-type: none"> 1. Age ≥ 18 years old 2. Diagnosis of idiopathic hypersomnia 3. Trial and failure, contraindication, or intolerance to at least one generic or preferred treatment such as methylphenidate or dextroamphetamine 4. For adults only - Trial and failure, contraindication, or intolerance to modafinil or armodafinil <p>Xywav will not be approved if patient is being treated with sedative hypnotic agents, other central nervous system (CNS) depressants or using alcohol</p> <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>
Yonsa	Coverage requires the treatment of FDA approved indications

Drug name	Current Blue Cross and BCN coverage criteria
Zavzpret	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. For acute treatment of migraine 2. Age ≥ 18 years old 3. Trial and treatment failure, contraindication, or intolerance to 2 generic triptan medications, one of which must be a generic intranasal triptan 4. Trial and treatment failure, contraindication, or intolerance to to Ubrelvy and Nurtec ODT <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>
Zejula	<p>Coverage requires the treatment of FDA approved indications</p> <p>Initial approval: 1 year Continuation of treatment requires a lack of disease progression</p>
Zelboraf	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of unresectable or metastatic melanoma with BRAF V600E mutation <p>OR</p> <ol style="list-style-type: none"> 1. Diagnosis of Erdheim-Chester Disease with BRAF V600 mutation <p>Initial approval: 1 year Continuation of treatment requires a lack of disease progression</p>

Drug name	Current Blue Cross and BCN coverage criteria
Zembrace SymTouch	<p>Coverage requires the following:</p> <p>Trial and failure of generic Imitrex (sumatriptan) injection and one other generic triptan (examples include: Maxalt (rizatriptan), Amerge (naratriptan), Zomig/ZMT(zolmitriptan))</p> <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>
Zepbound	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Age ≥ 18 years old 2. BMI ≥ 30, or ≥ 27 with one weight related comorbid condition 3. Current weight (within 30 days) must be submitted to the plan for review 4. Active participation for a minimum of 6 months in a covered BCBSM/BCN lifestyle modification program OR active participation for a minimum of 6 months in an alternative concurrent lifestyle modification program (e.g. recent food diaries, exercise logs, program receipts, app participation, etc.) if member does not have access to a covered BCBSM/BCN program 5. Not to be used in combination with other weight loss products 6. Cannot be used in combination with other glucagon-like peptide-1 (GLP-1) agonist containing products <p>Initial approval: 6 months Continued coverage will be reviewed annually and may be provided if the member has maintained at least a 5% weight loss from baseline AND requires continued participation in a lifestyle modification program. Current weight (within 30 days) and BMI ≥ 18.5kg/m2 must be submitted to the plan for review. Zepbound cannot be used in combination with other glucagon-like peptide-1 (GLP-1) agonist containing products</p>

Drug name	Current Blue Cross and BCN coverage criteria
Zeposia	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of ulcerative colitis 2. Age ≥ 18 years old 3. Treatment with an adequate course of conventional therapy (such as steroids for 7 days, immunomodulators such as azathioprine for at least 2 months) has been ineffective or is contraindicated or not tolerated 4. Trial and treatment failure of two of the following: Humira, Simponi, Stelara, Xeljanz/XR, or Rinvoq <p>OR</p> <ol style="list-style-type: none"> 1. Diagnosis of multiple sclerosis 2. Age ≥ 18 years old <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>
Zetonna	<p>Coverage requires trial and failure or intolerance of 2 of the following intranasal steroids:</p> <ol style="list-style-type: none"> 1. Generic fluticasone (Flonase) 2. Generic flunisolide (Nasalide) 3. Nasacort (over-the-counter) <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>

Drug name	Current Blue Cross and BCN coverage criteria
Zilbrysq	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of generalized myasthenia gravis (gMG) 2. Age ≥ 18 years old 3. Documented anti-acetylcholine receptor (AChR) antibody positive myasthenia gravis (MG) identified by: <ol style="list-style-type: none"> a. Lab record or chart notes identifying the patient is positive for anti-AChR antibodies AND <ol style="list-style-type: none"> b. One of the following confirmatory tests: <ol style="list-style-type: none"> i. Positive edrophonium test ii. History of clinical response to oral cholinesterase inhibitors (for example: pyridostigmine) iii. Electrophysiological evidence of abnormal neuromuscular transmission by repetitive nerve stimulation (RNS) or single-fiber electromyography (SFEMG) 4. Patients must NOT have a history of: <ol style="list-style-type: none"> a. Thymectomy within 12 months b. Current thymoma c. Other neoplasms of the thymus 5. Previous treatment courses of at least 12 weeks with one of the following standards of care have been ineffective: methotrexate, azathioprine, cyclophosphamide, cyclosporine, mycophenolate mofetil, or tacrolimus unless all are contraindicated or not tolerated 6. Patient is currently receiving, and will continue to receive, a stable standard of care regimen 7. Must not be used with other biologic therapies for myasthenia gravis or immunoglobulin therapy <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>

Drug name	Current Blue Cross and BCN coverage criteria
Zokinvy	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Age \geq 1 year old 2. Body surface area (BSA) \geq 0.39 m² 3. The requested dose is appropriate for the patient's current body surface area (BSA) 4. Diagnosis of Hutchinson-Gilford Progeria Syndrome (HGPS) confirmed by a mutation in the LMNA gene <p>OR</p> <ol style="list-style-type: none"> 4. Diagnosis of processing-deficient Progeroid Laminopathies with one of the following: <ol style="list-style-type: none"> a. Heterozygous LMNA gene mutation with progerin-like protein accumulation, OR b. Homozygous or compound heterozygous ZMPSTE24 gene mutations <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>
Zolinza	Coverage is provided for the treatment of the FDA approved indications
zolmitriptan nasal spray (Zomig)	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Trial and treatment failure or intolerance to two generic triptans (generic Imitrex, generic Maxalt, generic Amerge or generic Zomig/ZMT tablets) <p>OR</p> <ol style="list-style-type: none"> 1. Age 12-17 years old 2. Trial and treatment failure or intolerance to generic Maxalt (rizatriptan) <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>

Drug name	Current Blue Cross and BCN coverage criteria
zolpidem tartrate sublingual (Intermezzo)	<p>Coverage requires treatment failure of 3 of the following: immediate-release zolpidem (Ambien), eszopiclone (Lunesta), zaleplon (Sonata), trazodone (Desyrel), or doxepin (Silenor)</p> <p>Coverage will not be approved for combination therapy with other sedative hypnotics</p> <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>
Zolpimist	<p>Coverage requires treatment failure of 1 of the following: immediate-release zolpidem (Ambien), eszopiclone (Lunesta), zaleplon (Sonata), trazodone (Desyrel), or doxepin (Silenor)</p> <p>Coverage will not be approved for combination therapy with other sedative hypnotics</p> <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>
Zonisade	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Treatment of seizure disorder/epilepsy 2. Age ≥ 16 years old 3. Trial of 3 generic alternatives, one of which must be generic Zonegran (zonisamide) capsules <p>OR</p> <ol style="list-style-type: none"> 3. Member is unable to swallow tablets or capsules <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>

Drug name	Current Blue Cross and BCN coverage criteria
Zoryve cream	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of plaque psoriasis 2. Age ≥ 6 years old 3. Trial and failure, contraindication, or intolerance to a generic medium or high potency topical corticosteroid 4. Trial and failure, contraindication, or intolerance to at least one of the following generic topical steroid-sparing agents: calcipotriene, tazarotene, tacrolimus, or pimecrolimus <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>
Ztalmy	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of seizures associated with cyclin - dependent kinase - like 5 (CDKL5) 2. CDKL5 deficiency disorder (CDD) confirmed by genetic testing showing mutations on the CDKL5 gene 3. Age ≥ 2 years old <p>Initial approval: 1 year Renewal requires that current criteria are met, and that the medication is providing clinical benefit</p>
Zurzuvae	<p>Coverage requires the following:</p> <ol style="list-style-type: none"> 1. Age ≥ 18 years old 2. Diagnosis of postpartum depression (PPD) with an onset of depressive symptoms in the third trimester or within 4 weeks postpartum 3. Patient is currently ≤ 12 months postpartum 4. Will be used in combination with or a recommendation will be given for psychotherapy <p>Approval: 60 days</p>

*For drugs covered under the commercial Blue Cross or BCN medical benefit, please see the [Blue Cross and BCN Utilization Management Medical Drug List](#)
Blue Cross Blue Shield of Michigan and Blue Care Network are nonprofit corporations and independent licensees of the Blue Cross and Blue Shield Association.

Drug name	Current Blue Cross and BCN coverage criteria
Zydelig	Coverage requires the following: <ol style="list-style-type: none"> 1. Relapsed chronic lymphocytic leukemia (CLL), in combination with rituximab Initial approval: 1 year Continuation of treatment requires a lack of disease progression
Zykadia	Coverage requires the following: <p>Diagnosis of anaplastic lymphoma kinase (ALK) positive, metastatic non-small cell lung cancer as detected by an FDA-approved test</p> Initial approval: 1 year Continuation of treatment requires a lack of disease progression

We speak your language

If you, or someone you're helping, needs assistance, you have the right to get help and information in your language at no cost. To talk to an interpreter, call the Customer Service number on the back of your card.

Si usted, o alguien a quien usted está ayudando, necesita asistencia, tiene derecho a obtener ayuda e información en su idioma sin costo alguno. Para hablar con un intérprete, llame al número telefónico de Servicio al cliente, que aparece en la parte trasera de su tarjeta.

إذا كنت أنت أو شخص آخر تساعد به حاجة لمساعدة، ف لديك الحق في الحصول على المساعدة والمعلومات الضرورية بلغتك دون أية تكلفة. للتحدث إلى مترجم اتصل برقم خدمة العملاء الموجود على ظهر بطاقتك.

如果您，或是您正在協助的對象，需要協助，您有權利免費以您的母語得到幫助和訊息。要洽詢一位翻譯員，請撥在您的卡背面的客戶服務電話。

كيسطوق، بي بيد فيني نكك ديسويطوق، هسبمير مطوق فوبنكك *
كيسطوق كيبطكحوق فوبنكك ديسويطوق فوبنكك هسبمير دككوكك
طلعنكحوق دكك بليطكك. لبيطكككك كيم بيد حنكك، حنكك * مطوق جل
طلعنكك حنككك جل فيني كك ديسويطوق.

Nếu quý vị, hay người mà quý vị đang giúp đỡ, cần trợ giúp, quý vị sẽ có quyền được giúp và có thêm thông tin bằng ngôn ngữ của mình miễn phí. Để nói chuyện với một thông dịch viên, xin gọi số Dịch vụ Khách hàng ở mặt sau thẻ của quý vị.

Nëse ju, ose dikush që po ndihmoni, ka nevojë për asistencë, keni të drejtë të merrni ndihmë dhe informacion falas në gjuhën tuaj. Për të folur me një përkthyes, telefononi numrin e Shërbimit të Klientit në anën e pasme të kartës tuaj.

만약 귀하 또는 귀하가 돕고 있는 사람이 지원이 필요하다면, 귀하는 도움과 정보를 귀하의 언어로 비용 부담 없이 얻을 수 있는 권리가 있습니다. 통역사와 대화하려면 귀하의 카드 뒷면에 있는 고객 서비스 번호로 전화하십시오.

যদি আপনার, বা আপনি সাহায্য করছেন এমন কারো, সাহায্য প্রয়োজন হয়, তাহলে আপনার ভাষায় বিনামূল্যে সাহায্য ও তথ্য পাওয়ার অধিকার আপনার রয়েছে। কোনো একজন দেহাধারীর সাথে কথা বলতে, আপনার কার্ডের পেছনে দেওয়া গ্রাহক সহায়তা নম্বরে কল করুন।

Jeśli Ty lub osoba, której pomagasz, potrzebujesz pomocy, masz prawo do uzyskania bezpłatnej informacji i pomocy we własnym języku. Aby porozmawiać z tłumaczem, zadzwoń pod numer działu obsługi klienta, wskazanym na odwrocie Twojej karty.

Falls Sie oder jemand, dem Sie helfen, Unterstützung benötigt, haben Sie das Recht, kostenlose Hilfe und Informationen in Ihrer Sprache zu erhalten. Um mit einem Dolmetscher zu sprechen, rufen Sie bitte die Nummer des Kundendienstes auf der Rückseite Ihrer Karte an.

Se tu o qualcuno che stai aiutando avete bisogno di assistenza, hai il diritto di ottenere aiuto e informazioni nella tua lingua gratuitamente. Per parlare con un interprete, rivolgiti al Servizio Assistenza al numero indicato sul retro della tua scheda.

ご本人様、またはお客様の身の回りの方で支援を必要とされる方でご質問がございましたら、ご希望の言語でサポートを受けたり、情報を入力したりすることができます。料金はかかりません。通訳とお話される場合はお持ちのカードの裏面に記載されたカスタマーサービスの電話番号までお電話ください。

Если вам или лицу, которому вы помогаете, нужна помощь, то вы имеете право на бесплатное получение помощи и информации на вашем языке. Для разговора с переводчиком позвоните по телефону отдела обслуживания клиентов, указанному на обратной стороне вашей карты.

Ukoliko Vama ili nekome kome Vi pomažete treba pomoć, imate pravo da besplatno dobijete pomoć i informacije na Vašem jeziku. Da biste razgovarali sa prevodiocem, pozovite broj korisničke službe sa zadnje strane kartice.

Kung ikaw, o ang iyong tinutulungan, ay nangangailangan ng tulong, may karapatan ka na makakuha ng tulong at impormasyon sa iyong wika ng walang gastos. Upang makausap ang isang tagasalin, tumawag sa numero ng Customer Service sa likod ng iyong tarheta.

Important disclosure

Blue Cross Blue Shield of Michigan and Blue Care Network comply with Federal civil rights laws and do not discriminate on the basis of race, color, national origin, age, disability, or sex. Blue Cross Blue Shield of Michigan and Blue Care Network provide free auxiliary aids and services to people with disabilities to communicate effectively with us, such as qualified sign language interpreters and information in other formats. If you need these services, call the Customer Service number on the back of your card. If you believe that Blue Cross Blue Shield of Michigan or Blue Care Network has failed to provide services or discriminated in another way on the basis of race, color, national origin, age, disability, or sex, you can file a grievance in person, by mail, fax, or email with: Office of Civil Rights Coordinator, 600 E. Lafayette Blvd., MC 1302, Detroit, MI 48226, phone: 888-605-6461, TTY: 711, fax: 866-559-0578, email: CivilRights@bcbsm.com. If you need help filing a grievance, the Office of Civil Rights Coordinator is available to help you.

You can also file a civil rights complaint with the U.S. Department of Health & Human Services Office for Civil Rights electronically through the Office for Civil Rights Complaint Portal available at <https://ocrportal.hhs.gov/ocr/portal/lobby.jsf>, or by mail, phone, or email at: U.S. Department of Health & Human Services, 200 Independence Ave, S.W., Washington, D.C. 20201, phone: 800-368-1019, TTD: 800-537-7697, email: OCRComplaint@hhs.gov. Complaint forms are available at <http://www.hhs.gov/ocr/office/file/index.html>.